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Figure 49.  Size  Exclusion  Chromatography  profiles  and  SDS‐PAGE  analysis  of  the  best 






purification  conditions  as  it  was  done  before  (3xCMC)  (on  the  left),  or 
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Figure 67.  Scheme  of  the  steps  followed  to  generate  the  recombinant  baculovirus  to 
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A  Ala  alanine  M  Met  methionine 
C  Cys  cysteine  N  Asn  asparagine 
D  Asp  aspartate  P  Pro  proline 
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H  His  histidine  T  Thr  threonine 
I  Ile  isoleucine  V  Val  valine 
K  Lys  lysine  W  Trp  tryptophan 





1. Membrane protein transporters
1.1. Transport across the plasma membrane 
  Mammalian cells are delimited by a plasma membrane formed by a phospholipid bilayer, 
cholesterol, and proteins that protects mechanically the cell and contributes to the selective transport of 
molecules; furthermore, it also participates in cell adhesion and communication with nearby and distant 
cells. In addition, phospholipids and proteins in eukaryotic membranes are usually glycosylated on the 
external face of the cell membrane, conferring a “cell identity” that allows the immune system to 
recognize the cells and detect pathogens or cancer cells that have changed the glycosylation pattern from 
the healthy ones.  
 The selective permeability of the plasma membrane allows controlling the transport of specific 
molecules and conferring equilibrium between the extracellular and the intracellular medium. Only a 
limited number of molecules can cross plasmatic membranes without transmembrane proteins, like O2 or 
CO2 by diffusion. The uptake and efflux of sugars, amino acids, nucleotides, ions, and drugs and even 
water is controlled by transporters or channels. Depending on the energy expenditure transporters can be 
classified in passive, active transporters or channels. The passive transporters, also known as facilitated 
transporters, allow diffusion of solutes to cross the cell membrane using already existing ion/solute 
gradients.  
 In the active transport, molecules move against a concentration gradient utilizing diverse energy-
coupling mechanisms that classify them into primary or secondary active transporters. Primary active 
transporters use the free energy provided by ATP hydrolysis to transport against an electrochemical 
gradient. These pumps enable the generation and storage of electrochemical ion gradients across 
membranes that afterwards secondary-active ion-coupled transporters use to drive uphill transport of 
solutes. Cotransport or symport happens when the ion forming the electrochemical gradient and the 
driven molecule go in the same direction, and exchange or antiport in the case that they move in opposite 
direction.  
 Membrane transporters have high degree of specificity for the transported substrate and bind 
only one (or a few) substrates at the same time and the transporter undergoes conformational changes to 
allow the transport of the bounded substrate (Hediger et al., 2013). Channels allow as well the movement 
of solutes down their electrochemical gradients but are not so specific and do not translocate during 
transport (Armstrong, 2003; Decoursey, 2003; Jiang et al., 2003; Yu and Catterall, 2003).  
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1.2. Solute Carrier Transporters (SLC) 
In mammalian, genes encoding passive transporters, ion coupled transporters and exchangers are 
grouped into Solute Carrier transporters families (Figure 1).  
SLC classification proposed by the Human Genome Organization (HUGO) Nomenclature 
Committee Database (http://www.gene.ucl.ac.uk/nomenclature/) (Hediger et al. 2004) classifies the 
amino acid transporters in 11 different families (Table 2) from the 52 total families belonging to SLC 
nomenclature (Table 1). They are classified based on the number of predicted or observed 
transmembrane (TM) α-helices (usually 10–14) and sequence similarity, of at least 20% with at least one 
other family member (Schlessinger et al. 2013). Members within the same SLC family can have substrates 
with different physicochemical properties despite their common evolutionary origin. Conversely, SLC 
families can be unrelated evolutionarily but still have chemically similar substrates such as the amino acid 
transporter families SLC1 and SLC7 (Schlessinger et al. 2013). Although the majority of amino acid 
transporters have been identiﬁed and characterized, a signiﬁcant number of orphan transporters remain, 
for instance in the SLC16 and SLC38 families (Bröer & Palacín 2011). 
Figure 1. Cartoon of membrane transporters in a cell. SLC transporters are shown on the top and include passive 
transporters, secondary active transporters (cotransporters and exchangers), mitochondrial transporters and vesicular 
transporters. Other transport proteins do not belong to SLC (at the bottom) like water channels, ion channels, pumps, 







1.3. Importance of getting the 3D-structure of membrane proteins 
 Total membrane proteins in eukaryotic cells represent one third of the whole proteome (Krogh et 
al., 2001), and a majority of 75% in specialized organelle like mitochondria (Alberts B, Molecular Biology of 
the Cell. 4th edition, 2002). The number and type of membrane proteins are highly variable and give the 
different functional properties to each membrane. Therefore, dysregulation and malfunction of their 
biological activity often leads to severe diseases (Sanders & Myers, 2004).  
 Due to its physiologic relevance, membrane proteins represent two thirds of all current 
therapeutic targets (Hediger et al., 2013). Nevertheless, so far, only 466 unique structures (mainly 
prokaryotic) have been deposited in the Protein Data Bank (PDB, April 2014) representing less than 2% of 
all available protein crystal structures (Figure 2). Furthermore, very few of these structures were solved at 
high resolution (better than 2 Å). The small amount of solved membrane protein structures is mainly due 
to the hydrophobic segments of integral membrane proteins that are embedded in phospholipid bilayers, 
making difficulty to be overexpressed, purified and crystallized (Arinaminpathy et al., 2009; Bill et al., 
2011). 
Figure 2. Representation of membrane protein solved structures relative to each year. Blanco membrane protein 
database (http://blanco.biomol.uci.edu/mpstruc/) statistics of cumulative unique membrane proteins structures 
published since 1985 shows an n=440 of solved membrane proteins in 2013. 
For a long time it has been considered a difficult or even an impossible task, but last years the 
number of high-resolution structures solved has increased, including many homologues of SLC family 
members (Figure 3) (Hediger et al., 2013). Most of these proteins were obtained from lower organisms 
homologues due to the facility of expression, purification and crystallization compared with eukaryote 
systems. These structures have been used to model the putative structures of human homologues that 
can guide biochemical studies to study the structure of the eukaryotic homologues and give the start point 
for structure-based drug design. Nevertheless, work towards the elucidation of human transporters is still 
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required to learn the structural bases of these transporters. At 2012, from almost 400 membrane protein 
solved, 25 were SLC family members.  
Figure 3.  Representation of membrane protein solved structures belonging to the SLC family relative to each year. 
Cumulative number of membrane protein structure publications since 2002 show a exponential evolution of the 
number of SLC family members crystal structures during the 2002-2012 (Hediger et al., 2013). 
1.4. Amino acid transporters and their physiological relevance 
Amino acid transporters mediate amino acids transport across the cell membrane providing cells 
of one of the building blocks of live. Amino acids play key roles in all cells, such as protein synthesis, 
metabolism regulation, cell growth, regulation of cell volume, metabolic energy production, neural 
transmission, and cell signaling molecules. Amino acid transporters are essential for the absorption of 
amino acids from nutrition, mediating the transfer of amino acids between organs, between different 
cells, and between compartments in cells. Together with other membrane proteins the amino acid 
transporters help to the maintenance of ionic concentration, flowing nutrients, providing amino acids to 
all tissues of the body (Christensen et al., 1990). 
Our diet is composed of more than 30% protein, which after digestion, the resulting peptides and 
amino acids are absorbed by enterocytes in the small intestine (Adibi et al., 1967), there, peptides are 
hydrolyzed and released to blood by amino acid transporters and delivered to all tissues. Kidney filters 
blood and reabsorbs those valuable metabolites including amino acids. Amino acid transport across 
cellular membranes is mediated in most of the cases by multiple transporters with overlapping 
specificities (Palacín et al., 1998; Bröer, 2008). Moreover, they play a role in the reuptake of the nervous 
synapsis, where some amino acids like glutamate, glycine or aspartate, are neurotransmitters. Finally, in 
the placenta, amino acid transporters provide the nutrients from mother to fetal blood and help to 
detoxify it.  
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Absence, overexpression and malfunction of certain amino acid transporters can affect whole-
body homeostasis giving raise to diverse human diseases (Table 2).  
Table 2. List of the 11 SLC amino acid transporters family members, nomenclature, transport activity and 
involvement in diseases. Amino acid substrates indicated with their letter code and Cit, citrulline; Cn, cystine; O, 
ornithine. In the transport function column, the acronyms of the substrate specificity of the transporter follow a 
nomenclature: upper-case letters indicate Na+-dependent transporters (with the exception of system L, system T and 
the proton amino acid transporters); lower case is used for Na+-independent transporters (for example asc, y+ and x−c). 
X− or x− indicate transporters for anionic amino acids (as in X−AG and x−c); AG means that it transports aspartate and 
glutamate, and “c” indicates that the transporter also accepts cystine. Y+ or y+ to cationic amino acids transporters 
(still there is not an Na+-dependent cationic amino acid transporter well defined, thus, Y+ is not used); B or b accounts 
for amino acid transporters of broad specificity; superscript “0” indicates neutral amino acids transport and “+” 
cationic amino acid transporter. ”T” indicates aromatic amino acid transport, and “N”, selectivity for amino acids with 
nitrogen atoms in the side chain. In the rest of the cases, the amino acid letter code represents the preferred 








renal and  intestinal amino acid  transporters produce malabsorption and  renal problems  that affect  the 
whole‐body homoeostasis,  resulting  in malabsorption and  renal problems. Amino acid  transporters  that 






2. Heteromeric Amino acid Transporters (HATs)
Heteromeric Amino acid Transporters (HATs) are the only transporter family composed by two
different subunits: a light and a heavy subunit belonging to SLC7 and SLC3 families, respectively, linked by 
a disulphide bridge (Table 3). Interestingly, they are covalently linked by a disulphide bridge between the 
cysteines located a few residues away from the transmembrane domain of the heavy subunit and in the 
putative extracellular loop 2 of the light subunit (Figure 4), having found the cysteines involved in the 
disulphide bridge highly conserved in all the family members (Pfeiffer et al., 1998; Verrey et al., 1999; 
Chillarón et al., 2001; Palacín & Kanai, 2004). It is suggested that additional interactions between the 
heavy and the light subunit may occur, non-covalent ones, since mutation on cysteines responsible for the 
disulphide bond do not break the interaction (Estévez et al., 1998). 
Figure 4. Topology model of human 4F2hc/LAT1 (SLC3A2/SLC7A5) as a representative member of HAT proteins. The 
crystal structure of human 4F2hc-ED was solved and is displayed (Fort et al., 2007), and the 4 glycosylation sites of 
4F2hc are indicated on the structure. Topology of the single TMD and N-term of 4F2hc is illustrated in yellow. Identical 
and conserved residues within the corresponding families, i.e. CATs and the light subunits of HATs, are colored in 
violet and blue, respectively. Transmembrane topologies were predicted using the HMMTOP server (Tusnady and 
Simon, 2001) and topology data were plotted using T(E)Xtopo (Beitz et al., 2000). Adapted from (Fotiadis, Kanai & 
Palacín, 2013). 
The minimal functional unit of the transporter is formed by one heavy subunit and one light 
subunit, from which, the light subunit is the catalytic part of the transporter conferring the amino acid 
transport specificity to the HAT (Reig et al., 2002; Fernández et al., 2006), and the heavy subunit is the 
responsible of the trafficking of the holotransporter to the plasma membrane (Estévez et al., 1998; Pfeiffer 
et al., 1998; Deves et al., 2000; Palacín & Kanai, 2004). Ten different light subunits (asc1, LAT1, LAT2, xCT, 




identified  until  now  as  members  of  HATs  (Table  3).  Structurally,  light  subunits  are  polytopic  non‐
glycosylated (Kanai et al., 1998; Torrents et al., 1998) proteins composed by 12 predicted transmembrane 
domains  (TMD), with N  and C‐term  intracellular  (Gasol  et al., 2004)  (Figure 4). Their molecular weight 
is  5̴0 kDa; however, when visualizing them in SDS‐PAGE, they run anomalously at 35‐40 kDa due to their 
hydrophobicity (Verrey et al., 2000; Chillarón et al., 2001).  
Light  subunits belong  to  the L‐type amino acid  transporter  (LAT)  family within  the Amino acid, 
Polyamine  and  Organocation  (APC)  superfamily  described  by  the  Transporter  Classification  Database 
(TCDB;  http://www.tcdb.org).  LATs,  together with  CATs  are members  of  the mammalian  solute  carrier 
SLC7  family, but  this  second  ones have  14  TMD described,  are  glycosylated  proteins  and  do not  form 
heterodimers (Fotiadis et al., 2013).  
















They  transport  a  broad  spectrum  of  substrates  ranging  from  neutral  amino  acids  to  aromatic 
amino  acids,  negatively  charged  amino  acids  and  cationic  amino  acids  plus  neutral  amino  acids. 






























y+LAT2  SLC7A6  16q22.1  y+L  Na+ indep.: cationic AA 
Na+/large neutral AA  – 




LAT2  SLC7A8  14q11.2  L  Neutral L‐AA, T3, T4, BCH  – 
asc1  SLC7A10  19q13.1  Asc  small neutral AA  – 






b0,+AT  SLC7A9  19q13.1  b0,+  neutral/dibasic amino acids  Cystinuria Type B 










al.,  1992;  Wells  and  Hediger,  1992).  The  rBAT/b0,+AT  heterodimer  oligomerizes  into  stable 













subunits  also  show  functional  heterotetramers,  suggesting  that  the  heavy  subunit  dictates  the 
oligomerization state (Fernández et al. 2006). It has been proved that complete folding and maturation of 
rBAT  needs  interaction  with  b0,+AT  (Rius  et  al.,  2012).  When  expressed  alone,  rBAT  remains 
endoglycosidase H sensitive and  is degraded, whereas b0,+AT  is stable  (Bauch et al., 2002; Pineda et al., 
2004; Bartoccioni  et al., 2008). The  assembly with b0,+AT within  the endoplasmic  reticulum  (ER) blocks 
rBAT degradation  (Bartoccioni  et  al.,  2008).  Thus,  intracellular  assembly of  rBAT with b0,+AT  to  form  a 
disulfide‐linked  heterodimer  is  required  for  functional  expression.  Reconstitution  into  liposomes  of 
membranes  of  transfected  cells  with  only  b0,+AT  or  with  both  rBAT  and  b0,+AT  resulted  in  the  same 











within  the physiological  range  in plasma), while on  the  intracellular  side  the  affinity  for neutral  amino 
acids is in the milimolar range (e.g., ~ 2.5 mM for L‐leucine) (Reig et al., 2002). 
Mutations  in  either  of  the  transporter  subunits  rBAT  or  b0,+AT  can  cause  cystinuria  (Online 
Mendelian  Inheritance  in Man (OMIM) database, entry 220100) (Calonge et al., 1994; Feliubadaló et al., 
1999).  133  and  95  mutations  in  rBAT  and  b0,+AT,  respectively,  have  been  identified  so  far,  causing 
cystinuria type A, B or AB for patients with mutations in SLC3A1 gene, SLC7A9 gene or both, respectively 
(Dello Strologo et al., 2002; Chillarón et al., 2010). This autosomal recessive disorder is the most common 
primary  inherited  aminoaciduria. Cystinuria  causes  a  failure  in  the  reabsorption of  filtered  cystine  and 
dibasic  amino  acids  in  the  proximal  tubule  producing  hyperexcretion  of  dibasic  amino  acids  (lysine, 
arginine and ornithine) and cystine  in urine. High concentration of  the hyperexcreted amino acid  in  the 
urinary tract and  its poor solubility of cystine   results most often times  in  the  formation of renal calculi 
(urolithiasis), which can cause obstruction, infection and ultimately chronic kidney disease (Chillarón et al., 
2010).  Cystinuria  represents  1–2%  of  all  cases  of  renal  stone  formation  and  even  6–8%  in  pediatric 
patients (Milliner, et al., 1993). 
Cystinuria  specific mutations  in SLC3A1 and SLC7A9  cause  loss of  function.  In  the  case of  rBAT 
mutants, they showed problems in the trafficking of the heterodimer to the membrane (Bartoccioni et al., 
2008). Two different mechanisms underlie the trafficking defects. One type of mutation like L89P, located 
in  the  TMD, makes  the  assembly  of  rBAT  with  b0,+AT  really  slow,  resulting  in  very  small  amount  of 
functional  and  mature  glycosylated  (rBAT/  b0,+AT)2  in  the  membrane.  In  contrast,  mutations  in  the 
ectodomain of rBAT allow efficient assembly with b0,+AT to form disulfide‐linked heterodimers, but HATs 
remain  core‐glycosylated,  fail  to  oligomerize  and  are  degraded,  most  probably  via  the  proteasome. 
Cystinuria‐specific mutations  in b0,+AT studied so  far cause  lack of protein expression  (mutation G105R), 
defective  trafficking  to  the  plasma  membrane  (mutation  A182T)  and  defective  transport  function 
(mutations A354T and P482L) (Font et al., 2001; Reig et al., 2002; Shigeta et al., 2006). 
2.1.2.  rBAT/AGT1 
AGT1  (aspartate/glutamate  transporter  1) was  firstly  described when,  searching  for  new  light 
subunits,  it  was  cloned  from  a  cDNA  library  of  mouse  kidney  successfully  expressed  in  the  plasma 
membrane of Xenopus oocytes as fusion proteins of the transporter with 4F2hc or rBAT and functionally 
characterized (Matsuo et al., 2002). Actually, this transporter has the cysteine residue responsible for the 












Nakamura  et  al.,  1999;),  with  an  exclusively  basolateral  localization  in  intestine  and  kidney  epithelia  
(Quackenbush et al., 1986; Rossier et al., 1999). Moreover, 4F2hc is present in all cell lines and tumor cells 
(Quackenbush  et  al.,  1986;  Parmacek  et  al.,  1989;  Nakamura  et  al.,  1999;  Rossier  et  al.,  1999).  
Experimental   evidence   suggests   that   in   native   tissues   4F2hc‐associated   transporters   are  
single heterodimers, whereas rBAT/b0,+AT is a dimer of heterodimers[rBAT/b0,+AT]2 (Fernández et al., 2006). 
No mutations have been identified in 4F2hc causing any disease, since its defect is believed to be 
lethal  at  the  early  embryonic  phases.  Silencing  of  4F2hc  caused  a  defective  fetal  implantation  in  the 




tails  of  integrin‐β  chains  through  its  transmembrane  domain,  which  is  needed  and  suffices  integrin 
association  (Zent  et  al.,  2000;  Henderson  et  al.,  2004).  This  interaction mediates  β1‐  and  β3‐integrin 
signaling (Feral et al., 2005) that induces cell proliferation (Cantor et al., 2009), migration (Fogelstrand et 
al., 2009), and adhesion (Prager et al., 2007) all key roles in cancer and metastatic cells.  
4F2hc  attaches  pathogens,  like  enteropathogenic  E.coli  (EPEC)  and  Citrobacter  rodentium 















System L mediates  the  transport of  large branched and aromatic neutral amino acids  in a Na+‐









mediate  any measurable  amino  acid  efflux  in  the  absence of  extracellular  amino  acids.  They  transport 
mainly  large  neutral  and  aromatic  neutral  amino  acids,  including  leucine,  isoleucine  and  tyrosine  (the 
majority are essential amino acids) and BCH (Mastroberardino et al., 1998; Meier et al., 2002); it can also 
transport  thyroid hormone  (Kinne et al., 2011). The  selectivity of  the efflux  function  resembles  that of 
uptake, but with  some differences:  L‐leucine,  L‐isoleucine  and  L‐methionine  are  relatively better  efflux 
than influx substrates (Meier et al., 2002). This indicates that LAT1 equilibrate the relative concentrations 




thyroid hormones and amino acids  to  the developing  fetus  (Ritchie and Taylor, 2001).  In brain,  LAT1  is 
found expressed  in microvessels participating  in  the transport of L‐3,4‐dihydroxyphenylalanine  (L‐DOPA) 









‐  4F2hc/LAT1  overexpresses   in  cancer  
4F2hc/LAT1  is  upregulated  in  proliferative  cells,  cancer  cell  lines  and most of  types of human 
cancer tissues,  including  lung, colon, breast, prostate, head, neck, ovarian cancers, as well as  in gliomas 
(Wolf et al., 1996; Yanagida et al., 2001; Fuchs and Bode, 2005; Kaira et al., 2008; Kobayashi et al., 2008), 
suggesting that LAT1 is essential for tumor cell survival and progression. In addition, the overexpression of 





described  to be  assiated  there  are:  the neutral  amino  acid  transporter ASCT2  (SLC1A5);  the  lactate/H+ 
symporters (monocarboxylate transporter 1 (MCT1) (SLC16A1) and MCT4 (SLC16A3). As accessory protein 
it has been found CD147 (also called Basigin or Emmprin), which has been described to be responsible for 
the  trafficking  of MCT1  and MCT4  to  the  plasma membrane  (Halestrap  and Meredith,  2004).  In  the 
complex, also participate cell adhesion molecules as the epithelial cell adhesion molecule (EpCAM), which, 
in turn, is a regulator of cell proliferation (Xu and Hemler, 2005), and integrines that, in fact, interact with 
intracellular  domain  of  4F2hc.  At  the  same  time,  CD147  induces  the  expression  of  matrix 
metalloproteinases and hyaluronic acid  in the cell surface. Thus, this protein  is also a prognostic marker 
for a wide range of tumors (Weidle et al., 2010).  




2010). mTOR  is  a nutrient/energy/redox  sensor  that  controls protein  synthesis by  integrating  signaling 
from growth  factors  (via PI3K and Akt), energy metabolism  (via AMP‐dependent protein kinase; AMPK) 
and amino acids (particularly leucine) (Hay et al., 2004). 
In the uptake of  leucine  in tumor cells, needs the coordinated action of two transporters, LAT1 













Ohkawa  et  al.,  2011).  Thus,  LAT1  is  considered  to  be  both  a  prognosis marker  and  a  target  for  both 
imaging and therapy for cancer.  
In  this  regard,  efforts  have  been  focused  to  develop  different  anticancer  therapies  for  LAT1: 
anticancer drugs that could be transported and  internalized (del Amo et al., 2008), or  inhibitors of these 
transporters with the aim to reduce  in that way tumor proliferation and progression. Still the number of 
specific  inhibitors  is scarce.  In this direction compound KYT‐0353 was develop as specific LAT1  inhibitor, 
which  inhibits  leucine uptake and cell growth  in colon cancer cell  line HT‐29 with  IC50s of 60 nM and 4 
µM, respectively (Oda et al., 2010); it also diminished growth of the HT‐29 tumors transplanted into nude 
mice (Oda et al., 2010). 




(L‐p‐(2‐[18F]fluoroethyl)‐phenylalanine)  (Wang  et  al.,  2011),  tryptophan  (5‐(2‐18F‐fluoroethoxy)‐L‐
tryptophan)  (Kramer  et  al., 2012)  and methionine  (S‐(3‐[18F]fluoropropyl)‐D‐homocysteine)  (Denoyer  et 
al., 2012). Similarly, the LAT1 selective α‐methyl amino acid probe L‐3‐[123I]‐α‐methyl tyrosine has been 
used for tumor imaging by SPECT (Wiriyasermkul et al., 2012).  
Nevertheless,  this  strategy  has  met  limited  success  for  oncologic  imaging  outside  of  brain 
(Oluwatayo et al., 2013). The limited sensitivity is a consequence of the bi‐directional nature of LAT1 and 
other  system  L  transporters, which mediate both  influx  and  efflux of  substrates  from  cells  through  an 
exchange mechanism of transport. Thus, LAT1 cannot directly concentrate substrates, leading to relatively 
low  tumor  to  tissue ratios. Additionally,  the selectivity  for radiolabeled amino acids targeting LAT1 over 
other system L transporters (LAT2, LAT3 and LAT4) is not typically complete. For that it has been develop a 




2.2.1.2.        4F2hc/  LAT2  
4F2hc/LAT2  is a sodium‐independent, high‐affinity obligatory exchanger,  that  transports a wide 
variety of neutral amino acids,  including  small ones,  like alanine, glycine,  cysteine and  serine, all  them 
poor substrates for LAT1 (Meier et al., 2002; Pineda et al., 1999; Rossier et al., 1999).  
Its  expression  is more  ubiquitous  than  LAT1  in  quiescent  cells.  It  is  found  in many  tissues  in 
different  levels  (kidney >>> placenta >> brain,  liver > spleen, skeletal muscle, heart, small  intestine and 
lung) (Pineda et al., 1999); also found expressed at high  levels  in the prostate, the testes, ovaries and  in 
the fetal liver (Park et al., 2005). Its localization in polarized cells is basolateral both in renal and intestinal 
epithelial cells (Rossier et al., 1999). 
In  heterologous  expression  systems  and  cell  culture  models  of  renal  epithelia  4F2hc/LAT2 
efficiently exports L‐cysteine (Bauch et al., 2003; Fernandez et al., 2003). In contrast, the null knockout of 




System  y+L  (Torrents  et  al.,  1998;  Deves  and  Boyd,  1998),  molecularly  represented  by 
4F2hc/y+LAT1  and  4F2hc/y+LAT2,  mediates  the  electro  neutral  exchange  of  cationic  amino  acids  (y+) 
(sodium‐independent)  and  large  neutral  amino  acids  (L)  (sodium‐dependent)  (Chillarón  et  al.,  2001). 
Under physiological conditions (i.e., 150 mM Na+ gradient) system y+L transporters would maintain a ~5‐












4F2hc/y+LAT1  is expressed  in  the small  intestine,  the kidney,  the placenta,  the  lung,  the spleen 
and  in circulating monocytes and macrophages  (Barilli et al., 2010; Pfeiffer et al., 1999; Torrents et al., 
1998; Yeramian et al., 2006). In the epithelial cells of the small intestine and in the renal proximal tubule, 
y+LAT1 has a basolateral  location  (Torrents 1998; Pfeiffer, 1999b).  It  is expected that  in cells with active 
influx of cationic amino acids (e.g., cells expressing rBAT/b0,+AT or CATs) 4F2hc/y+LAT1 will mediate export 
of cationic amino acids. Similar  to LAT2 and b0,+AT, y+LAT1 expression along  the proximal kidney  tubule 
follows a decreasing axial gradient (Bauch et al., 2003). 
Mutations  in  the SLC7A7 gene encoding y+LAT1 cause Lysinuric Protein  Intolerance  (LPI; OMIM 
database, entry 222700)  (Borsani et al., 1999; Torrents et al., 1999). LPI  is a very rare primary  inherited 
aminoaciduria of cationic amino acids (mainly  lysine, but also arginine and ornithine) with an autosomal 
recessive  mode  of  inheritance  (Palacin  et  al.,  2001;  Simell,  2001).  There  are  different  clinical 
manifestations  of  LPI  that  appear  after weaning  and may  include  diarrhea,  vomiting,  failure  to  thrive, 
hepatosplenomegaly,  lung  involvement,  osteoporosis,  bone‐marrow  abnormalities, mental  retardation, 
episodes of coma, altered  immune response and chronic renal disease. LPI  is highly prevalent  in Finland 
(1/60,000), Southern  Italy and  Japan  (1/50,000)  (Palacin et al., 2005). LPI  leads  to urine hyperexcretion 
and  intestinal  malabsorption  of  cationic  amino  acids  (Palacin  et  al.,  2005).  As  a  result,  a  metabolic 




2013;  Mykkänen,  et  al.,  2000),  and  some  point  mutations  have  been  identified  to  inactivate  the 
transporter. L334R and G54V y+LAT1 mutants reached  the Xenopus oocyte plasma membrane when co‐
expressed with 4F2hc but  showed  inactivated  the  transport  (Mykkänen, et al., 2000). No LPI mutations 
have been identified in the heavy subunit SLC3A2 (4F2hc).  










System asc  is a Na+‐independent  transport  system  for  short  chain neutral amino acids  such as 






in particular D‐serine, with high apparent affinity  (Km  values of ~50 µM), and  second, 4F2hc/asc1 also 
works as a facilitate diffuser, although it preferentially works as an exchanger.  
It  is  expressed  in  the  brain,  lung,  skeletal muscle,  heart,  kidney,  small  intestine  and  placenta 
(Fukasawa et al., 2000; Nakauchi et al., 2000).  It  is a neuronal  transporter distributed all over  the CNS 
(Helboe et al., 2003), with the main physiological role in the CNS to control the synaptic concentration of 
the  glutamate  co‐agonists  that  activate  the N‐methyl‐D‐aspartate  (NMDA)  receptors,  like D‐serine  and 
glycine (Hashimoto and Oka, 1997). A Slc7a10 knockout mice model shows tremors, ataxia, seizures and 
early  postnatal  death  (Xie  et  al.,  2005),  probably  due  to  over‐activation  of  NMDA  receptors  for  the 
elevated extracellular D‐serine which causes hyper‐excitability of Slc7a10 mice.  
2.2.4.   System Xc‐ 
System  Xc‐  is  a Na+‐independent  and  electroneutral  exchanger  of  extracellular  anionic  cystine  (for 
which  it  has  a  high‐affinity)  and  intracellular  glutamate with  a  1:1  stoichiometry  (Bannai  et  al.,  1980; 
Makowske et al., 1982; Sato et al., 1999; Bassi et al., 2001). This system plays an  important antioxidant 
role because it provides cystine for the synthesis of the major endogenous antioxidant responsible for the 
maintenance  of  intracellular  redox  homeostasis  (reduced  tripeptide  glutathione  (GSH)),  and  it  also 
supports the non‐vesicular release of glutamate in brain (Bridges et al., 2012; Conrad and Sato, 2012). 









xCT  is  expressed  in  neuronal  cells,  macrophages,  fibroblast,  pancreas,  hepatocytes,  kidney  and 
cell culture lines (Sato et al., 1999; Bassi et al., 2001). Expression of xCT is up‐regulated in cells requiring 
GSH,  like  activated  macrophages  and  in  various  cancers  including  primary  malignant  brain  tumors 
(gliomas), leukemias, lymphomas, Karposi’s sarcoma or pancreatic cancer (Sato et al., 1999; Bridges et al., 
2001;  Kim  et  al.,  2001;  Huang  et  al.,  2005;  Lo  et  al.,  2008;  Seib  et  al.,  2011).  Cancer  cells  adjust  their 
increased demand for nutrients due to their excessive glucose metabolism via anaerobic glycolysis (called 
Warburg effect; Warburg, 1956; Ganapathy et al., 2009). To keep up with increased energy demand due to 
this  permanent  respiratory  defect  that  bypasses  the  Pasteur  effect,  cancer  cells  express  nutrient 
transporters for lactate and amino acids, which increase the reactive oxygen species (ROS) and redox cycle 
regulation  (Vafa  et  al.,  2002; Semenza, 2003; Kroemer  and  Pouyssegur,  2008).  Thus,  overexpression  of  
4F2hc/xCT may protect  tumor cells against oxidative stress by  increasing glutathione  synthesis  (Takeuchi  
et  al.,  2013),  which  indeed,  would  protect  from  the  oxidative  stress  induced  by  radiotherapy  and  
chemotherapy. On  the other hand, xCT  loss‐of‐function  in cellular and mouse models presents defective 
protection against oxidative stress in activated macrophages (Nabeyama et al., 2010) and activation of the 




much  to  the  important  role  contributing  to  the  balance  of  glutathione  levels,  protecting  cells  from 
oxidative stress as it was though before (Sato et al., 2002). Nowadays it is known that system Xc‐, due to its 
role of transporting glutamate, can affect excitability and have behavioral consequences; it is required for 
optimal spatial working memory, and  its  inactivation decreases susceptibility for  limbic epileptic seizures 





diminished  stimulation  of  extrasynaptic  group  II  metabotropic  glutamate  receptors  in  the  nucleus 




In addition to its transport function, xCT serves as a fusion-entry receptor for the Kaposi’s 
sarcoma-associated herpesvirus (KSHV; human herpesvirus 8) (Kaleeba and Berger, 2006), causative agent 
of Kaposi’s sarcoma, since overexpression of xCT increases severely the effectiveness of fusion of the KSHV 
in different cell lines (Kaleeba and Berger, 2006; Qin et al., 2010).   
2.3. Light subunits with unknown heavy subunits 
2.3.2. asc2 
asc-2 (asc-type amino acid transporter-2) has a relatively low, but significant, amino acid 
sequence identity and similarity (~30%) to other HATs. A human ortholog of mouse Slc7a12 is not present 
in the human genome, and it is still not known the heavy subunit associated with mouse asc2. Mouse asc2 
is expressed in kidney collecting duct cells, placenta, spleen, lung and skeletal muscle (Chairoungdua et al., 
2001). There are some evidences of a possible heavy subunit associated with asc2. Firstly, mouse asc-2 has 
the cysteine residue in the 2nd extracellular loop (between TMDs III and IV) that is conserved in all light 
subunits. Secondly, western blot analysis of mouse erythrocytes and kidney detected asc2 as multiple 
bands under non-reducing conditions and as a single band with a lower molecular mass under reducing 
conditions (Chairoungdua et al., 2001), suggesting its association with other protein(s) via a disulfide bond.  
Although co-expression of asc2 and 4F2hc or rBAT does not induce any transport activity at the 
cell plasma membrane, mouse asc2 was possible to be functionally characterized using fusion proteins of 
asc2 and 4F2hc or rBAT that were sorted to the plasma membrane. These fusion proteins exhibited a 
transport function corresponding to the Na+-independent transport system asc (Chairoungdua et al., 
2001). Unlike the other system asc isoform (4F2hc/asc1), asc2 does not accept some of the high-affinity 
substrates of asc-1, such as α-aminoisobutyric acid and β-alanine.  
2.3.3. arpAT 
The Slc7a15 cDNA encoding arpAT (aromatic-preferring amino acid transporter) was the last 
member identified belonging to SLC7 family in mammals. It was found by sequence similarity search in 
vertebrate genomes using known human and mouse light subunit sequences (Fernandez et al., 2005). 
Slc7a15 mRNA is expressed mainly in the small intestine and in some areas of the brain. In the intestine it 
shows a decreasing expression gradient in the enterocytes from the crypts to the tip of the villi. SLC7A15 is 
inactivated in the primate lineage (Casals et al., 2008). 
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Like the other SLC7 members ArpAT has the conserved cysteine residue responsible for the 
disulfide bridge formation. It was tried the co-expression of mouse arpAT with the human heavy subunits 
rBAT and 4F2hc and both formed disulfide-linked heterodimers that allowed the functional 
characterization of the transporter. arpAT transported, sodium-independently, L-alanine, L-tyrosine, L-
DOPA, L-glutamine, L-serine, L-cystine and L-arginine (Fernandez et al., 2005). Kinetic and cis-inhibition 
studies showed a Km of 1–2 mM for L-alanine and an IC50 in the millimolar range for most amino acids, 
except L-proline, glycine, anionic and D-amino acids, which were not inhibitory. L-DOPA and L-tyrosine 
were the most effective competitive inhibitors of L-alanine transport, with IC50 values in the physiological 
micromolar range (Fernandez et al., 2005). Nevertheless, the associated heavy subunit (rBAT and/or 
4F2hc) in the original tissue remains unknown (Fotiadis et al., 2013). So far, any new member of SLC3 has 
been identified by homology search through the genome databases, nevertheless everything points 
toward the existence of (a) yet unknown heavy subunit(s). 
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3. Structural information about HATs
Elucidating the atomic structures of the heteromeric amino acid transporters may provide 
valuable information to understand the translocation mechanism of the transporter and the substrate 
binding, which will be a tool to drive the design of specific therapeutic drugs (Kim et al., 2006). 
Unfortunately, due to the nature of these proteins, structural data of HATs remains very scarce. At 
present, it has only been possible to solve at atomic level the structure of the human 4F2hc ectodomain 
(Fort et al., 2007).  Therefore, there are no available atomic structures of eukaryotic light subunits and the 
corresponding heterodimers.  
3.1. Structure of heavy subunits 
The atomis structure of human 4F2hc ectodomain was solved in 2007 in our laboratory using 
monoclinic (PDB 2DH2) and orthorhombic (PDB 2DH3) crystal forma at 2.1 Å and 2.8 Å of resolution, 
respectively (Fort et al., 2007).  4F2hc-ED (Glu111-Ala529) shows similar structure as α‐amylases, having in 
common domains A and C, but lacking of the B domain (Janacek et al., 1997; Chillarón et al., 2001; Fort et 
al., 2007) (Figure 5). The domain A is a TIM barrel (or (βα)8 barrel) containing a pseudo-active site;  domain 
B is a long loop region inserted between the third β strand and the third α‐helix of domain A that contains 
calcium-binding site(s) (present in rBAT-ED, but not in 4F2hc-ED); finally, domain C is a C-terminal β‐sheet 
domain which consists in 8 antiparallel β sheets. Although presenting some variability in sequence and 
length between amylases, domain C is always present in such proteins (Pujadas and Palau, 2001).  
Figure 5. 4F2hc-ED structure. Top view on the left and lateral views on the right of the structure of 4F2hc-ED, that has 
in common with α-amylases the A domain (TIM barrel (β / α)8) and C domain (8 antiparallel β-sheets), but lacks the B 
domain (alpha-helixs are colured in purple and beta-sheets in green) (From Fort et al., 2007). 
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Despite this structural similarity, 4F2hc lacks the key catalytic residues corresponding to the 
active site of amylases necessary for glycosidase activity. Until now, no enzymatic activity was detected in 
purified 4F2hc-ED when tested D-glucose, D-galactose, or D-manose derivatives of 4-methylumbelliferone 
as substrates (Fort et al., 2007).  
Interestingly, rBAT ectodomain (rBAT-ED) presents all (A, B (α2-β3 loop) and C domains), 
suggesting a possible glycosidase-like activity, which has not yet been proved. Unfortunately, rBAT-ED was 
neither possible to be expressed in E.coli nor purified as it was 4F2hc-ED. Nevertheless, it was possible to 
build a model structure using as templates the 4F2hc-ED and oligo-1,6-glucosidase from Bacillus cereus 
(PDB: 1UOK), that has 49% of amino acid sequence identity with domain β of rBAT (Joana Fort, 
unpublished).  
Figure 6. rBAT-ED 3D-model. Top view on the left and lateral views on the right of the 3D model of rBAT-ED obtained 
from 4F2hc-ED and oligo-1,6-glucosidase (PDB: 1UOK), that has all the domains characteristic of α-amylases: the A and 
C- domains present also in 4F2hc-ED and even the α2β3 B-domain, absent in 4F2hc (Adapted from Laura R. de la 
Ballina thesis) (alpha-helixs are colured in blue and beta-sheets in green). 
When studying the surface charge distribution in 4F2hc-ED, it was shown a macromolecular 
dipole of the protein, with two charged faces: with a predominantly negative charge residues located on 
top (at the C termini of the Beta-sheets of the A domain) and lateral sides, and predominant positively 
charge residues on the bottom side (facing at the N termini of the beta-strands of the A-domain) and 
where the N-terminal of the ectodomain is located (Fort et al., 2007). This two differentiated large positive 
and hydrophobic patches suggest two types of interactions.  
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Figure 7. 4F2hc-ED electrostatic surface monomer in the monoclinic structure (2DH2). The electrostatic surface of 
the 4F2hc-ED monomer has a dipolar distribution of charges with a positive patch in N-terminal region (on the left) 
and negative surface residues on the other side of the protein (on the right). 
The homodimer structure of 4F2hc opened the question about its orientation on the membrane, 
which was modeled by a collaborating group (Dr. Modesto Orozco) with our laboratory. The proposed 
model showed an electrostatic interaction between 4F2hc-ED (the positive charge region near the Cys109) 
and the phospholipid polar heads of the plasma membrane, which is characteristic of several peripheral 
and integral membrane proteins (McLaughlin and Aderem, 1995; Bhatnagar and Gordon, 1997; Conte and 
Matthews, 1998; Mulgrew-Nesbitt et al., 2006).  
4F2hc tends to homodimerize when is overexpressed in different cell types presenting a 190 KDa 
band in SDS-PAGE cleavable by DTT. Both monomers are linked by a disulphide bridge between cysteine 
residues. The same cysteine responsible for the disulfide bridge in the heterodimer formation (Fort et al., 
2007). Human 4F2hc homodimers showed sensitivity to endo H treatment, demonstrating they are 
formed in the endoplasmic reticulum (ER), and surface biotin labeling revealed that these homodimers 
arrived to the plasma membrane (Fort et al., 2007). Human 4F2-ED has been crystallized as a monomer 
(PDB 2DH2) and as a homodimer (PDB 2DH3) (Fort et al., 2007). A Zn++ atom was found at the interface of 
the two subunits presenting a tetrahedral coordination (Figure 8). Nevertheless, Zn++ does not seem to 
play a role in the homodimerization since mutation of the coordinating residues did not affect 4F2hc-
4F2hc interaction even in the absence of the Cys109-intervening disulfide bridge (Fort et al., 2007).  
Figure 8. Homodimer of 4F2hc ectodomain (PDB 2DH3) with a zinc atom (orange sphere) coordinated in the 
interface zone between the two 4F2hc-ED.  And on the right, detail of the residues involved in the coordination of the 
zinc atom:  D439, H441, H455 (Fort et al., 2007, adapted from R. de la Ballina thesis). This coordination patch is not 
conserved in all mammals.  
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Surprisingly, when Cys109 was mutated to serine to abolish disulfide bridge formation, 4F2hc still 
was able to form homodimers, suggesting that there is an important interaction area between monomers 
(Estévez et al., 1998; Fort et al., 2007). In fact, the crystallized 4F2hc-ED homodimer does not present 
Cys109. These results suggest that this residue would be relevant in the stabilization of the interaction but 
is not essential for the homodimerization process. Homo and heterodimerization both require the Cys109 
to form the disulfide bridge between 4F2hc and its light subunits (3 Å distant with the cysteine residue of 
the subunit partner), and apparently it has preference for the light subunit in vivo. Nevertheless, it seems 
that the homodimer of 4F2hc is an artefact as it has not been found in normal tissues or tumours. 
Moreover, homodimerization of the 4F2hc-ED in solution has yet not been demonstrated (Turnay et al., 
2011). 
Analyzing possible helix-helix interaction motifs, it was found in 4F2hc, but not in rBAT, the 
Engelman’s motif, GxxxG, which can be considered as a framework for homodimerization of 
transmembrane α-helices (Russ et al., 2000; Senes et al., 2000; Senes et al., 2004), and was first described 
in Glycophorine-transmembrane homodimerization (Lemmon et al., 1994). 4F2hc GxxxG residues are 
Gly94 and Gly98 which are located in the transmembrane domain of the protein and are highly conserved 
in all vertebrates. This motif seems to be sufficient to drive homodimerization of transmembrane α-
helices. Nevertheless, this motif is not found in any of the light subunits associated with 4F2hc. In contrast, 
it is found in integrins (Berger et al., 2009). So, this motif may be important in the 4F2hc 
homodimerization and in the 4F2hc-integrin interaction. 
Apart from Cys109 responsible for the disulfide bridge, 4F2hc has another cysteine residue, 
Cys330 which is conserved in all mammals but not in the rest of vertebrates. By checking the structure of 
4F2hc-ED it is possible to see that Cys330 is buried into the TIM barrel and it is not accessible to the 
outside (Figure 9). Nevertheless, it has been reported to participate in processes of cell fusion (Okamoto et 
al., 1997). These results suggest that even Cys330 appears hidden in the solved structure; there might be a 
conformational movement that would make Cys330 accessible and able to interact with other proteins 
like β1-integrins. Actually, when Dr. Rodríguez de la Ballina and co-workers (unpublished results) analyzed 
the temperature factor (B factor) to analyze if Cys330 position was determined in the structure with 
accuracy (low B factor) or poorly defined area (high B factor) it was shown that helixes Aα5 and Aα6 have 
a higher B factor values than the rest of the helixes of the TIM barrel (Figure 9), meaning that they are 
more mobile, and that a movement of Aα5 and Aα6 could render an accessible Cys330.  
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Figure 9. Cys330 location in 4F2hc-ED and analysis of the mobile areas by B factor data. A) Cys330 colored in cyan is 
highlighted on the 4F2hc-ED structure (lateral and top views are represented, upper and bottom parts of the figure). 
B) On the right panel the B factor parameter is represented in a gradient color to visualize the parts of the protein that 
are well defined (low B factor, colored in blue) from those that are not so well (high B factor, colored in red) (adapted 
from R. de la Ballina thesis) 
3.2. Light subunit paradigm structures 
Still there are not 3D structures of HAT light subunits (LHAT) available. The closest structural 
models are several crystal structures of prokaryotic membrane transporters homologues of the SLC7 
family (Table 4). Although presenting low amino acid sequence identity with the eukaryotic light subunits 
all APC superfamily members structures have in common (≤ 20% amino acid sequence identity) the 
number of TMD as eukaryotic light subunits (Gasol et al., 2004) (or, when additional transmembrane 
domains they appear on the periphery of this common helix core) (Faham et al., 2008; Weyand et al., 
2008; Ressl et al., 2009; Jeschke et al., 2012); and a structural fold, called “5+5 inverted repeat fold” or 
LeuT fold (see 3.b.1. The Leu T fold), that is also expected to appear in eukaryotic light subunit structures. 









AdiC Tetramer Fab Fragment 3.2 Å 3NCY Fang et al., 2009 
Dimer - 4 Å 3LRC Gao et al., 2009 
L-arginine 3 Å 3L1L Gao et al., 2010 
L-arginine 3 Å 3OB6 Kowalczyk et al., 2011 
ApcT - - 2.32 Å 3GIA Shaffer et al., 2009 
Fab Fragment 2.48 Å 3GI9 
2.59 Å 3GI8 
GadC Dimer - 3.1 Å 4DJK Ma et al., 2012 
Table 4. List of the APC superfamily crystal structures of the closests homologues to LAT (SLC7). This table lists the 
available structures in the PDB of the prokaryotic homologues of LAT family which are the present structural 
paradigms of LATs. The oligomeric state, if co-crystallized, its resolution (Å) and protein data bank accession number 




3.2.1.   The LeuT fold 
The LeuT fold groups distant families of secondary transporters (sequence-unrelated symporters 
and antiporters) into a single structural family which their 3D structure elucidation revealed the common 
structure fold. It was discovered for first time in the bacterial LeuT (Na+-dependent and Cl--dependent 
amino acid transporter (Yamashita et al., 2005). Other crystallized transporters showing the LeuT fold 
were the APC superfamily members (Table 4): AdiC (arginine/agmatine antiporter) (Fang et al., 2009; Gao 
et al., 2009, 2010; Kowalczyk et al., 2011); ApcT (H+-dependent amino acid transporter) (Shaffer et al., 
2009); GadC (glutamate/ GABA antiporter) (Ma et al., 2012) as well as transporters from other families; 
Mhp1 (benzyl hydantoin transporter) (Weyand et al., 2008; Shimamura et al., 2010); CaiT (carnitine/γ-
butyrobetaine antiporter)  (Shulze et al., 2010; Tang et al., 2010); BetP (betaine transporter) (Ressl et al., 
2009; Pérez et al., 2012) and vSGLT (Na+-coupled glucose transporter) (Faham et al, 2008). The LeuT fold is 
characterized by a pseudosymmetry where TMDs 1 to 5 (1st repeat) are related with 6 to 10 TMDs (2nd 
repeat) by a pseudo two-fold axis of symmetry located in the plane of the membrane, thus, the second 
repeat has an inverted topology in the membrane respect the first repeat (Figure 10) (Yamashita et al., 
2005). 
Figure 10. Topology of LeuTAa. The 12 transmembrane domains (TMD) are numbered and colored in gradient. In 
triangles, are represented the TMD that form the “Leu T fold” or “5+5 inverted repeat fold” between TMD1-5 and 
TMD 6-10. Substrate (leucine) is depicted as a yellow triangle, and the two sodium ions as two blue circles. Figure 
adapted from (Yamashita et al., 2005).  
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3.2.2. The closest paradigm to HAT light subunits: AdiC (L-Arginine+/L-
Agmatine++ antiporter) 
AdiC belongs to the Amino acid/Polyamine Antiporter (APA) subfamily, and, together with the 
LAT subfamily, they form part of the APC superfamily of transporters (Casagrande et al., 2008). AdiC is an 
arginine/agmatine antiporter expressed as a dimer in the plasma membrane of enteric bacteria, like E. 
coli, to survive in extreme acidic environments of the stomach (pH 1.5-4) and cause gastrointestinal 
infections (Donnenberg, 2000). AdiC forms a multiprotein complex with the cytoplasmatic decarboxylase 
enzyme AdiA that works together in the acid resistance system. When AdiC transports arginine into the 
cytoplasm, AdiA descarboxilates arginine+ to form a C-H bond on agmatine2+, which is afterwards, 
exported out by AdiC, and a new arginine is importet in a one-to-one exchange stoichiometry, maintaining 
in this way the cytoplasmic pH in 4.7 (Foster, 2004).  
The atomic structure of AdiC is the closest paradigm to HAT light subunits (with   ̴15-17% amino 
acid sequence identity with LAT subfamily), and represents an excellent model for understanding the 
molecular architecture of transporters from the APC superfamily. The first structure of AdiC, obtained in 
2008 at 6.5 Å by cryo-TEM, showed a dimeric protein assembly (Casagrande et al., 2008). In the last years 
it has been solved the atomic structure of AdiC in three conformational states (Table 4; Figure 12): the 
outward-open substrate free conformation (PDB: 3LRB and 3NCY) (Gao et al., 2009; Fang et al., 2009); the 
open-to-out Arg+ bound conformation (PDB: 3OB6) (Kowalczyk et al., 2011); and the occluded substrate-
bound conformation (PDB: 3L1L) (Gao et al., 2010), but remain to be elucidated the rest of conformers 
(i.e., the inward-facing structures) of the LeuT fold transport cycle for this protein (Figure 12). 
In our laboratory, the crystal structure of the N101A mutant of AdiC transporter in the open-to-




Figure 11. Structure of AdiC-N101A bound to Arg+. A) Lateral and B) periplasmic views of the AdiC-N101A-Arg+ 
complex homodimer (in purple, protomer 1 and in orange, protomer 2). The bound substrate is depicted with a ball-
and-stick model. The two-fold subunit axes (ovals or arrows) are colored as their corresponding protomers. The dimer 
axis (arrow or ovals) is indicated in black. C) Model of the open-to-in conformation (gray cylinders) generated by the 
application of the 5 + 5 inverted repeat symmetry to the first 10 TMs of the open-to-out conformation (colored as in A 
and B). The conformational changes occur away from the dimer interface and along each subunit axis (Kowalczyk et 
al., 2011). 
The combination of structural, functional, substrate docking, and molecular dynamics (MD) 
studies reveal the coordination of the substrate guanidinium group with AdiC residues Trp293 (in TMD8) 
and Asn101 (in TMD101) during the transit to the occluded state (Figure 12). In both conformations, open-
to-out apo and occluded conformations, the guanidinium group interacts with the side chain of Trp293 
through π-cation interaction, and with the side chain of Asn101 to form a hydrogen bond (Kowalczyk et 
al., 2011).  
Interestingly, molecular dynamics also showed the high mobility of L-arginine in the AdiC N101A 
structure between residues Trp293 and Trp202, whereas the position of L-arginine docked in the open-to-
out apo structure of AdiC (PDB 3LRB) (Gao et al., 2009) is very stable (Kowalczyk et al, 2011). In the later 
structure, Trp202 (in TMD6) and Phe350 (loop between TMD9-10) have the orientation and distance of a 
π-π interaction, contributing to hold Trp202 in a rotamer closer to the substrate. Indeed, the presence of 
L-arginine freeze Trp202-Phe350 interaction (molecular dynamic studies), which in turn might contribute 
to hold L-arginine (guanidinium group)-Trp293 (π-cation interaction) (i.e. semi-occluded state) (Kowalczyk 
et al, 2011). This represents the second L-arginine-induced fitting mechanism (or conformational 
sampling) in the interaction of periplasmic L-arginine with AdiC. Transition from the semioccluded state to 
the outward-facing L-arginine occluded state (PDB 3L1L) (Gao et al., 2010) occurs through 40º tilting of 
TMD6 (i.e. the N-terminal part of TMD6) and 10º tilting of TMD10 towards the substrate. In conclusion, 
Trp293 and Asn101, two high conserved residues among APA family members, play a dual role in the 
transport cycle: first, they recognize the substrate in the open-to-out state, and second, they stabilize the 




Figure 12. Proposed mechanism of substrate (Arginine) recognition and induced fit by AdiC. In this scheme it is 
represented the transition from the Apo to the occluded conformations where: a) Arg is recognized by the apo 
conformation of AdiC (3NCY), b) bound (3OB6), c) semi-occluded and finally d) occluded (Kowalczyk et al., 2011). 
3.2.3. The alternative access mechanism of prokaryotic transporters 
with LeuT fold 
When the substrate binds, the transporters undergo changes not only at the level of internal 
residues, but also, there is a general conformational change that makes the protein transit from outward 
to inward conformation. It has been described that transporters belonging to the LeuT structure family 
translocate the substrate transiting through different conformations in a common way (Figure 13).  
The appearance of more atomic structures of functionally different yet structurally related 
transporter families has provided insight into the principle of alternating-access mechanism which 
describe this transport cycle (Figure 13): it starts in an open-to-out conformation (or apo outward-facing) 
in which the substrate binding pocket is accessible from the extracellular side. The binding of the substrate 
to the apo transporter (substrate-bound open) triggers the transition to the occluded state, where first, a 
so called thin gate encloses the substrate (occluded outward-facing conformation). At this step, the 
protein undergoes a conformational change that makes a fully occluded state of the protein; the substrate 
is blocked by a thin (usually the side chain of a single residue) and a thick (usually several TMDs) gate 
preventing the diffusion of the substrate to either side of the membrane). Transition to the open-to-in 
state starts by an occluding inward-facing conformation in which the substrate remains occluded by a thin 
gate in the inner side. This state is followed by the substrate-bound inward-facing conformation, to the 
apo inward facing conformation in which substrate is finally released to the cytoplasmatic side of the 
membrane. At a given time, the substrate can only be accessed from one side of the membrane 
(Kowalscyk et al., 2011).  
Only one of these gates is open at a time, allowing substrates and ions to reach the primary 
binding sites without opening up a continuous transmembrane pore. This is consistent with the alternating 
access mechanisms depicted in the 1950s (Mitchell, 1957; Patlak, 1957). 
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Figure 13. Conformational states of the alternative access mechanism of prokaryotic transporters with LeuT fold. 
Substrate is represented by a red ellipse. Binding to the open-to-out apo state, the substrate-bound state evolves to 
an occluded state, where two gates (thick and thin) prevent the diffusion of the substrate to either side of the 
membrane. Occlusion of the substrate by a thin gate is a common mechanism in the transport cycle of these 
transporters, in spite of involving different molecular events, as described for LeuT, vSGLT, Mhp1, BetP and AdiC. The 
inward-facing states are symmetrically related to the outward-facing ones. Transition to the inward-facing states 
requires a transient fully occluded symmetrical intermediate. In ion-coupled symporters (LeuT, vSGLT, Mhp1, ApcT 
and BetP) a free transition between the apo structures (outward- and inward-facing) is required to close the transport 
cycle. The apo occluded structure of ApcT is close to this state. In antiporters (AdiC and CaiT), the return to the 
outward-facing states requires the binding and translocation of a new intracellular substrate that will move the 
transporter back through all the states but in the opposite direction. PDB access codes of the corresponding 
transporter structures/conformational states are indicated in parentheses. (Adapted from (Fotiadis et al., 2013). 
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3.2.4. Closest bacterial SLC7 transporter characterized: SteT (L-serine/L-
threonine antiporter) 
The first prokaryotic member of the SLC7 family (~30% amino acid identity with eukaryotic light 
subunits) cloned and functionally characterized in our laboratory was L-serine/L-threonine antiporter 
(SteT) of Bacillus subtilis (Reig et al., 2007). Differently to all vertebrate SLC7 members, SteT lacks of the 
conserved cysteine between TMD3 and TMD4 responsible for the disulfide bridge formation. Nowadays, is 
still not known the existence of any HAT heavy subunit homologue in prokaryotic organisms. The single-
particle negative-staining electron microscopy (TEM) of detergent-purified SteT showed that this protein 
expresses as a monomer and has elliptical shape according to its dimensions (diameters 6x7 nm), and 
presents a central vestibule (Figure 14) (Reig et al., 2007).  
Figure 14. Single particles of detergent-solubilized and purified SteT were visualized by negative staining 
transmission electron microscopy (TEM).  Detergent-solubilized SteT was purified and analyzed by SP-NS TEM 
showing an homogeneous population of monomers, with a diameter around 7 nm, corresponding to the protein and 
the additional mass arising from the detergent belt and endogenous lipid bound to the protein that have to be 
considered.  
Functionally, SteT is an electroneutral obligatory exchanger that transports preferentially L-serine 
and L-threonine (1:1 stoichiometry), although it can also recognize with less affinity aromatic amino acids 
(Reig et al., 2007). The binding pocket of SteT has been studied by testing cysteine reactivity of single-
cysteine mutants of TMD 8 introduced in a functional cysteine-less SteT mutant combined with functional 
assays (Bartoccioni et al., 2010). This work revealed that Cys 291 and Lys 295 are implicated in the 
substrate recognition and specificity (Bartoccioni et al., 2010). Due to the lack of atomic structures 
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available of SteT, it was built a structural model of this transporter based on AdiC. Substitution of the 
residue Lys295 for a smaller residue opers in a wider space in the substrate binding site that results in 
acquisition of a broader substrate profile (Bartoccioni et al., 2010). At the moment there are no atomic 
structures of SteT wild type available, since it behaves as a very unstable protein and mutants have 
diffracted not at high resolution after several trials performed in our laboratory. Nevertheless, two mutant 
forms of SteT, I134V-A377T and L210Q-229V have been found to be better candidates for crystallization 
studies (Rodríguez-Banqueri et al., 2012). These mutants were generated by random mutagenesis and 
selected using the GFP-split technology adapted for membrane protein (Rodríguez-Banqueri et al., 2012) 
and the adapted high-through put pipeline to screen membrane proteins for crystallization from E. coli 
(Drew et al., 2005; Kawate and Gouaux, 2006; Rodríguez-Banqueri et al., 2012). 
3.3. Interaction between heavy and light subunits 
The first evident interaction that exists between heavy and light subunits is the disulphide bridge 
that is conserved in all amino acid transporters in mammals (HATs) (Palacín et al., 2005). In the heavy 
subunits this Cys is located a few amino acids away from the transmembrane domain, in the extracellular 
neck, located in the Cys 114 in human rBAT and Cys 109 in human 4F2hc. Light subunits have also a 
conserved cysteine between transmembrane domains 3 and 4 (Mastrobernardino et al. 1998; Pfeifer et al. 
1998; Torrents et al. 1998; Nakamura et al. 1999,). 
The mutation of the cysteines responsible for the disulfide bond reduces, but does not abolish, 
trafficking of the heterodimer to the cell plasma membrane, which is observed by reduced transport 
activity (Pfeiffer et al. 1998; Nakamura et al. 1999). This observation suggests that other types of 
interactions (non-covalent) occur between the heavy and the light subunit (Estévez et al., 1998; Pfeiffer et 
al., 1998).  
Several studies have been conducted to address which region of heavy subunit is needed to 
interact with light subunits: 
Chimaeric and truncated forms of rBAT and 4F2hc co-expressed in Xenopus oocytes with b0,+AT or 
LAT1 were analyzed by immunoprecipitation and transport function, and resulted that cytoplasmatic tail 
and transmembrane domain of rBAT play a dominant role in selective functional interaction with b0,+AT; 
and the extracellular domain of rBAT appears to facilitate specifically L-cystine uptake (Franca et al., 2005). 
In the case of 4F2hc, it is dispensable either the cytoplasmatic or extracellular glycosidase-like domains are 





A different group demonstrated that 4F2hc truncations in the C-terminal slowed down the traffic 
of the light subunit LAT1 to the plasma membrane but did not kill the transport, behaving as efficiently as 
the wild type (Bröer et al., 2001). Conversely, the same truncations produced a complete loss of function 
in LAT2 and y+LAT2, indicating that LAT1 might have different characteristics that the rest of light subunits 
interacting with 4F2hc. In these experiments, deletion of 4F2hc-ED abolished the heterodimer formation 
and transport at the plasma membrane with LAT2, y+LAT2 subunits (Bröer et al., 2001). 
Interestingly, chimeras of 4F2hc and CD69 (type II glycoprotein) showed that the relevant part of 
4F2hc interaction with LAT1 was the extracellular domain (-COOH) (not the transmembrane or the 
cytoplasmatic domain) to keep the transport activity of LAT1 (Fenczic et al. 2001) (Figure 15). It was shown 
that the lack of transport was due to a defect in the trafficking of the holotransporter to the plasma 
membrane (L.R. de la Ballina PhD thesis, 2011). These results suggest that the different light subunits 
recognition would require non-covalent interactions of the ectodomain to reach the plasma membrane. In 
addition, they demonstrated that the cytoplasmatic and the transmembrane domains of 4F2hc are 
needed for its effects on integrin function. And, that transport activity and integrin interaction functions of 
4F2hc are independent and are  mediated by different domains in 4F2hc (Fenczik et al., 2001; Henderson, 
2004; Cai et al., 2005). 
Thus, different group’s results are in concordance about the importance of the heavy subunit 
ectodomain for the light subunit trafficking to the plasma membrane and transport function. In addition, it 
is also shown that additional interactions are present between both subunits and needed, but still the 
specific way of interaction has not been cleared.  
 
Figure 15. Scheme of the results obtained from testing the interaction between the different chimeras generated of 
4F2hc and CD69 (another type II glycoprotein not implicated in amino acid transport or integrin signaling) with 
integrins or with amino acid transporters indicated by transport function.  Chimeras were constructed by 
combinations of the ectodomain, transmembrane and cytoplasmic domains. (Fenczik et al., 2001; Henderson, 2004; 
Cai et al., 2005 and L.R. de la Ballina, PhD thesis, 2011). 
In addition, 4F2hc interacts and stabilizes other transporters like GLUT1 without the need of a 
disulphide bridge. Endogenous association was observed in brain (mouse) and HeLa cells, and also by 







glucose transport. In addition, GLUT1 degradation by cycloheximide was significantly diminished by 4F2hc 
overexpression and increased by 4F2hc siRNA treatment, indicating that 4F2hc is involved in the 
stabilization of GLUT1 and contribut to the regulation of also glucose metabolism (Ohno et al., 2011).  
On the other hand, when light subunits do not reach the plasma membrane due to a lack of heavy 
subunit or a lack of the interacting domain of heavy subunit, it does not mean that they are not functional, 
since it has been demonstrated that reconstituted light subunits in proteoliposomes are functional (Reig et 
al., 2002). All these data point out that non-covalent interaction between heavy subunit and light subunit 
are present, and needed to keep trafficking to the plasma membrane the holotransporter, but still the 

















HATs  play  central  roles  in  human  physiology  and  are  involved  in  diseases  such  as  inherited 
aminoacidurias, viral infection and cancer. The low amino acid sequence identity of the eukaryotic light 
subunits with  transporters of  known  structure preclude  the  generation of  robust human  transporter 
models. Moreover,  these  solved  structures  give  no  clues  about  the  supramolecular  organization  of 
HATs, i.e., the architecture and interactions between the heavy and the light subunits. When the atomic 
structures of HATs be available,  these  structures will  facilitate  the  comprehension of  their molecular 
mechanisms of transport, the generation of HAT‐specific ligands by structure‐based drug design, and the 
understanding of the mechanisms  involved  in the functional  interaction between  integrins and 4F2hc‐
associated transporters. 









Validation of the first low resolution 3D model of human 
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Chapter I: Introduction 
Previous work in the laboratory carried out by Dr. Rosell and Dr. Costa culminated with the 
selection of human 4F2hc/LAT2 as the best candidate for structural studies after having tested all 
human light and heavy subunits, and the heterodimers of those with high overexpression yields in the 
yeast Pichia pastoris and efficiently solubilized in detergent. n-Dodecyl-β-D-maltopyranoside (DDM) 
resulted the most efficient solubilizing the heterodimer and 4F2hc and LAT2 monomers (Costa et al., 
2013). Functionality of the overexpressed heterodimer was then tested in vivo in Pichia cells by 
analyzing the [3H]L-leucine uptake, which showed transport function compared with the untransformed 
cells (Figure 16). 
Figure 16. Expression, function and solubilization of the human heterodimer 4F2hc/LAT2. A) In vivo uptake of 
radiolabeled [3H]L-leucine (10 µM) into P. pastoris cells overexpressing human 4F2hc/LAT2 is observed when 
compared with control (untransformed) cells (Costa et al., 2013). B) Western blot analysis of membranes isolated 
from Pichia cells expressing 4F2hc and LAT2. The anti-StrepTagII antibody indicated the presence of heterodimers 
only and no LAT2 monomers under non-reducing conditions. Under reducing conditions (+ DTT), the heterodimer 
disappeared yielding the LAT2 monomer band. The anti-4F2hc antibody indicated the presence of 4F2hc/4F2hc 
homodimer, 4F2hc/LAT2 heterodimer and 4F2hc monomer in the absence of DTT. Under reducing conditions (+ 
DTT), only 4F2hc monomers were visible. Western blot analysis using anti-StrepTagII antibody of isolated 
membranes from LAT2 expressing Pichia cells indicated the presence of LAT2 (major fraction; at ~50 kDa) and an 
artefactual LAT2 homodimer (minor fraction; at ~100 kDa), both under reducing and non-reducing conditions. Such 
dimerizations of light subunits in PAGE have been reported (Fernández et al., 2006). C) The detergent DDM 
completely solubilized 4F2hc/LAT2 and 4F2hc/4F2hc from isolated membranes: all protein is found in the 
supernatant (SN) and none in the pellet (P) after ultracentrifugation. 
This heterodimer was then purified by Co2+ and Strep-Tactin affinity chromatographies and its 
behavior analyzed by size exclusion chromatography. Human 4F2hc/LAT2 eluted in a peak 
corresponding to the heterodimer size, even though, the heterodimer was not stable enough for 3D 
crystallization studies, since it tended to aggregate during the purification process. Fortunately, the 
amount and quality of the purified heterodimer was good enough to determine the structure and 
oligomeric state of detergent-solubilized human 4F2hc/LAT2 from projection images obtained by 
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Transmission Electron Microscopy and Single Particle Analysis (TEM-SPA). In collaboration with Dr. 
Fotiadis (University of Bern), the first 3D low resolution model at 21Å of a human HAT, the 4F2hc/LAT2 
was obtained (Rosell et al., 2014).  
The electron micrographs of the purified 4F2hc/LAT2 contained different particles composed of 
two globular domains of different sizes (Figure 17).  
 
Figure 17. Transmission Electron Microscopy and Single Particle Analysis (TEM-SPA). Overview electron 
micrograph of purified, negatively stained 4F2hc/LAT2 heterodimers. The 4F2hc/LAT2 heterodimers are boxed, 
magnified and are displayed in the gallery bellow. Disrupted heterodimers lead to some monomeric forms of 4F2hc 
or LAT2 that are indicated with arrowheads, and asterisks indicate small protein aggregates. (Scale bar: 50 nm.) The 
frame sizes of the magnified particles in the gallery are 21.8 nm (Rosell et al., 2014). 
The different particle projections were image refined, filtered and contrasted to increase the 
signal to noise ratio (Figure 18A) and a gallery of 15,000 images was built from which single particle 
projections class averages were calculated (Figure 18B). Most class averages indicate a clear difference 
in size between the two domains. 
  
Figure 18. TEM image refinement (A) and gallery of the different single particle projections class average (B) 
(Rosell et al., 2014).  
The structure of 4F2hc/LAT2 was determined by 3D reconstruction from negatively stained 
complexes (Fig. 17). The resolution of the 3D map obtained from the final refinement run was 21 Å (see 
Figure S1B in Rosell et al., 2014) and had a homogeneous angular distribution of projections (see Figure 
S1C in Rosell et al., 2014). The calculated 3D map reflects a structure composed of a smaller and a larger 
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density (Figure 19; see also Figure S1D for additional views in Rosell et al., 2014). The smaller domain 
lies tilted (not flat) on the larger domain (Figure 19A, see black, dotted line indicating tilt). Consequently, 
the complex has on one side a cleft (Figure 19A, arrowhead) and on the opposite side a seal (Figure 19A, 
white, dotted curve). Importantly, the crystal structure of 4F2hc-ED (Fort et al., 2007) nicely fits into the 
smaller density (Figure 19B) making the assignment of 4F2hc and LAT2 in the 3D map possible. 
Figure 19. 3D reconstruction of 4F2hc/LAT2 calculated from projections of negatively stained heterodimer 
particles. A) Different side views of the 3D model are shown. 4F2hc/LAT2 is composed of a large and a small 
density. The small density is located on top of the large density and is tilted, as indicated by the black dotted line. As 
indicated by an arrowhead, the 3D model features a distinct cavity. On the opposite side, both subunits are in close 
contact, as marked by the white, dotted curve. (Scale bar: 5 nm.). B) Side (Upper) and top (Lower) views of the 
4F2hc/LAT2 3D reconstruction without and with the fitted crystal structure of the 4F2hc-ED (Protein Data Bank ID 
code: 2DH2). The fitting assigns the small and large subunits to 4F2hc and LAT2, respectively. The structure of 
4F2hc-ED is represented as a cartoon and surface model. Asterisks indicate the location of the N terminus in the 
4F2hc-ED crystal structure. (Scale bar: 5 nm.) (Rosell et al., 2014). 
As determined by scanning transmission electron microscopy mass measurement, unstained n-
dodecyl-β-D-maltoside (DDM) purified membrane proteins prepared in a conventional way for TEM are 
associated with >55 kDa of co-purified endogenous lipids and DDM molecules (Jastrzebska et al., 2011). 
Thus, the total mass of the LAT2/lipid/DDM ternary complex plus the single TMD and the cytoplasmic N-
terminal domain of 4F2hc containing His-tag and protease cleavage site (>120 kDa) is significantly larger 
than that of the 4F2hc-ED (~50 kDa). This, together with the fitting of the 4F2hc crystal structure into 
the smaller density, supports the assignment of LAT2 to the larger domain of the 3D map. In figure I.4.B 
the location of the N-terminus in the 4F2hc-ED crystal structure is marked by an asterisk. This location is 
close to an additional density connecting small and large domain that possibly arises from the N-
terminal TMD of 4F2hc and extracellular loops of LAT2. This low resolution 3D model represents the first 
structural information on the supramolecular organization of the heteromeric amino acid transporters, 
and it suggests that 4F2hc ectodomain (4F2hc-ED) covers the extracellular surface of the transporter 
subunit LAT2. 
Due to the low resolution of the 4F2hc/LAT2 structure obtained from TEM-SPA, part of this 
thesis focuses on the validation of this model. To that aim, intersubunit crosslinking between sulfhydryl 
groups of cysteine residues in both subunits was performed. Pairs of cysteines, site-specific introduced 
into each subunit, were tested for crosslinking in purified 4F2hc/LAT2 heterodimers, with the molecular 
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rulers, bismaleimidoethane (BMOE) and/or 1,8-Bismaleimido-diethyleneglycol (BM(PEG)2) which are 
homobifunctional thiol-reactive probes with a dynamic simulated average length of 6.27-10.52Å and 
3.51-14.26Å respectively (Green et al., 2001). Chemical crosslinking is found to be a ideal strategy for 
unambiguous demonstration of protein-protein interactions, in vitro. The formation of crosslinks 
between two distinct proteins is a direct and convincing evidence of their close proximity. In addition to 
information on the identity of the interacting proteins, crosslinking experiments can reveal the regions 
of contact between them.  
Interestingly, whereas the purified human 4F2/LAT2 heterodimer was soluble, it was impossible 
the purification of LAT2 alone because this light subunit aggregated fast during the purification process 
(Rosell et al., 2014). Moreover, isolated Pichia membranes expressing 4F2hc/LAT2 heterodimers or LAT2 
monomers were solubilized in DDM and reconstituted into proteoliposomes. In addition, only 
4F2hc/LAT2 heterodimers but not LAT2 monomers could be successfully reconstituted as functional 
proteins into proteoliposomes because LAT2 monomers aggregated before inserting into liposomes 
(Figure 20). These results indicated a possible role of 4F2hc stabilizing the light subunit.   
Figure 20. Reconstitution into liposomes of 4F2hc/LAT2 and LAT2. Reconstitution of heterodimers and LAT2 into 
liposomes. Membranes from Pichia pastoris co-expressing His-4F2hc and Strep-LAT2, or expressing Strep-LAT2 
alone were solubilized with 1 % DDM. Detergent was then removed to induce reconstitution of the membrane 
proteins into proteoliposomes. To distinguish between reconstituted and aggregated proteins, preparations were 
centrifuged (1,500 × g, 1 h, 4 ºC) to precipitate proteoliposomes or ultracentrifuged (250,000 × g, 1 h, 4 ºC) to 
precipitate proteoliposomes and protein aggregates (scheme). Western blot analysis under non-reducing conditions 
with αStrep was used to detect Strep-LAT2, as monomers (LAT2) or heterodimers (4F2hc/LAT2). P, pellet. SN, 
supernatant (Results and image from Dr. Costa thesis). 
These results opened a new question, whether the ectodomain alone could suffice this 
stabilizing effect on LAT2. To that aim, the second part of this chapter is focused in the study of 4F2hc-
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I.1.  Crosslinking of 4F2hc-ED and LAT2 and docking analysis 
To confirm the interaction between 4F2hc-ED and LAT2 that has been observed in the 3D 
model of 4F2hc/LAT2, different cysteine mutants on each subunit were generated to test intersubunit 
crosslinking between cysteine (Cys) residues. Crosslinking experiments were performed in mammalian 
cells (HEK 293T cell line) (co-transfected with both subunits), because of the convenience in generating 
mutants compared to Pichia pastoris. To mimic the most the conditions of the 3D model, crosslinking 
was assessed in purified 4F2hc/LAT2 heterodimers using the same detergent conditions (solubilized with 
n-dodecyl β-D-maltoside (DDM) and purified by Ni2+-affinity chromatography) using the same protein 
tag design (N-terminally His-tag 4F2hc (His-4F2hc) and N-terminally Strep-TagII-tag LAT2 (Strep-LAT2)).  
Endogenous Cys forming the disulphide bridge were maintained in order to restrict the 
heterodimer mobility, through the original fixed position between C109 in 4F2hc and C154 in LAT2. In 
fact, these Cys were not expected to interfere in the crosslinking reaction since they are not reactive. 
For that reason, crosslinkers resistant to DTT were chosen, so that, remaining heterodimers after 
crosslinking reaction and DTT addition (to quench reagent excess and cleave endogenous disulphide 
bridge) would correspond only to crosslinked subunits. Finally, western blotting under reducing 
conditions and using an anti-Strep antibody would reveal intersubunit crosslinking as DTT-resistant 
heterodimers. Interestingly, coimmunoprecipitated Strep-tag-LAT2 will also reveal percentage of 
crosslinking. Thus, CoIP Strep-tag-LAT2 monomers would correspond to immunoprecipitated 
4F2hc/LAT2 heterodimers not crosslinked. In contrast, CoIP Strep-tag-LAT2 heterodimers would 
represent CoIP of crosslinked 4F2hc/LAT2 heterodimers. 
Since several new Cys site-directed mutants were generated, they were validated previous 
crosslinking experiments: checking the heterodimer formation of new Cys mutants and their 
functionality (i.e., transport activity). 
I.1.1.  Residues selected in LAT2 and 4F2hc to perform intersubunit cysteine 
crosslinking assays 
At the beginning of this project, there was no human LAT2 3D model built and no docking of 
4F2hc-ED on LAT2 was still calculated. The different cysteine mutants generated were located in the 
region of 4F2hc most probable to be interacting with LAT2 extracellular loops. That means, that 4F2hc-
ED region with glycosylated residues was orientated facing the extracellular medium.   
In the case of LAT2, the extracellular loops are the expected region to be interacting with 
4F2hc-ED. Analyzing the endogenous LAT2 Cys residues predicted to be located at the extracellular face, 
we found that it has two: Cys 154, which is the cysteine responsible to form the disulphide bridge with 
the heavy subunit (colored in blue, Figure 21); and Cys 210, not conserved cysteine present at the 
beginning of the extracellular loop 2 of LAT2 (between TMD5 and TMD6) (colored in purple, Figure 21). 
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This endogenous cysteine is localized far enough of the disulphide bridge cysteine at the external 
surface of LAT2 to be a good candidate residue to test crosslinking with 4F2hc-ED.  Then, LAT2 wild-type 
was selected to be assayed for crosslinking with the different 4F2hc cysteine mutants through its 
endogenous Cys 210. 
Figure 21. Reactive cysteines of human LAT2 located on SteT 3D model based on AdiC structure (Bartoccioni et 
al., 2010). C154 and C210 are the only Cys located at the extracellular side. Cys 154 colored in blue corresponds to 
the Cys responsible for the disulphide bridge with 4F2hc. Cys 210 colored in purple is an endogenous Cys on LAT2 
that is located in a desired area for crosslinking with 4F2hc, and kept for crosslinking studies. In red the Cys located 
in the intermembrane area are depicted. And in yellow, those cysteines located intracellularly.    
Regarding the endogenous Cys present in human 4F2hc, it has only two: Cys109, participating in 
the intersubunit disulphide bridge (located in the “neck” connecting TMD and the ectodomain) and 
Cys330, a partially hidden residue (located in the A-subdomain of the ectodomain). To avoid doubtful 
results, residue Cys330 was mutated into serine (Ser) to avoid any kind of interference during 
crosslinking reaction. Thus, all mutants were generated on a C330S background, and residue Cys109 was 
maintained to hold the disulfide intersubunit bridge (Figure 22 A), as for LAT2 was kept the Cys154. 
Then, nine Ser residues spread over the surface of 4F2hc-ED potentially facing LAT2 (Fort et al., 2007) 
were selected and mutated individually to Cys for crosslinking experiments (see locations in Figure 22 B). 
Figure 22. Representation of the different serine to cysteine mutants of 4F2hc-ED generated on a background 
C330S conserving the Cys 109 responsible for the disulphide bridge. A) 4F2hc-ED endogenous cysteines: C330 and 
C109 responsible for the disulphide bridge. Cys 330 was mutated to Ser to avoid background signal. C atoms for Cys 
residues are colored in grey, O atoms in red, N atoms in blue and S atoms in yellow. B) 4F2hc-ED most probable area 
to be interacting with the extracellular loops of LAT2 is represented. The nine different Cys mutants generated on 
C330S background are colored as Cys in figure (A). Only Cys109, responsible for the disulphide bridge is 
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differentiated by having C atom colored in purple. The N-terminal end of 4F2hc-ED (C109-S-E-L-P113; one letter 
code amino acid sequence) is colored in orange to denote its high mobility (Fort et al., 2007). (C atoms, gray; O 
atoms, red; N atoms, blue; S atoms, yellow). 
I.1.2.  Validation of new mutants, previous crosslinking assays, by checking 
heterodimerization and functionality 
Previous crosslinking, the new mutants generated on 4F2hc were validated by demonstrating i) 
its heterodimerization by western blot (from total cell extract) (Figure 23 and 24) and ii) the induction of 
L-Ala transport in HEK 293T cells. These parameters were first assessed for the control conditions 
corresponding to transfected: a) empty vector, b) 4F2hc C330S, c) LAT2 WT, and d) co-transfected 4F2hc 
C330S and LAT2 WT (Figure 23). 
Figure 23. Heterodimer formation and amino acid transport in HEK 293T cells co-transfected with 4F2hc C330S 
and LAT2 wild-type. Western blot analysis of 1 % DDM-solubilized homogenates of cells transfected with the 
indicated versions of His-4F2hc and Strep-LAT2 using αStrep (A, C) and αHis (B) antibodies. Bands corresponding to 
heterodimers (4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc) and monomers (4F2hc or LAT2) are indicated under 
non-reducing conditions (A, B). In contrast, under reducing conditions only LAT2 monomers are visible (C). The low 
expression of 4F2hc/LAT2 heterodimers in cells transfected only with LAT2 WT (wild-type) (panel A, lane 2) is most 
probably due to heterodimerization with endogenous 4F2hc. (-): Transfection with the corresponding empty vector. 
4F2hc monomers were revealed as a doublets of bands (B) that correspond to core and mature N-glycosylation 
forms, as previously described (Fort et al., 2007). D) Transport of L-Alanine. Cells were analyzed for transport of 10 
µM L-[3H] Alanine for the indicated times. Co-transfection with His-4F2hc (C330S) and Strep-LAT2 wild-type (closed 
squares) resulted in the induction of L-Ala transport over background (mock transfected or His-4F2hc (C330S) 
transfected cells). Transfection with Strep-LAT2 alone induced L-Ala transport over background, but less than co-
transfection with both proteins (p ≤0.001; Student T-test). Induction of L-Ala transport by LAT2 alone could be the 
result of heterodimerization with endogenous 4F2hc and thus traffic to the plasma membrane or LAT2 monomers 
reaching the cell surface due to overexpression. Data (mean ± S.E.M) are from 3 experiments run in quadruplicates. 
From the nine 4F2hc mutants tested to form heterodimer with LAT2 wild type, only four were 
selected as good candidates for crosslinking experiments: S151C, S185C, S393C and S412C (Figure 24A 
and C, lanes 1, 3, 5 and 6) and induced L-Ala transport to values similar than 4F2hc C330S (Figure 24D). 
The remaining five from nine mutants were not considered for further studies because they 
produced proteolyzed proteins (S191C and S200C) (Figure 24B, lanes 2 and 3), or lacked (S270C) (Figure 
24B, lane 4) or inefficiently formed intersubunit disulphide bridges (S497C and S506C) (Figures 24A and 
C, lanes 7 and 8) when co-transfected with Strep-LAT2.  
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Figure 24. Heterodimer formation and amino acid transport in HEK 293T cells co-transfected with 4F2hc and LAT2 
mutants. A and C) Expression of 4F2hc/LAT2 heterodimers by mutants of 4F2hc and LAT2 generated before the 
docking studies. Western blot analysis of 1 % DDM-solubilized homogenates of HEK 293T cells transfected with the 
indicated versions of His-4F2hc band Strep-LAT2 using αStrep (A) and αHis (C) antibodies under non-reducing 
conditions. All mutants in 4F2hc were generated in C330S background. Bands corresponding to heterodimers 
(4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc) and monomers (4F2hc or LAT2) are indicated under non-reducing 
conditions (A, C). WT, wild-type version of LAT2. B) Lack of formation of 4F2hc/LAT2 heterodimers by some mutants 
of 4F2hc in HEK 293T cells. Western blot analysis of cells transfected with the indicated versions of His-4F2hc and 
Strep-LAT2 using αHis under non-reducing conditions (top) or αStrep under reducing conditions (bottom). Bands 
corresponding to heterodimers (4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc) and monomers (4F2hc or LAT2) are 
indicated. Degraded 4F2hc, bands corresponding to proteolytic fragments of the protein. WT, wild-type version of 
LAT2. D) Induction of L-Alanine transport by the 4F2hc and LAT2 mutants generated before the docking analysis. 
HEK 293T cells were transfected with WT or C210S mutant of Strep-LAT2 alone or together with the indicated 
mutants of His-4F2hc. Cells were analyzed for transport of 10 µM L-[3H] Alanine for 15 seconds. Transport due to 
4F2hc and LAT2 co-expression was calculated by subtraction of that elicited by transfecting Strep-LAT2 alone. For 
4F2hc C330S and LAT2 WT these transport values were 2463 ± 163 L-Ala uptake (pmol/mg protein) during 15 
seconds (mean ± S.E.M. from 4 experiments run in quadruplicates). For the mutants shown, transport is expressed 
as percentage of that of 4F2hc C330S and LAT2 WT. Data (mean± S.E.M.) are from two experiments run in 
quadruplicates. The co-expression of all the indicated mutants induced L-Ala transport over the background due to 
expression of the corresponding LAT2 version alone. Thus, all LAT2 mutants studied were functional. 
I.1.3.  Crosslinking assays with the validated mutants 
Mutants S151C and S412C in 4F2hc were crosslinked with wild-type LAT2, through its 
endogenous C210, using BMOE and BM(POE)2 crosslinkers (Figure 25, lanes 1 and 7 (BMOE) and lanes 9 
and 12 (BM(POE)2)). Interestingly, crosslinking with 4F2hc mutants S151C and S412C was totally 
abolished when LAT2 Cys210 was mutated to Ser (C210S) (Figure 25A, lanes 2 and 6 (BMOE) and lanes 8 
and 11 (BM(POE)2)). It is worth mentioning that C210S (LAT2) mutant is fully functional (it 
heterodimerized (Figure 24A and C, lanes 2 and 4) and induced L-Ala transport with 4F2hc (Figure 24D)). 
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In contrast, mutant C330S (Figure 25, lanes 5 and 10), and mutants S185C (Figure 25, lane 3) and S393C 
(Figure 25, lane 4) incorporated in this background did not show crosslinking with wild-type LAT2. These 
results demonstrated specific crosslinking between Cys residues at positions 151 or 412, which are 
located in the loop Aα1-Aβ2 and helix Aα8’’’, respectively, of subdomain A of 4F2hc-ED, with Cys210, 
which is located in the extracellular loop TMD5-6 in LAT2. 
Figure 25. Intersubunit crosslinking between 4F2hc and LAT2.  A) Versions of His-4F2hc/Strep-LAT2 heterodimers 
expressed in 293T HEK cells and purified by His-affinity chromatography were treated with the DTT uncleavable 
crosslinkers BMOE or BM(POE)2. Crosslinking was detected as DTT-resistant 4F2hc/LAT2 heterodimers (arrowhead) 
by Western blotting using αStrep antibodies under reducing conditions. The band of LAT2 monomer corresponds to 
LAT2 forming heterodimers with 4F2hc (i.e., co-purified) but not crosslinked. Single Cys mutants were introduced in 
4F2hc (C330S) and LAT2 wild-type (WT). In all cases, crosslinking was abolished when 4F2hc (C330S) or LAT2 (C210S) 
was used, indicating specificity of the crosslinked sites. B) Schematic representation of 4F2hc-ED visualizing the 
interacting region with LAT2. Crosslinked 4F2hc-ED residues, S412C and S151C are colored as C atoms in gray; O 
atoms in red; N atoms in blue; S atoms in yellow. Both are crosslinked with the endogenous Cys 210 in LAT2, 
colored as C atoms in cyan; O atoms in red; N atoms in blue; S atoms in yellow, that is represented at the most 
probable region between both residues. Non-crosslinked residues, S393C, S185C, are colored in black. And 
disulphide bridge between C109 in 4F2hc and C154 in LAT2 is illustrated (-S-S-), and Cys residues colored as C atoms 
in pink; O atoms in red; N atoms in blue; S atoms in yellow. 
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I.1.4.  Human LAT2 model from AdiC and multialignment 
Due to the difficulty to work without a 3D structure of human LAT2 and/or the heterodimer, a 
collaboration was started with the group of Dr. Fernández-Recio and Dr. Pérez (from the Joint Barcelona 
Supercomputing Center-IRB Program in Computational Biology) who built 20 homology models of 
human LAT2 and, a docking of 4F2hc-ED with LAT2. To that aim, they used as a template the atomic 
structure of the bacterial homologue L-arginine/agmatine exchanger AdiC in the open-to-out Arg+ bound 
conformation (PDB 3OB6) (Kowalczyk et al., 2011) and an extensive multiple sequence alignment 
between AdiC and 250 close homologues including bacterial (part of the alignment is showed in the 
Figure 26), simple eukaryotic and metazoan LATs. They used Modeler 8v1 (Eswar et al., 2008) to build 
the 20 homology models of human LAT2 (Figure 27A).  
    TMD1a 
LAT2    ----------MEEGARHRNNT-----EKKHPGGGESDASPEAGSGGGGVALKKEIGLVSA 45 
asc1  ----------MAGHTQQPSGR-----GNPRPAPSPSPVPGTVPGASERVALKKEIGLLSA 45 
LAT1  MAGAGPKRRALAAPAAEEKEE-----AREKMLAAKSADGSAPAGEGEGVTLQRNITLLNG 55 
y+LAT2  ----------MEAREPGRPTPTYHLVPNTSQSQVEEDVSSPPQRSSETMQLKKEISLLNG 50 
y+LAT1  ---------MVDSTEYEVASQ-----PEVETSPLGDGASPGP----EQVKLKKEISLLNG 42 
xCT ---------MVRKPVVSTISKGG--YLQGNVNGRLPSLGNKEPPGQEKVQLKRKVTLLRG 49 
b0,+AT  ----------MGDTGLRKRRE-----DEKSIQSQEP----------KTTSLQKELGLISG 35 
Stet  -------------------------------------------MHTEDNGLKKEIGLLFA 17 
AdiC  ---------------------------------------------MSSDADAHKVGLIPV 15 
    TMD1a         TMD1b   ooooo           TMD2   
LAT2    CGIIVGNIIGSGIFVSPKGVLENAGSVGLALIVWIVTGFITVVGALCYAELGVTIPKSGG 105 
asc1  CTIIIGNIIGSGIFISPKGVLEHSGSVGLALFVWVLGGGVTALGSLCYAELGVAIPKSGG 105 
LAT1  VAIIVGTIIGSGIFVTPTGVLKEAGSPGLALVVWAACGVFSIVGALCYAELGTTISKSGG 115 
y+LAT2  VSLVVGNMIGSGIFVSPKGVLVHTASYGMSLIVWAIGGLFSVVGALCYAELGTTITKSGA 110 
y+LAT1  VCLIVGNMIGSGIFVSPKGVLIYSASFGLSLVIWAVGGLFSVFGALCYAELGTTIKKSGA 102 
xCT VSIIIGTIIGAGIFISPKGVLQNTGSVGMSLTIWTVCGVLSLFGALSYAELGTTIKKSGG 109 
b0,+AT  ISIIVGTIIGSGIFVSPKSVLSNTEAVGPCLIIWAACGVLATLGALCFAELGTMITKSGG 95 
Stet  LTLVIGTIIGSGVFMKPGAVLAYSGDSKMALFAWLLGGILTLAGGLTIAEIGTQIPKTGG 77 
AdiC  TLMVSGNIMGSGVFLLPANLASTGG--GIAIYGWLVTIIGALGLSMVYAKMSFLDPSPGG 73 
    TMD3               ooooooooooo TMD4 
LAT2    DYSYVKDIFGGLAGFLRLWIAVLVIYPTNQAVIALTFSNYVLQPLFPTCFPPESGLRLLA 165 
asc1  DYAYVTEIFGGLAGFLLLWSAVLIMYPTSLAVISMTFSNYVLQPVFPNCIPPTTASRVLS 165 
LAT1  DYAYMLEVYGSLPAFLKLWIELLIIRPSSQYIVALVFATYLLKPLFPTCPVPEEAAKLVA 175 
y+LAT2  SYAYILEAFGGFIAFIRLWVSLLVVEPTGQAIIAITFANYIIQPSFPSCDPPYLACRLLA 170 
y+LAT1  SYAYILEAFGGFLAFIRLWTSLLIIEPTSQAIIAITFANYMVQPLFPSCFAPYAASRLLA 162 
xCT HYTYILEVFGPLPAFVRVWVELLIIRPAATAVISLAFGRYILEPFFIQCEIPELAIKLIT 169 
b0,+AT  EYPYLMEAYGPIPAYLFSWASLIVIKPTSFAIICLSFSEYVCAPFYVGCKPPQIVVKCLA 155 
Stet  LYTYLEEVYGEFWGFLCGWVQIIIYGPAIIGALGLYFGSLMAN-LFGW---GSGLSKVIG 133 
AdiC  SYAYARRCFGPFLGYQTNVLYWLACWIGNIAMVVIGVGYLSY--FFPILKDP-LVLTITC 130 
    TMD4                  TMD5             oooooooooooooooooo 
LAT2    AICLLLLTWVNCSSVRWATRVQDIFTAGKLLALALIIIMGIVQICKGEYFWLEPKNAFEN 225 
asc1  MACLMLLTWVNSSSVRWATRIQDMFTGGKLLALSLIIGVGLLQIFQGHFEELRPSNAFAF 225 
LAT1  CLCVLLLTAVNCYSVKAATRVQDAFAAAKLLALALIILLGFVQIGKGDVSNLDPNFSFEG 235 
y+LAT2  AACICLLTFVNCAYVKWGTRVQDTFTYAKVVALIAIIVMGLVKLCQGHSEHF--QDAFEG 228 
y+LAT1  AACICLLTFINCAYVKWGTLVQDIFTYAKVLALIAVIVAGIVRLGQGASTHF--ENSFEG 220 
xCT  AVGITVVMVLNSMSVSWSARIQIFLTFCKLTAILIIIVPGVMQLIKGQTQNF--KDAFSG 227 
b0,+AT  AAAILFISTVNSLSVRLGSYVQNIFTAAKLVIVAIIIISGLVLLAQGNTKNF--DNSFEG 213 
Stet  IIAVLFLCVINIIGTKYGGFVQTLTTIGKLIPIACIIVFGLWKGDQ--HIFTAVNESISD 191 
AdiC  VVVLWIFVLLNIVGPKMITRVQAVATVLALIPIVGIAVFGWFWFRGETYMAAW-NVSGLG 189 
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     Oooo      TMD6a        TMD6b               TMD7 
LAT2    FQEPDIGLVALAFLQGSFAYGGWNFLNYVTEELVDPYKNLPRAIFISIPLVTFVYVFANV 285 
asc1  WMTPSVGHLALAFLQGSFAFSGWNFLNYVTEEMVDARKNLPRAIFISIPLVTFVYTFTNI 285 
LAT1  -TKLDVGNIVLALYSGLFAYGGWNYLNFVTEEMINPYRNLPLAIIISLPIVTLVYVLTNL 294 
y+LAT2  -SSWDMGNLSLALYSALFSYSGWDTLNFVTEEIKNPERNLPLAIGISMPIVTLIYILTNV 287 
y+LAT1  -SSFAVGDIALALYSALFSYSGWDTLNYVTEEIKNPERNLPLSIGISMPIVTIIYILTNV 279 
xCT -RDSSITRLPLAFYYGMYAYAGWFYLNFVTEEVENPEKTIPLAICISMAIVTIGYVLTNV 286 
b0,+AT  -AQLSVGAISLAFYNGLWAYDGWNQLNYITEELRNPYRNLPLAIIIGIPLVTACYILMNV 272 
Stet  -----MNF-GAAILATLFAYDGWILLAALGGEMKNPEKLLPRAMTGGLLIVTAIYIFINF 245 
AdiC  ----TFGAIQSTLNVTLWSFIGVESASVAAGVVKNPKRNVPIATIGGVLIAAVCYVLSTT 245 
     Oooooooooooooooooooooooo             TMD8 
LAT2    AYVTAMSPQELLASNAVAVTFGEKLLG--VMAWIMPISVALSTFGGVNGSLFTSSRLFFA 343 
asc1  AYFTAMSPQELLSSNAVAVTFGEKLLG--YFSWVMPVSVALSTFGGINGYLFTYSRLCFS 343 
LAT1  AYFTTLSTEQMLSSEAVAVDFGNYHLG--VMSWIIPVFVGLSCFGSVNGSLFTSSRLFFV 352 
y+LAT2  AYYTVLNISDVLSSDAVAVTFADQTFG--MFSWTIPIAVALSCFGGLNASIFASSRLFFV 345 
y+LAT1  AYYTVLDMRDILASDAVAVTFADQIFG--IFNWIIPLSVALSCFGGLNASIVAASRLFFV 337 
xCT  AYFTTINAEELLLSNAVAVTFSERLLG--NFSLAVPIFVALSCFGSMNGGVFAVSRLFYV 344 
b0,+AT  SYFTVMTATELLQSQAVAVTFGDRVLY--PASWIVPLFVAFSTIGAANGTCFTAGRLIYV 330 
Stet  ALLHILSANEIVTLGENATSTAATMLFGSIGGKLISVGIIVSIFGCLNGKVLSFPRVSFA 305 
AdiC  AIMGMIPNAALRVSASPFGDAARMALG-DTAGAIVSFCAAAGCLGSLGGWTLLAGQTAKA 304 
    TMD9      ooooooooooo  TMD10 
LAT2    GAREGHLP--SVLAMIHVKRCTPIPALLFTCISTLLMLVTSDMYTLINYVGFINYLFYGV 401 
asc1  GAREGHLP--SLLAMIHVRHCTPIPALLVCCGATAVIMLVGDTYTLINYVSFINYLCYGV 401 
LAT1  GSREGHLP--SILSMIHPQLLTPVPSLVFTCVMTLLYAFSKDIFSVINFFSFFNWLCVAL 410 
y+LAT2  GSREGHLP--DLLSMIHIERFTPIPALLFNCTMALIYLIVEDVFQLINYFSFSYWFFVGL 403 
y+LAT1  GSREGHLP--DAICMIHVERFTPVPSLLFNGIMALIYLCVEDIFQLINYYSFSYWFFVGL 395 
xCT   ASREGHLP--EILSMIHVRKHTPLPAVIVLHPLTMIMLFSGDLDSLLNFLSFARWLFIGL 402 
b0,+AT  AGREGHML--KVLSYISVRRLTPAPAIIFYGIIATIYIIPGDINSLVNYFSFAAWLFYGL 388 
Stet  MAERKQLPFAEKLSHVHPSFRTPWIAISFQIALALIMMLISNPDKLSEISIFMIYIFYVM 365 
AdiC  AADDGLFP--PIFARVN-KAGTPVAGLIIVGILMTIFQLSSISPNATKEFGLVSSVSVIF 361 
     TMD10                              TMD11     ooo   TMD12 
LAT2    TVAGQIVLRWKK--PDIP-----RPIKINLLFPIIYLLFWAFLLVFS-LWSEPVVCGIGL 453 
asc1  TILGLLLLRWRR--PALH-----RPIKVNLLIPVAYLVFWAFLLVFS-FISEPMVCGVGV 453 
LAT1  AIIGMIWLRHRK--PELE-----RPIKVNLALPVFFILACLFLIAVS-FWKTPVECGIGF 462 
y+LAT2  SVVGQLYLRWKE--PKRP-----RPLKLSVFFPIVFCICSVFLVIVP-LFTDTINSLIGI 455 
y+LAT1  SIVGQLYLRWKE--PDRP-----RPLKLSVFFPIVFCLCTIFLVAVP-LYSDTINSLIGI 447 
xCT   AVAGLIYLRYKC--PDMH-----RPFKVPLFIPALFSFTCLFMVALS-LYSDPFSTGIGF 454 
b0,+AT  TILGLIVMRFTRK-ELE------RPIKVPVVIPVLMTLISVFLVLAP-IISKPTWEYLYC 440 
Stet  AFFAVFILRKRAKGEK-----RAYSVPLYPFMPILAIAGSFFVLGST-LITDTMSCGLSI 419 
AdiC  TLVPYLYTCAALLLLGHGHFGKARPAY--LAVTTIAFLYCIWAVVGSGAKEVMWSFVTLM 419 
  TMD12  
LAT2    AIMLTGVPVYFLGVYWQ--HKPKCFSDFIELLTLVSQKMCVVVYPEVERGSGTEEANEDM 511 
asc1  IIILTGVPIFFLGVFWR--SKPKCVHRLTESMTHWGQELCFVVYPQDAP----------- 500 
LAT1  TIILSGLPVYFFGVWWK--NKPKWLLQGIFSTTVLCQKLMQVVPQET------------- 507 
y+LAT2  GIALSGVPFYFMGVYLPESRRPLFIRNVLAAITRGTQQLCFCVLTELDVAE--------- 506 
y+LAT1  AIALSGLPFYFLIIRVPEHKRPLYLRRIVGSATRYLQVLCMSVAAEMDLEDG-------- 499 
xCT  VITLTGVPAYYLFIIWD--KKPRWFRIMSEKITRTLQIILEVVPEEDKL----------- 501 
b0,+AT  VLFILSGLLFYFLFVHYK---FGWAQKISKPITMHLQMLMEVVPPEEDPE---------- 487 
Stet  LIGLAGLPVYYGMKKRKAS----------------------------------------- 438 
AdiC  VITAMYALNYNRLHKNPYPLDAPISKD--------------------------------- 446 
Figure 26. Human LAT2 homology models. Part of the extensive multiple amino acid sequence alignment between 
AdiC from E. coli and 250 close homologs (including bacterial, simple eukaryotic and metazoan LATs) (Bartoccioni et 
al., 2010) used for homology modeling of human LAT2 is shown. The TMDs in human light subunits of HATs and the 
prokaryotic LAT SteT (Serine/Threonine exchanger) from Bacillus subtilis based on the crystal structure of AdiC are 
indicated over the alignment and the TMD residues in AdiC are highlighted in green. Residues in external loops are 
shown as open circles. Conserved cysteine residues involved in the intersubunit disulphide bridge are boxed (in 
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black). Other endogenous Cys residues in human LAT2 are boxed in blue. Small adjustments have been done by 
hand in loops TMD5-6, TMD7-8, TMD8-9, TMD10-11 and TMD11-12 of SteT and human LATs. The C-terminal ends 
(intracellular) of LAT2 (24 residues), asc1 (23 residues), y+LAT2 (9 residues) and y+LAT1 (12 residues) are truncated.  
The loops between TMD5-6 and TMD7-8 are shorter in AdiC. Due to the structural uncertainty 
in these regions it was decided to select 20 models of LAT2 for the docking calculation. As shown in 
Figure 27, the 20 superposed models differ mainly in the extracellular loops mentioned before. In 
addition, the calculated LAT2 model was situated into a predicted membrane and the Cys residues C210 
and C154 were confirmed to be located at the extracellular face.  
Figure 27. Human LAT2 homology 3D models. A) Superposition of the 20 homology models of human LAT2 built 
from AdiC monomer atomic structure (PDB ID: 3OB6; (Kowalczyk et al., 2011)). Maximal divergence between the 
selected models occurs in the more flexible loops TMD5-6 and TMD7-8. B) Cys residues in the best human LAT2 
homology model. Lateral view with atoms of Cys residues shown as spheres. The orientation of LAT2 in the 
membrane (marked by horizontal lines) was predicted using OPM (Lomize et al., 2006) (A and B). There are only two 
external Cys residues: C154 (C atoms in purple), involved in the intersubunit disulphide bridge and C210 (C atoms in 
cyan), which is located almost diametrically opposite. 
To characterize the interactions between 4F2hc-ED and LAT2, Dr. Fernández-Recio and Dr. 
Pérez (from BSC) used each of the 20 models (Figure 27A) and the atomic structure of 4F2hc-ED (PDB ID 
code 2DH2) (Fort et al., 2007), and allowing only two restrictions: 
i) Allowing the formation of the disulphide bridge between residues Cys109 (4F2hc-ED) and 
Cys154 (LAT2),  
ii) Avoiding clashes between 4F2hc-ED residues and the plasma membrane. Out of 3,145
possible docking poses, the model with the lowest-energy is depicted in Figure 28.
Interestingly, the lowest-energy 4F2hc-ED-LAT2 model complies with the above mentioned 
crosslinking analysis (Figure 28). 
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Figure 28. Docking model of the 4F2hc-ED and LAT2 complex. Lowest energy model of the 4F2hc-ED-LAT2 complex. 
Highlighted Cys residues (endogenous or added through mutation) are shown as sphere models (C atoms, gray; O 
atoms, red; N atoms, blue; S atoms, yellow). The putative N-glycosylation sites (N264, N280, N323 and N405 
indicated in purple) and the not crosslinked residues (C185 and C393 in gray) of 4F2hc are located in the most 
external face. 
Thus, crosslinked residues S151C (4F2hc) – Cys210 (LAT2) and S412C (4F2hc) – Cys210 (LAT2) 
were located at minimal interatomic distances of 13.4 Å and 11.5 Å, respectively (Table 5). These 
distances are in good agreement with the results obtained from crosslinking with BMOE and BM(POE)2, 
which have a range of distances separating both reactive maleimide ends of 6.3 Å to 10.5 Å, and 3.5 Å to 
14.3 Å, respectively (Green et al., 2001). In contrast, 4F2hc residues that did not crosslink, S393C and 
S185C, are located at 18.8 Å and 28.2 Å distance from LAT2 Cys210, respectively, also corroborating the 
docking model (Table 5). 
I.1.5.  Docking confirmation and guidance for new crosslinking pair positions 
Then, guided by this docking model new Cys mutants in protein secondary structure elements 
and subdomains not studied previously were considered for crosslinking: S195C in helix 2 of subdomain 
A, and S487C and G505C in subdomain C of 4F2hc-ED, and A235C, A315C, G392C and S441C in four 
external loops of LAT2 (Table 5). To ascribe unequivocally the crosslinked residues, 4F2hc mutants were 
generated in C330S background as previously done and those of LAT2 in C210S background taking 
advantage of the fact that LAT2 C210S heterodimerized with the new considered mutants of His-4F2hc 
(Figure 29A and B, lanes 7, 12 and 17) in HEK 293T cells.  Moreover, the rest of the new 4F2hc and LAT2 
mutants heterodimerized and induced L-Ala transport in the transfected cells (Figure 30).  
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Figure 29. Expression of 4F2hc/LAT2 heterodimers of the new mutants of 4F2hc and LAT2 generated after the 
docking studies. Western blot analysis of 1 % DDM-solubilized homogenates of HEK 293T cells transfected with 
the indicated versions of His-4F2hc and Strep-LAT2 using αStrep (A) and αHis (B) antibodies under non-reducing 
conditions. Bands corresponding to heterodimers (4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc) and monomers 
(4F2hc or LAT2) are indicated. WT, wild-type version of LAT2. 
Figure 30. Induction of amino acid transport by mutants of 4F2hc and LAT2 generated after the docking studies. 
Transport of L-Alanine by the generated 4F2hc and LAT2 mutants. HEK 293T cells were transfected with WT or the 
indicated mutants of Strep-LAT2 alone or together with the indicated mutants of His-4F2hc. One day after, cells 
were analyzed for transport of 10µM L-[3H] Alanine for 15 seconds. Transport is expressed as percentage of that 
elicited by the co-expression of 4F2hc C330S and LAT2 WT and has been calculated as indicated in the legend to 
Figure 18E. Data (mean± S.E.M.) from 1-2 experiments run in quadruplicates. The co-expression of all the indicated 
mutants induced L-Ala transport over the background due to expression of the corresponding LAT2 version alone. 
Thus, all LAT2 mutants studied were functional. 
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I.1.6. Crosslinking results corresponding to the mutants generated by docking 
guidance 
Six new paired positions in 4F2hc and LAT2 were crosslinked by BMOE and/or BM(POE)2, 
(Figure  31). The crosslinked heterodimer bands of the western blot results were quantified by 
densitometry using ImageJ. Interestingly, the new paired positions G505C (4F2hc) with A235C and 
S441C (LAT2) (Figure 31A, lanes 6 and 7), and the already mentioned S151C and S412C (4F2hc) with 
Cys210 (LAT2) (Figure 28) crosslinked almost completely (80-95%) (Table 5).  
Figure 31. Additional intersubunit crosslinking analysis confirming the lowest energy docking model of 4F2hc-ED 
and LAT2 complex. A) Strong crosslinking was detected between the following positions (4F2hc-LAT2): S151C-
A315C (lane 1), G505C-A235C (lane 6) and G505C-S441C (lane 7) by BMOE, and between position S151C-A315C 
(lane 10) by BM(POE)2 . B) Weak but significant crosslinking was detected between the following positions (4F2hc-
LAT2): S487C-G392C by BMOE (lane 4), and between positions S195C-A315C (lane 1), S195C-Cys210 (LAT2 WT) (lane 
5) and S487C-G392C (lane 13) by BM(POE)2. These crosslinking products were specific of these positions because
crosslinking could be abolished when using the single mutants C330S (4F2hc) or C210S (LAT2). Crosslinking by BMOE 
and by BM(POE)2 was negative for the following positions (4F2hc-LAT2): S151C-A235C, S412C-A235C, S412C-A315C 
and S487C-A235C. Crosslinking by BMOE was negative for the paired positions S487C-S441C. 
Together with the intersubunit disulphide bridge between Cys109 (4F2hc) and Cys154 (LAT2), 
which links to 4F2hc >95% of the expressed LAT2 mutants (Figure 24C, lanes 1 and 3, and Figure 29A, 
lanes 15 and 16), these results triangulate the location of 4F2hc-ED over the external face of LAT2 
(Figure 32). Indeed, our crosslinking studies showed that four of the six external loops of LAT2 (Cys210 
and Ala235 in TMD5-6, Ala315 in TMD7-8, Gly392 in TMD9-10 and Ser441 in TMD11-12) (Figure 27, 
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asterisks) are in the vicinity of residues in subdomains A and C of the 4F2hc-ED. Moreover, the 
intersubunit disulphide bridge connects Cys154 in TMD3-4 of LAT2 and Cys109 located five residues 
apart from the C-terminal end of the 4F2hc TMD (Figure 32 and Table 5).  
Figure 32. Summary of the crosslinked residues. The 4F2hc-ED-LAT2 model in (Figure 20) was rotated by 90º, i.e., 
view on the 4F2hc-ED. Of the 4F2hc-ED only the Cys residues (endogenous or added through mutation) are shown 
as sphere models with C atoms in green. In LAT2 (cartoon in blue) the Cys residues (endogenous or added through 
mutation) are shown as sphere models with C atoms in gray. Crosslinked residues are connected by a line denoting 
the percentage of crosslinking (solid red line: 80-95%, solid yellow line: ~60% and red dotted line: 5-10%). Similarly, 
the intersubunit disulphide bridge between C109 (4F2hc) and C154 (LAT2) is represented by a solid red line because 
it is present in >95% of the expressed LAT2 (see text for details). 
According to the lowest-energy 4F2hc-ED-LAT2 model, all the crosslinked positions in the 
present work are between 8.1 Å and 17.5 Å apart (Table 5). In contrast, paired positions separated >15 Å 
or >18 Å were not crosslinked by BMOE or BM(POE)2, respectively (Figures 25A and 31B, and Table 5). 
Table 5. Crosslinking analysis summary. a The structural element where the residues are located is shown. b The 
range of crosslinking distance of BMOE and BM(POE)2 is indicated in brackets. Percentage of LAT2 crosslinked was 
calculated as the amount of LAT2 crosslinked from the total LAT2 co-immunoprecipitated with His-4F2hc. NO, 
residues not crosslinked. na, not analyzed for crosslinking. C Minimal interatomic distance between crosslinking 
residues in the lowest-energy docking model. 
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I.1.7. Discarding that negative crosslinking Cys were not forming a disulphide bridge 
Blocking Cys residues by direct disulphide bridge formation, due to very close proximity, was 
not the cause of the lack of crosslinking in the indicated paired positions (Figure 33).  
Figure 33. Cysteine pairs negative for crosslinking do not form direct intersubunit disulphide bridges. HEK 293T 
cells were transfected with the indicated mutants of His-4F2hc and Strep-LAT2. Two days after transfection Western 
Blot analyses using αStrep (A) or αHis (B) under non-reducing conditions were performed to detect the formation of 
intersubunit disulphide bridges. As indicated, analyzed mutants were introduced in 4F2hc (C330S/C109S) and LAT2 
(C154S/C210S) or LAT2 (C154S) where the endogenous Cys residues involved in the intersubunit disulphide bridge 
have been eliminated. In this way, 4F2hc/LAT2 heterodimers connected by a possible new disulphide bridge will be 
revealed under non-reducing conditions. With the exception of the positive control (co-transfection of 4F2hc C330S 
and LAT2 WT (lanes 7 and 11)) none of the studied mutants showed the formation of 4F2hc/LAT2 heterodimers. 
Cysteine residues in several positions (S151C, S195C, S393C, S412C and S487C), but not in position S185C, produced 
disulphide bridge-linked homodimers of 4F2hc (D). Induction of L-Ala transport in transfected HEK 293T cells (C and 
D). To validate our strategy, one day after transfection, the mutants studied in (A) and (B) were assayed for L-Ala 
transport during 15 seconds (C and D). Transport is presented as percentage of that induced by co-transfection of 
4F2hc (C109S/C330S) and LAT2 (C154S/C210S) (C), and 4F2hc (C109S/C330S) and LAT2 (C154S) (D) as described in 
the legend to Figure 30. Transport in these control conditions were 3062 ± 167 and 3017 ± 280 pmol L-Ala during 15 
seconds (mean ± S.E.M. from 2 experiments run in quadruplicates), respectively. Induction of L-Ala transport over 
the background elicited by LAT2 alone demonstrates the functional interaction of the mutants of 4F2hc and LAT2 
studied. 
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When analyzing the crosslinking results with the different docking calculated, it is observed that 
the experimental data is coincident with the docking model of lowest energy. Moreover, the five 
strongest (≥60% efficiency) crosslinking experiments are in concordance with the three best lowest-
energy-docking models of 4F2hc-ED-LAT2 (Figure 34).  
Figure 34. 4F2hc-ED-LAT2 docking models that satisfy the crosslinking experiments. The three 4F2hc-ED-LAT2 
docking models that satisfy the crosslinking experiments (see Table 5) are displayed. The lowest-energy docking 
model (4F2hc-ED in red; LAT2 in gray) is the one that satisfies best the crosslinking experiments. There are two 
additional docking models (ranked 3 and 15) that satisfy the five strongest (≥ 60 %) crosslinking experiments 
(considering an additional distance of 6 Å to account for small conformational changes). Docking models ranked 3 
and 15 are shown in (4F2hc-ED-LAT2) green-blue and yellow-cyan, respectively. 
Interestingly, all these docking models, as well as the TEM-SPA 3D model position the 4F2hc-ED 
tilted on top of LAT2 (Figure 34 and 19). Even though the atomic structure of the ectodomain of 4F2hc 
(Fort et al., 2007) can be fitted in the small density of the 3D map, the ‘larger domain’ of the map, which 
contains LAT2, the TMD and N-terminal domain of 4F2hc, lipid and detergent and the low resolution of 
the 3D model of 21 Å preclude a reliable fitting of the 4F2hc-ED-LAT2 docking model into the 3D 
4F2hc/LAT2 map. 
In summary, TEM, SPA, docking and crosslinking studies strongly indicate that 4F2hc-ED is 
positioned tilted on LAT2 covering almost completely the extracellular face of the transporter. 
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I.2.  4F2hc increases the stability of LAT2 
According to this model, 4F2hc-ED interacts with all the extracellular loops or ends of TMDs of 
LAT2. 4F2hc is N-glycosylated in Pichia (Costa et al., 2013) and mammalian cells (Fort, et al., 2007), and 
the four putative sites are located in the model in the most external face of 4F2hc-ED, out of the 
interface with LAT2 (Figure 35). There is a large interaction surface between the two proteins, the LAT2 
buried surface area upon 4F2hc binding being 1,735 Å2 (Figure 35). As much as 60% of the LAT2 
interaction surface is formed by hydrophobic residues, and 40% is actually formed by aromatic residues. 
This is consistent with the major contribution of desolvation to the binding energy as calculated by our 
scoring function. The most important contacting residues are shown in Figure 35B. 
Figure 35. LAT2 residues interacting with 4F2hc-ED. Most important residues of LAT2 for binding to 4F2hc-ED 
according to docking-derived NIP values (A and B). Residues with NIP >0.4 are highlighted in the representation of 
LAT2 (blue, atoms as spheres) with the following color code: aromatic residues (orange), aliphatic residues (yellow), 
Asn (light-pink), Glu (red) and Lys (cyan). The cartoon representation of 4F2hc-ED on top of LAT2 is shown in green. 
The hydrophobic patch of LAT2 interacts with subdomain C (antiparallel β8) of 4F2hc-ED. The Cys residues involved 
in the disulphide bridge are indicated: LAT2 C154 is partially hidden and one of its C atoms is indicated by a circle, 
and 4F2hc C109 corresponds to the N-terminal end of the structure of 4F2hc-ED (indicated by black line). Location 
of NIP-based interacting residues with cartoon representation of LAT2. B) Two defined patches (separated by the 
broken line) are evident: one hydrophobic and one mixed patch. The residues are represented by sticks with the 
same color code as in (A). C154 is highlighted with its atoms represented in spheres (C, grey; O, red; N, blue and S, 
yellow). Totally or highly conserved residues are written in red and non-conserved residues in black. Residues not 
conserved in cyanobacteria, yeast and fungi homologs of LAT2 are underlined. Loop TMD5-6, containing residues 
N221 and F223, is larger in LAT2 than in AdiC and other bacterial LATs, precluding the generation of a robust 
homology model. The fact that a significant part of this loop is not at the interface with 4F2hc-ED might be the 
consequence of the poor modeling of this loop. 
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The interaction between 4F2hc-ED and the overall external face of LAT2 suggests a possible 
effect of the heavy subunit on the stability of the light subunit.  
To answer this question the behavior of purified 4F2hc/LAT2 and LAT2 was studied. 
Solubilization with DDM of isolated membranes from yeast cells co-expressing His-4F2hc and Strep-
LAT2, and sequential purification by Co2+- and Strep-Tactin affinity chromatographies yielded 
4F2hc/LAT2 heterodimers (Costa et al., 2013). In contrast, DDM solubilization of yeast membranes 
expressing Strep-LAT2 alone and subsequent Strep-Tactin affinity chromatography and size exclusion 
chromatography yielded only aggregates of LAT2 (results obtained by Dr. Costa) (Figure 36A).  
Figure 36. A) Size exclusion chromatography profiles of purified 4F2hc/LAT2 (thick curve) and purified LAT2 (thin 
curve). 4F2hc/LAT2 elutes at 9.8 mL whereas LAT2 is eluted in the void volume (8 mL). B) Time-course of L-Leucine 
uptake in 4F2hc/LAT2 and 4F2hc proteoliposomes. Transport of 10 µM L-[3H]Leucine into proteoliposomes was 
measured during 10, 30, 60, 90, 120, 150, 180 and 210 min and 20 h. Proteoliposomes were loaded or not with 4 
mM cold L-Isoleucine. Data (mean ± S.E.M.) corresponds to triplicates of a representative experiment. Transport of 
10 µM L-[3H]Leucine into 4F2hc/LAT2 proteoliposomes preloaded with 4 mM L-Isoleucine resulted in an overshoot. 
In contrast, L-Leucine transport into 4F2hc/LAT2 proteoliposomes with no amino acids inside showed passive 
diffusion similar to that shown by 4F2hc proteoliposomes filled or not with L-Isoleucine. This behavior is 
characteristic of coupled transporters like the H+/lactose cotransporter LacY (Newman et al., 1981) or exchangers 
like the LAT transporter SteT, an L-Serine/L-Threonine exchanger from Bacillus subtilis (Reig et al., 2007). 
To study if 4F2hc was able to modulate the functionality of LAT2, we tried the reconstitution of 
purified 4F2hc/LAT2 heterodimers into liposomes but our attempts failed. As an alternative approach to 
test the functionality of 4F2hc/LAT2 heterodimers and LAT2 monomers, isolated Pichia membranes 
were solubilized in DDM and reconstituted into proteoliposomes. Interestingly, only 4F2hc/LAT2 
heterodimers but not LAT2 monomers could be successfully reconstituted as functional proteins into 
proteoliposomes (Figure 36B) because LAT2 monomers aggregated before inserting into liposomes 
(results obtained by Dr. Costa) (Rosell et al., 2014). Surprisingly, expression of Strep-LAT2 alone, as well 
as co-expression of His-4F2hc and Strep-LAT2, resulted in a similar transport of 10 µM L-Leucine over 
background in Pichia pastoris cells (results obtained by Dr. Costa) (Rosell et al., 2014). These results 
suggest that LAT2 is properly folded and trafficked to the plasma membrane in yeast cells. However, the 
interactions with 4F2hc would be essential to maintain the correct folding of the light subunit in 
detergent. 
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I.2.2. The ectodomain of the heavy subunit 4F2hc increases the stability 
of LAT2 
Next, we asked whether the ectodomain of 4F2hc is able to stabilize LAT2 without the 
generation of the conserved disulphide bridge between both HAT subunits and without the TMD and N-
terminus of 4F2hc. Pichia membranes expressing Strep-LAT2 were incubated with purified His-4F2hc-ED, 
and then LAT2 was solubilized with different concentrations of DDM (Figure 37A). Interestingly, pre-
incubation with 4F2hc-ED, but not with same concentration of BSA, increased the solubilization of LAT2 
at the three concentrations (1%, 0.5% and 0.25% DDM) of detergent tested. These results suggested 
that 4F2hc-ED stabilizes LAT2 in solution. To test this possibility, 1% DDM-solubilized LAT2 in the 
absence and presence of 4F2hc-ED was ultracentrifuged 2 h, 24 h and 72 h after solubilization. 
Remarkably, the presence of 4F2hc-ED prevented dramatically the precipitation of LAT2 (Figure 37B and 
C).  
Figure 37. 4F2hc-ED increases LAT2 solubility and stability. A) Western blot analysis of DDM-solubilized LAT2 in the 
presence of 1 mg/mL of 4F2hc-ED or BSA, or plain buffer as indicated. B) Western blot analysis of solubilized LAT2 
(1% DDM) in the presence or absence of 1 mg/mL of 4F2hc-ED after different times. C) Quantification of the soluble 
LAT2 after the indicated time. Data (mean ± SEM) corresponds to three independent experiments as the one shown 
in (B). Soluble LAT2 was considered as the remaining in solution after ultracentrifugation. LAT2 was detected 
using αStrep antibody. The presence of 4F2hc-ED increased LAT2 stability at all analyzed times. D) Scheme 
representing the Pichia pastoris membranes overexpressing Strep-LAT2 and the addition of buffer, purified 
4F2hc-ED or BSA to test its interaction were kept overnight at 4ºC and next day solubilized with DDM.
In summary, these results indicate that the ectodomain of 4F2hc suffices to increase the 
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I. Discussion 
Three lines of evidence (TEM and SPA, docking and crosslinking analyses) strongly support the 
idea that 4F2hc-ED covers, almost completely, the extracellular surface of the transporter subunit LAT2. 
Indeed, we identified specific residues that nearly completely (>80%) crosslinked 4F2hc and LAT2 (Figure 
25 and 31) and triangulate with the endogenous intersubunit disulphide bridge (Figure 24 and 32). 
Importantly, the proposed docking model, as well as two additional and highly similar poses, fulfills the 
steric restrictions defined by the results from crosslinking (Figure 34). 
The docking analysis used the atomic structure of human 4F2hc-ED and homology models of 
human LAT2 based on the atomic structure of the amino acid transporter AdiC in an outward-facing 
conformation. Because of the low sequence conservation in the loops of AdiC and LAT2 (Figure 27), the 
docking models do not intend to represent high-resolution structures of the 4F2hc-ED and LAT2 
complex. Nevertheless, docking analysis revealed desolvation as the main contributor to the binding 
energy of 4F2hc-ED and LAT2. Indeed, the LAT2 residues that are predicted to be more relevant for the 
interactions are mainly hydrophobic, and they could be grouped clearly in two defined patches (see 
Normalized Interface Propensity (NIP) residues in Table 6 and Figures 35A and B).  
Table 6. Conservation of the NIP residues placed in the human 4F2hc/LAT2 interface. The amino acid sequence of 
72 proteins belonging to the LAT family (SLC7) and grouped in 8 categories (LAT2, LAT1, y+LAT1, y+LAT2, asc1, xCT, 
b0,+AT (8 vertebrate proteins per category) and  cyanobacterial, yeast and fungal LATs (16 proteins per this 
category)) were aligned by the ClustalW2 program. The conservation of the NIP residues was analyzed in vertebrate 
LAT2, in other vertebrate light subunits associated to 4F2hc (L.S light subunit), in vertebrate b0,+AT ,in 
cyanobacterial LATs and in fungal LATs. The protein sequences were retrieved from the UniProt (a) and GenBank 
databases (b): LAT2: Homo sapiens (Q9UHI5)a, Mus musculus (Q9QXW9)a, Ornithorhynchus anatinus  
NIP
Loop residue Location LAT2 b0,+AT Cyanobacteria, yeast and fungi
human all
TMD1-2 K63 TMD1 YES NO1 NO1 YES NO
G64 TMD1 YES YES YES NO NO
E67 TMD1 (C-term) YES NO NO NO NO
TMD3-4 F155 Loop YES NO NO NO NO
P157 Loop YES YES YES YES NO
TMD5-6 N221 Loop YES2 Polar Polar Polar NO
F223 Loop YES YES YES YES NO
L239 TMD6 YES L/Y L/Y L/Y V/Y/I 
TMD7-8 L297 Loop YES YES L/I/V3 YES NO
N300 Loop YES Polar Polar Polar Polar 
A301 Loop YES YES YES YES NO
A303 Loop YES YES YES YES YES
TMD9-10 M384 Loop  YES4 NO NO NO NO
Y385 Loop  YES Y/F5 Y/F5 NO Y/F
Y390 Loop  YES Y/F Y/F Y/F Y/L/F
F393 TMD11 (N-term)  YES YES YES YES NO
TMD11-12 F440 Loop  YES F/V/L F/V/L NO NO
L442 TMD12  YES L/F L/F/Y L/Y/I L/V/F/Y
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(XM_003429011)b, Orcinus orca (XM_004283215)b, Anolis carolinensis (H9GCK9)a, Xenopus tropicallis (Q6P891)a, 
Carassius carassius (B8YMU3) a, Danio rerio (NM_001271897.1)b. LAT1: Homo sapiens (Q01650)a, Mus musculus 
(Q9Z127)a, Ornithorhynchus anatinus  (XM_001508884)b, Orcinus orca (XM_004280070)b, Gallus gallus 
(XM_414194)b, Xenopus tropicallis (F6QFZ9)a, Takifugu rubripes  (H2SUN0)a, Danio rerio (NM_001128358)b. y+LAT1: 
Homo sapiens (NP_001119577.1)b, Rattus norvergicus (AAF07216.1)b, Ornithorhynchus anatinus  
(XP_003430084.1)b, Orcinus orca (XP_004283244.1)b, Anolis carolinensis (H9G4U3)a, Xenopus tropicallis (F6S1W4)a,  
Latimeria chalumnae (H3A009)a, Danio rerio (NP_001032648.1)b. y+LAT2: Homo sapiens (Q92536)a, Mus musculus 
(Q8BGK6)a, Orcinus orca (XM_004273192)b, Gallus gallus (F1ND99)a, Anolis carolinensis (XM_003222960)b, Xenopus 
tropicallis (Q28I80)a, Pelodiscus sinensis (K7G1V4)a, Danio rerio (NM_001020474)b. asc1: Homo sapiens (Q9NS82)a, 
Mus musculus (P63115)a, Orcinus orca (XM_004284140)b, Gallus gallus (XM_414136)b, Pelodiscus sinensis 
(K7GB90)a, Xenopus tropicallis (XM_002935793)b, Xiphophorus maculatus (M4AC17)a, Danio rerio (XM_690716)b. 
xCT: Homo sapiens (Q9UPY5)a, Mus musculus (Q9WTR6)a, Orcinus orca (XM_004265135)b, Gallus gallus (E1C734)a, 
Anolis carolinensis (XM_003221678)b, Pelodiscus sinensis (K7FII9)a, Xenopus tropicallis (XM_002932048)b, Danio 
rerio (XM_002664447)b. b0+AT: Homo sapiens (P82251)a, Rattus norvergicus (NM_053929)b, Orcinus orca 
(XM_004284134)b, Gallus gallus (E1BT87)a, Anolis carolinensis (H9GCM6)a, Xenopus laevis (A9JS28)a, Danio rerio 
(F1QGJ2)a, Salmo salar (NM_001173819)b. Cyanobacterial LATs: Chroococcidiopsis sp. (WP_015152622.1)b, 
Cyanothece sp. (WP_012630008)b, Fischerella sp. (WP_009454021.1)b, Gloeobacter violaceus (NP_924598)b, 
Oscillatoria sp.(WP_007357767)b, Pleurocapsa minor (WP_015143465)b, Microcoleus sp. (WP_015184929.1)b, 
Rivularia sp. (WP_015120455.1)b. Yeast and Fungal LATs: Saccharomyces cerevisiae (NM_001181184)b, 
Arthroderma gypseum (XM_003171846)b, Schyzophyllum commune (XM_003036114)b, Yarrowia lipolytica 
(XM_505103)b, Aspergillus niger (XM_001396535)b, Coprinopsis cinerea (XM_001833155)b, Nectria haematococca 
(XM_003050065)b, Ajellomyces dermatitidis  (XM_002620161)b.  1 K not present only in LAT1; 2 H in Anolis 
carolinensis LAT2; 3 M in Xenopus tropicallis and H in Mus musculus y+LAT2; 4 I in Anolis carolinensis LAT2; 5 D in 
human xCT and H in  Xiphophorus maculatus and Danio rerio asc1; 6 I in human asc1.        
One of the patches, which is totally hydrophobic, is composed of nine residues distributed 
along three external loops or TMD ends of LAT2 (TMD3-4, which harbours Cys154 residue involved in 
the disulphide bridge, TMD9-10 and TMD11-12). The other is a mixed patch composed of four polar and 
five hydrophobic residues located in loops TMD1-2, TMD5-6 and TMD7-8. 
The interaction between 4F2hc-ED and LAT2 brings the question of whether the heavy subunit 
might have an impact on LAT2 transport cycle. The structural paradigms of HAT light subunits, the 
bacterial APC transporters, present the LeuT-fold (Shi et al., 2013). Secondary transporters, upon 
binding of an external substrate, transit to inward-facing conformations to release the substrate inside 
the cell. Besides transporter-specific changes, atomic structures of LeuT-fold transporters showed a 
commonality of features in this transition (Shimamura et al., 2010 and Krishnamurthy et al., 2012): the 
“hash” domain (TMDs 3, 4, 8 and 9) and the extracellular ends of the “bundle” domain (TMDs 1, 2, 6 and 
7) get closer and the loop TMD7-8 occludes the external vestibule of the transporter. Our results
indicate that these conformational changes are compatible with a direct contact of 4F2hc-ED with the 
external loops or ends of TMDs of LAT2. The highly conserved hydrophobic patch glues to 4F2hc-ED the 
“hash” domain, with the intersubunit disulphide bridge, and TMDs 11 and 12, the most static domain of 
LAT2 according to the structural homologue AdiC (Kowalczyk et al., 2011).  
In contrast, the mixed patch is less conserved and involves the “bundle” domain and the 
occluding loop (TMD7-8). This architecture suggests that 4F2hc/LAT2, and probably other HATs, have 
evolved to bind firmly the ectodomain of the heavy subunit to the “hash” domain. In this scenario, 
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energetically similar interactions of 4F2hc-ED with the “bundle” domain and loop TMD7-8 would be 
broken and replaced with the different conformations that the light subunit undergoes during the 
transport cycle. 
According to amino acid transporters with LeuT-fold, the substrate binding site in LAT2 is 
expected to be located at the bottom of the extracellular vestibule (Fotiadis et al., 2013 and Bartoccioni 
et al., 2010), and therefore far away from the interacting 4F2hc-ED residues (Figures 38A and B). 
Moreover, our docking analysis located 4F2hc-ED tilted with subdomain C interacting with LAT2 TMD11-
12 and leaving open a window in the opposite location flanked by LAT2 TMD7-8 for the entrance of the 
substrate to the binding site (Figure 38A).  
Figure 38. The LAT2 external substrate vestibule is accessible in the lowest-energy 4F2hc-ED-LAT2 model. To 
visualize the accessibility of the LAT2 substrate vestibule from the exterior, we have docked L-Isoleucine substrate 
with AutoDock and show here the most populated docking poses (in blue and red). A) We can see that the entrance 
of the substrate vestibule, where one of the most populated L-Isoleucine positions is located, is accessible from the 
exterior (A). TMD7-8 loop (cartoon in cyan) flanks the entrance to this vestibule. The interior of the substrate 
vestibule is visualized showing a second putative binding site of L-isoleucine (red) as determined by docking (B).  
In spite of the different structures of the LAT2 monomer and the 4F2hc/LAT2 heterodimer, the 
measured KM values for L-Leucine transport in Pichia cells were comparable (178±15 µM and 120±7 µM, 
respectively) suggesting that 4F2hc would have no significant impact on the substrate affinity of LAT2 
(Figure 39). Thus, the interaction between 4F2hc and the extracellular surface of LAT2 increases the 
stability of the detergent-solubilized light subunit but did not alter dramatically the substrate apparent 
affinity of this transporter in vivo. 
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Figure 39. Kinetic analysis of L-Leucine transport in Pichia pastoris cells. Kinetic analysis of L-Leucine transport in 
Pichia pastoris cells transformed with His-4F2hc and Strep-LAT2 (left) or Strep-LAT2 alone (right) yielded 
comparable KMs of 178±15 µM and 120±7 µM, respectively. Transport was measured in linear conditions during 3 
min. Data points were corrected for basal activity in untransformed yeast cells. The concentrations used were 10, 
30, 50, 100, 300, 500 and 1000 µM. Eadie-Hofstee plots are shown as insets. Data (mean ± S.E.M.) corresponds to 
triplicates from representative experiments. When not visible, error bars are smaller than symbol. R2, is the 
correlation coefficient of the linear regression. 
The hydrophobic character of the interaction between 4F2hc-ED and LAT2 might be at the basis 
of the stabilization of this light subunit by 4F2hc. We show that 4F2hc allows functional reconstitution 
into proteoliposomes and purification of the transporter after solubilization with DDM. Moreover, we 
show here that 4F2hc-ED suffices to increase the stability of DDM-solubilized LAT2. The binding of 
4F2hc-ED to the extracellular surface of LAT2 would bury a large hydrophobic patch that would be 
otherwise exposed to solvent, thus reducing aggregation and increasing stability. In addition, the 
compact and thermally stable structure (Tm~59º C) (Turnay et al., 2011) of 4F2hc-ED may have 
additional effects in the improvement of LAT2 stability. 
HATs appeared in metazoans with an ancient heavy subunit that evolved to differentiated 
4F2hc and rBAT in vertebrates (Fotiadis et al. 2013). The fact that LAT2 monomers elicited amino acid 
transport in Pichia cells, which do not express 4F2hc or related proteins, indicates that 4F2hc is not 
required for proper folding of LAT2, as it has been demonstrated for the light subunit b0,+AT in the 
absence of rBAT (Reig et al., 2002). In contrast, 4F2hc and rBAT are necessary for heterodimerization 
and functional expression at the cell surface of its light subunits when expressed in Xenopus oocytes and 
mammalian cells (Fotiadis et al. 2013). Specifically, 4F2hc-ED is necessary for these functions (Fenczik et 
al., 2001 and Bröer et al., 2001). Desolvation of hydrophobic residues might be extended to the 
recognition of other light subunits by 4F2hc. The hydrophobic NIP residues in our docking analysis are 
highly conserved in 4F2hc-associated light subunits, but poorly conserved in cyanobacterial, yeast and 
fungal LATs, which are the closest homologs to vertebrate LATs (up to 37% amino acid sequence 
identity) not interacting with a heavy subunit (Table 6). Hydrophobic NIP residues are largely conserved 
in b0,+AT also (Table 6). Thus, desolvation of hydrophobic residues might also contribute to the binding 
of the ectodomain of rBAT and its light subunit. Indeed, co-transfection of 4F2hc and b0,+AT (i.e., the 
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rBAT-associated light subunit) in mammalian cells yielded functional transporter at the cell surface 
(Rajan et al., 2000). Interaction through a hydrophobic patch looks like a clever solution to glue 4F2hc to 
six different light subunits (LAT1, LAT2, y+LAT1, y+LAT2, asc1 and xCT) that share as little as ~43% amino 
acid sequence identity (Fotiadis et al. 2013). Our work revealed that 4F2hc-ED covers the external face 
of LAT2 increasing transporter stability. The idea of a common hydrophobic patch for subunit 
recognition by 4F2hc is susceptible to future experimental examination.  
An experiment where the NIP residues corresponding to the hydrophobic patch would be 
mutated one by one and in groups with the aim to change the charge properties of the LAT2 surface and 
hence lose the interaction with 4F2hc-ectodomain in a non-disulfide bridge background would be the 
aim for the next steps to confirm the existence of this hydrophobic patch. To demonstrate it, the same 
strategy to check heterodimer formation and functionality would be followed. In addition, heterodimer 
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I. Materials & Methods 
I.1.    Cloning of human 4F2hc and human LAT2 for mammalian cell expression  
Human His-4F2hc (N-terminally tagged) cloned in pcDNA4His-MaxC (Fort et al., 2007) was used. 
The gene encoding human LAT2 was cloned into the EcoRI and XbaI sites of pcDNA3.1+ (Invitrogen) 
using the same fusion protein design (N-terminal Strep II tag-Factor X protease site) as it was done for 
the overexpressed human LAT2 in Pichia pastoris (Costa et al., 2013), since the objective was to perform 
complementing studies in mammalian cells to those obtained in P.pastoris.  Human Strep-TagII-LAT2 (N-
terminally tagged) cloned in pPICZ was subcloned adapting to the mammalian Kozak.  
 
Table 7. Oligonucleotides and PCR conditions to clone human LAT2 into pcDNA3.1+ (Invitrogen). A) 
Oligonucleotides to clone human LAT2 into pcDNA3.1+ are indicated on top (F: forward primer; R: reverse primer). 
EcoRI and XbaI sequences sites were designed according to NEB recommendations to achieve higher digestion rate: 
https://www.neb.com/~/media/NebUs/Files/Chart%20image/cleavage_olignucleotides_old.pdf. StrepIITag, factor X protease 
were exact as for pPICZ (Costa et al., 2013) and Kozack sequence was adapted for human LAT2. B) C) Reaction mix 
and PCR for insert amplification are detailed in the tables below.    
 
Human LAT2 cDNA was amplified by PCR (Polymerase Chain Reaction) using the proofreading 
enzyme Expand High Fidelity Taq polymerase (Roche). The sequence of the corresponding 
oligonucleotides and the PCR conditions are showed in Table 6. To analyze and separate the PCR 
product by size, DNA samples with 6x loading buffer were loaded to agarose gels of 1% (SeaKem LE, 
Lonza) prepared with TAE buffer (40 mM Tris base, 20 mM acetic acid, 1 mM EDTA) and run at 80-100 V 
for ~1 hour. SyberSafe (Invitrogen) at a 1/10,000 dilution was used as intercalating DNA agent to 
visualize the DNA. 1 kb ladder from Fermentas were used to reference our samples. Gels were visualized 
with the GeneGenius Gel Imaging system (Syngene) or with a UV-transilluminator. The PCR product was 
purified from agarose gel using the Gel Band Purification kit (GE Healthcare). 
79 
 
Chapter I: Materials & Methods 
pcDNA3.1+ plasmid and the amplified and purified human Strep-TagII-LAT2 cDNA were 
digested with EcoRI and XbaI restriction enzymes. FastDigest from Thermoscientific or New England 
Biolabs enzymes were used. The first ones digest in 5-15 minutes at 37°C, whereas the second ones 
need longer incubation times, and depending on the enzyme they were kept for 4 hours – overnight at 
37°C. The amounts of DNA, enzymes and buffers used were strictly the ones recommended by the 
manufacturers. 
 To prevent self-annealing of linearized vector prior to the insertion of DNA fragments during 
ligation a phosphatase enzyme was used which dephosphorylate the 5’ and 3’ ends of DNA. To that aim, 
1 µl of calf intestinal alkaline phosphatase (CIP) (Biolabs) was added to the pcDNA3.1+ digestion mixture 
for 1 hour at 37°C. Thereafter, the linearized and dephosphorylated pcDNA3.1+ plasmid was separated 
from the remaining circular DNA by gel electrophoresis and purified using the Gel Band Purification kit 
(GE Healthcare). 
Ligation between the linearized vector and insert was performed using the T4 DNA ligase kit 
from Biolabs following their recommendations and incubating the sample overnight at 16oC. The molar 
ratios used for each DNA were calculated using the NEBioCalculator (http://nebiocalculator.neb.com). 
The ligated product was then transformed using E. coli supercompetent cells by heat shock method. 
XL1 Blue E.coli cells were thawed in ice, 80 µl of competent cells were mixed with the ligation 
mixture and kept on ice during 20 minutes. Heat shock was done at 42oC for 90 seconds, and kept on ice 
for 2 minutes. Then, 900 µl of LB (1% tryptone, 0.5% yeast extract, 0.5% NaCl, pH 7.5) broth media was 
added and incubated for 1 hour at 37oC shaking at 900 rpm. Cell culture was concentrated before 
plating to increase the probability of obtaining positive colonies: the 900 µl of cell culture were 
centrifuged for 3 minutes at 5,000 rpm, discarded 800 µl, resuspended the pellet in the remaining 100 µl 
cell culture and plated into LB plates containing ampicillin (50 μg/mL). Plates were incubated overnight 
at 37oC.  
Colony PCR was used to screen the positive colonies containing the ligated gene of interest. In 
this case, instead of using purified DNA, it was used DNA directly from one bacterial colony which was 
diluted in 20 µl Milli-Q water. Then, a PCR was performed using 1 µl of the dilution as a DNA template, 
LAT2 (EcoRI) F and LAT2 (XbaI) R primers, and Taq DNA polymerase (Biotools). The PCR products were 
analyzed in a 1% agarose gel to check the positive colonies.  
The pcDNA3.1+/Strep-TagII-LAT2 generated construct was sequenced using the BigDye® 
Terminator v3.1 Cycle Sequencing Kit following manufacturer’s protocol. Samples were analyzed by the 
Genomic Unit of the UB Scientific and Technical Services (Parc Científic, Barcelona). LAT2 was sequenced 
with the universal primers T7 promoter and BGH reverse (see Annex I: Molecular Biology, 1.1. 
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I.2.  Generation of cysteine mutants for intersubunit crosslinking by site-directed 
mutagenesis
For crosslinking experiments, the following 4F2hc mutants were generated: S151C, S185C, 
S191C, S195C, S200C, S393C, S412C, S487C, G505C on a 4F2hc C330S or in a 4F2hc C109S/C330S 
background. The 4F2hc C330S and the 4F2hc C109S/C330S cDNA templates were already available in 
the laboratory since they were previously generated on His-4F2hc pcDNA4His-MaxC (Fort et al., 2007). 
Using the pcDNA3.1+/Strep-TagII-LAT2 as a template (see 1.1.), the mutant C210S was firstly generated, 
and using this one as template the following different mutants were produced on a LAT2 C210S 
background: A235C, A315C, G392, S441C, C154S. Secondly, the LAT2 C154S/C210S mutant was created, 
on this background the mutants A235C, A315C, G392, S441C were generated.  
The “QuikChange site-directed mutagenesis” kit (Stratagene) was used to introduce the 
previous site-directed point mutations in human 4F2hc and LAT2, although for the most difficult clones, 
the “QuickChange Lightning site-directed mutagenesis kit” (Stratagene) was used following strictly the 
commercial protocol. The proofreading PfuTurbo DNA polymerase, which replicates both plasmid chains 
with the incorporated mutation, was used. Two synthetic oligonucleotide primers, around 25 
nucleotides long, containing the desired mutation in the middle of the sequence were designed (see 
Annex I: Molecular Biology, 1.2. Mutagenesis oligonucleotides). The DNA templates used were 
pcDNA4His-MaxC/His-4F2hc and pcDNA3.1+/Strep-TagII-LAT2 (see I.1). The PCR program used for that 
aim and the corresponding reaction mixture are described in Table 8.  
Table 8. PCR conditions for site-directed mutagenesis. A) mix conditions used from QuickChange Site-directed 
mutagenesis kit and B) PCR conditions used to generate the different mutants. 
To remove the parental methylated and hemimethylated DNA, 1 µl of Dpn I endonuclease was 
added to the PCR reaction mixture for 1 hour at 37oC, but to avoid not complete digestions it was kept 3 
hours or overnight in some cases, thus, reducing the number of non-positive sequenced colonies. The 
nicked vector DNA containing the desired mutations is then transformed into XL1-Blue supercompetent 
cells (see I.1). Finally, mutants were selected and sequenced (see I.1). 4F2hc was sequenced using D1 
forward and AS4 reverse primers (see Annex I: Molecular Biology, 1.1. Sequencing oligonucleotides).  
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I.3.      Transitory co-transfection in HEK 293T 
Human Embryonic Kidney 293T (HEK 293T) cell line is an adherent cell line that was originally 
derived from human embryonic kidney cells and grown in tissue culture. Nowadays represents one of 
the most used cell lines due to its high rate of transfection and fast growing. Cells were grown with 
Dulbecco's Modified Eagle Media (DMEM; Gibco ®) supplemented with 10% Fetal Bovine Serum (FBS; 
heat inactivated 30 min at 56 °C) and 1x penicillin/streptomycin (100 U/mL) (Gibco), at 37°C and in an 
humidified atmosphere containing 5% CO2. DMEM is a basal medium consisting of amino acids, 
vitamins, glucose, salts, and a pH indicator, which contains no proteins or growth promoting agents. 
Adherent cell lines grow until they cover the available surface area (100% confluence) or 
medium is depleted of nutrients. To maintain HEK 293T cell line, cells were sub-cultured before they 
reach 100% confluence (2-3 times a week) in order to avoid culture damage. To do this, cells were 
detached from the culture dish by trypsinization: removing medium carefully to not detach cells, 
washing with 10 mL of sterile Phosphate Buffered Saline (PBS), treating with 1 mL of trypsin (37°C) 
(Gibco) for 1-5 minutes until cells become into suspension, then the desired medium is added 
(depending on dilution desired) and finally cells are reseeded into new dishes. Mycoplasma tests were 
periodically done in the laboratory to avoid contamination in cell cultures (LookOut mycoplasma PCR 
detection kit). Cells were frozen gradually with 10% DMSO (Sigma Aldrich) until -80 °C or stored in liquid 
nitrogen for long term storage. HEK 293T cultures were manipulated in sterile conditions by using 
laminar flux hoods.  
Cells were transiently transfected at 60-70% cell confluence using polyethylenimine (PEI) in 15 
cm diameter plates with a mixture of DNA containing 15 μg of pcDNA4HisMax/ human 4F2hc mutants, 
and 15 μg of pcDNA3.1+ human/ Strep-TagII–tagged LAT2 (wild type or mutants) (see 1.1 and 1.2). The 
mixture was vortexed for 10 seconds and incubated for 15 minutes at room temperature, finally, it was 
added to the cell culture carefully not to detach cells.  A transfection of a single construct was 
cotransfected with the same amount of the corresponding empty vector DNA. Cell medium was 
replaced 4 hours after transfection.  
I.4.  Protein purification from HEK 293T cells 
Two days after transfection, cells were washed with 10 mL PBS (pH 6.5; this pH is set from the 
beginning of the protocol since it is the optimal for later crosslinking, see 1.5.), scrapped with 1 mL of 
lysate buffer [1% n-Dodecyl-β-D-maltopyranoside (DDM; Anatrace) in PBS (pH 6.5) supplemented with 
Complete EDTA free (Roche)] per 15 cm plate, and transferred into a 1.5 mL Eppendorf tube. Cell 
disruption was facilitated by homogenizing 15 times with a 25 gauge syringe and incubation on a 
rotating orbital shaker at 4°C. After 1 hour, the insoluble material was removed by centrifugation at 
200,000g for 30 minutes at 4°C. A sample of the supernatant was used to quantify protein by the BCA 
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Protein Assay Kit (Pierce), and to analyze the protein expression by Western Blot (see I.6.). 75 µL of this 
sample were stored at −20°C after adding 25 µL of 4xLaemmli sample buffer (277.8 mM Tris-HCl, pH 6.8, 
4.4% SDS, 44.4% (w/v) glycerol, 0.02% bromophenol blue).  
Solubilized proteins were purified in batch by incubating in a rotor for 1 hour at 4 °C the 
supernatants (1 mL) with 150 μL of Ni-NTA-agarose beads (Qiagen), previously equilibrated with 1 mL of 
lysate buffer. Washing was done with 1 mL of lysate buffer containing 25 mM imidazole, and proteins 
were eluted by shaking incubation for 15 min at 4 °C with 250 μL of elution buffer (lysate buffer 
containing 250 mM imidazole).  
I.5.  4F2hc-LAT2 intersubunit crosslinking 
Bis(maleimido)ethane (BMOE; Pierce) and 1,8-bis(maelimido)diethylene glycol [BM(PEG)2; 
Pierce] crosslinkers were selected due to these characteristics: they conjugate sulfhydryl groups (-SH), 
they are not cleavable by reducing agents, and they are the shorter spacer arm length crosslinkers 
available in Pierce with the previous characteristics, of 8 Å and 14.7 Å respectively (according to Pierce 
description). Actually, accurate measures of the lengths of these molecules (Green et al., 2001) showed 
a range of distances between 6.27-10.52 Å and 3.51-14.26 Å for BMOE and BM(PEG)2, respectively 
which make them even more convenient.   
The main objective of the experiment was to determine specific pair residues in 4F2hc and LAT2 
that were close enough to crosslink with BMOE or BM(PEG)2,  and that were located in positions that 
could triangulate with the endogenous disulfide bridge (see figure 40; see Chapter I: Results I.1 for 
detailed Cys residues selection for crosslinking). Thus, the region near the endogenous disulfide bridge 
was not explored since the disulphide bond is already a positive natural crosslinking position between 
both subunits. Crosslinking experiments were done in purified 4F2hc/LAT2 (through His-4F2hc) samples, 
and then the disulfide bridges that were not made through the crosslinker, including the endogenous 
disulfide bridge, were cleaved with reducing agents. Hence, a Western Blot visualizing the StrepII-LAT2 
would show the positive crosslinked pair of mutants in the corresponding molecular weight for the 
heterodimer (see chapter 1: Results I.1). 
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Figure 40. Schematic view of Cys location on 4F2hc/LAT2 heterodimer for crosslinking experiments (left) and 
crosslinkers used (right). On the left, schematic representation of His-4F2hc and Strep-LAT2 linked by the 
endogenous disulfide bridge (-S-S-), and the cysteine targets (yellow stars) candidates to crosslink. In the center and 
on the right, BMOE and BM(PEG)2 (Pierce) molecules are represented respectively. 
 
Once the heterodimers were purified with Ni-NTA, crosslinking protocol was followed. Firstly, 
BMOE or BM(PEG)2 crosslinker 40Mm stocks were prepared by solubilizing in DMSO anhydrous each 
compound (2.2mg BMOE in 0.25mL DMSO, and 3.1mg BM(PEG)2 in 0.25mL DMSO). Then, crosslinking 
buffers were prepared by diluting (1:1) these stocks to a final 20mM concentration by adding 0.25mL of 
lysate buffer (1% DDM in PBS at pH 6.5 supplemented with Complete EDTA free), generating the same 
stock concentration as the Pierce manufacturer suggests, but, diminishing 50% the amount of DMSO, 
which was observed to give better results. 
Then, from the 250 μL of purified protein obtained (see I.4.), 2 μL were used to quantify protein 
by the BCA Protein Assay Kit (Pierce). Protein concentration of all the different conditions tested in a 
same experiment was adjusted to the lower one (around 2.5 μg/μL). Then, 100 μL of the purified protein 
was incubated with 30 μL of the crosslinking buffer [200 μM BMOE or BM(PEG)2  crosslinking buffer] for 
1 hours at 4°C. The crosslinking reaction was terminated by adding 100 mM DTT. Fourfold concentrated 
Laemmli sample buffer was added for Western blot analysis which was run directly on SDS-PAGE to 
avoid losing heterodimer fraction due to aggregation process by freezing and thawing the sample (see 
I.6.) (Hizukuri et al., 2010).  
  
 
I.6.  Western blot analysis 
Western blot was used to detect specifically His-4F2hc and StrepII-LAT2 coming from different 
kinds of samples: from HEK 293T total cell extracts (detergent-solubilized membrane protein) (see I.4), 
from purified and crosslinked protein expressed in HEK 293T cells (see I.5), from P.pastoris total 
membrane protein extracts (see I.9) and from detergent-solubilized P.pastoris membrane proteins (see 
I.10). When it was required, 100 mM dithiothreitol (DTT) was added with the aim to reduce the disulfide 
linkages.  
The samples stored at -20°C with Laemmli sample buffer were preheated at 65°C, and 20 μg 
were loaded into a sodium dodecyl sulphate 8% polyacrylamide gel electrophoresis (SDS-PAGE). Then, 
proteins in the gel were transferred into an activated PVDF membrane (Immobilon-P, Millipore).  
Membranes were blocked with 5% skimmed powder milk or 5% BSA in PBS 0.1% Tween 20, for α-His or 
α-StrepIITag-antibodies, respectively, overnight at 4 °C. Then, membranes were incubated with the 
primary antibody (1:20,000 dilution) of anti–HisG-HRP (Invitrogen) or Strep MAB-Classic-HRP (IBA) for 1 
hour at room temperature. Antibody was reused until signal started to lose (around 10 times). Then, 
three washes of 10 minutes with PBS 0.1% Tween 20 were done to remove unbound primary antibody, 
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and finally, to develop the membrane, it was incubated with enhanced chemiluminescent substrate 
(ECL, Millipore) for detection of horseradish peroxidase (HRP) activity.  
 
I.7.  Transport of L-Alanine in HEK 293T Cells 
Transfected cells (see 1.3.) were scraped and transferred into 24-well dishes previously treated 
with poly-L-lysine (100 μL per well at 0.1 mg/mL for 30 min at 37 °C). One day later, L-alanine transport 
was measured. To this end, cells were washed twice with 2.5 mL of MGA buffer [10 mM Hepes (pH 7.4), 
137 mM N-methyl-D-glucamine, 2.8 mM CaCl2·2H2O, 1.2mM MgSO4·7H2O, 5.4mMKCl] at 37 °C. The 
uptake solution (270 μL per well) contained 50 μM of cold L-alanine plus 0.5 μCi per well of L-[3H]alanine 
(Hartman) in MGA buffer at 37 °C. After the indicated time, uptake was stopped by two washes with 
MGA buffer at 4 °C (2.5 mL per well). Cells were then lysed with 250 μL per well of lysis solution (100 
mM NaOH, 0.1% SDS) by agitation for 30 min at room temperature. Then, 200 μL was used for 
radioactivity counting in a Packard Tri-Carb Liquid Scintillation Counter, and 25 μL duplicates were used 
to determine protein content by the BCA Protein Assay Kit (Pierce). Transport activity was calculated as 
pmol L-Ala/mg protein at 0, 15 and 30 seconds for control conditions. Since at 30 seconds the biggest 
differences were seen, transport activity of all the new mutants generated were measured at 30 
seconds. All the transport conditions were normalized by the corresponding LAT2 transport activity 
(each heterodimer condition compared with its same LAT2 monomer transport). % transport activity 
was calculated comparing with the heterodimer control corresponding to each group. 
 
I.8.  4F2hc-ED overexpression in Escherichia coli and purification 
4F2hc-ED cloned in pTRC-His vector was overexpressed in E.coli BL21 (DE3) cells. E.coli cultures 
were grown at 37°C and 200 rpm until reach a 0.6-0.7 cell density (at 3.5 hours after inoculation). 
Overexpression induction was started by 1mM IPTG addition at 0.6-0.7 cell density. After 16 hours, cell 
culture was pelleted at 3,000g at 4°C for 20 minutes. Pellets were resuspended in lysis buffer (Tris 20 
mM NaCl 150mM, pH 8.0) and frozen at -80°C (Fort et al., 2007). 
Cells were thawed on ice, added complete EDTA free protease inhibitor (Roche) and DNase. 
Cells were then lysed in a continuous flow Cell Disrupter (Constant Systems TS series) in two rounds of 
22 Kpsi, and centrifuged the resulting cell lysate twice at 16,000g for 45 min (to remove the non-lysated 
cells). The soluble fraction was filtered. Purification was performed by using preequilibrated Ni-NTA 
resin, binding in batch, washing with same buffer with 20mM imidazol and eluting with 300mM imidazol 
in the same buffer. The final yield was around 2 mg of 4F2hc-ED/liter of initial culture. Buffer was then 
changed to remove imidazole by centrifugation using Amicon Ultra 15 10,000 Da and protein 




Chapter I: Materials & Methods 
I.9.  Human LAT2 overexpressed in Pichia pastoris membrane obtantion 
Media preparation for heterologous overexpression in Pichia pastoris 
YPD Yeast Extract Peptone Dextrose Medium: 450mL were prepared with 10g peptone and 
5g yeast extract and autoclaved. 50mL of autoclaved 20% dextrose were added previous 
use.  
BMGY Buffered Glycerol-complex medium: 10g of yeast extract, 20g peptone with 700 mL 
deionized water were autoclaved. The same day of use, it was complemented with: 100 
mL 1M phosphate buffer (autoclaved), 100 mL 10% glycerol (autoclaved), 100 mL Yeast 
Nitrogen Base (134g YNB in 1 L deionized water filtered and light protected, 2 mL Biotin 
500x (0.02%) (20 mg biotin in 100 mL deionized water and filtered). 
BMMY Buffered Methanol-complex medium: 10g of yeast extract, 20g peptone in 140 mL of 
deionized water were autoclaved, and, the same day of use, it was complemented with: 
20 mL 1M phosphate buffer , 20 mL 10% methanol, 20 mL YNB and 400 µL biotin 
(0.02%). 
Table 9. Media preparation to overexpress membrane proteins in P.pastoris.  
Human LAT2 (with N-terminal StrepIItag) cloned in pPICZB vector and transformed into 
P.pastoris KM71H strain (Costa et al., 2013) was overexpressed following the next procedure:  firstly, 
5mL of YPD were inoculated from a glycerol of the best selected human LAT2 clone. It was grown at 
30°C, 250 rpm, for 16 hours. Then, 20 µL from the first YPD culture were inoculated into selective 
media: 5 mL of YPD with Zeocin (100 µg/mL) and grown at 30°C, 250 rpm for 16 hours.  
200 µL from the zeocin resistant starter (YPD) were inoculated in 1 L of BMGY, grown at 30°C, 
250 rpm, until culture reaches an OD600 = 2–6 (approximately 16–18 hours). After pelleting at 1,500g 
and 4°C for 5 min, the cells were resuspended in 200 mL buffered complex methanol medium (BMMY) 
to start induction and grown for 72 hours at 30°C. Additional methanol was added after 24 and 48 h to 
a final concentration of 1% (v/v), in order to maintain inducing conditions. Cell were centrifuged  at 
2,500g for 5 minutes at room temperature and cell pellets were resuspended in 50 mM sodium 
phosphate, pH 7.4, 1 mM EDTA, 5% (w/v) glycerol and complete EDTA free protease inhibitors (Roche).  
Cells were then lysed in a continuous flow Cell Disrupter (Constant Systems TS series) in three 
rounds of 25, 35 and 40 Kpsi. After centrifugation at 20,000g and 4°C for 15 min (to remove the non 
lysated cells), supernatant was recovered and ultracentrifuged at 250,000g and 4°C for 1 hour. The 
pellet was resuspended and homogenized (50 mL glass homogenizer) in 20 mM Tris–HCl, pH 7.4, 150 
mM NaCl, 5% glycerol, and ultracentrifuged again. Finally, the membrane pellet was resuspended in 20 
mM Tris–HCl, pH 7.4, 150 mM NaCl, 5% glycerol at a protein concentration between 20 and 25 mg/mL 
(the protein content was determined using the bicinchoninic acid protein (BCA) assay (Pierce)). Aliquots 
of 1 mL were frozen in liquid nitrogen and stored at -80°C until use. 
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I.10.  4F2hc-ED impact on solubilization/stability of LAT2 overexpressed in P.pastoris
To solve the question whether 4F2hc-ED interacts with LAT2, and whether it has a stabilizing 
role on LAT2, several experiments were designed to address this issue. In all of them, purified 4F2hc-ED 
was added in exceed to P.pastoris membranes overexpressing human LAT2 and mixed overnight. Next 
day sample containing 4F2hc-ED addition and sample without 4F2hc-ED were detergent-solubilized, and 
removed the aggregated protein by ultracentrifugation. Afterwards by western blot or Fluorescence Size 
Exclusion Chromatography (in the case of LAT2-GFP overexpressed (see 2.4)) the remaining soluble LAT2 
was analyzed.   
In all the experiments, 2 mg/mL of purified 4F2hc-ED in 20 mM Tris·HCl (pH 7.4), 150 mM NaCl 
(see 2.1) or just the same volume buffer where mixed with P.pastoris membranes overexpressing LAT2 
(total membrane protein 20 mg/mL) on a rotating orbital shaker overnight at 4ºC. The final 
concentration of 4F2hc-ED was 1mg/mL. 2 mg/mL of Bovine Serum Albumin (BSA, Sigma) was added, 
instead of 4F2hc-ED, in the same buffer as a negative control condition, in order to check whether the 
possible 4F2hc-ED impact on LAT2 is exclusive.  
In a first experiment, after 4F2hc-ED/Pichia membranes overnight incubation, three different 
decreasing concentrations of DDM were tried for LAT2 solubilization (1, 0.5 and 0.25%) to detect a more 
dramatic effect in case there was. Samples were solubilized for 1 h at 4°C and aggregates were removed 
by ultracentrifuged at 200,000g for 1 h. Supernatant samples (100 µL) were mixed with 4xLaemmly 
sample buffer and stored at -20°C. For protein stability analysis, the sample solubilized with 1% DDM 
was considered time 0. The rest of supernatant was kept 2, 24 and 72 hours previous a second 
ultracentrifugation. Again, supernatant samples (100 µL) were stored with 4xLaemmly sample buffer at -
20°C. All samples were analyzed by western blot visualizing human StrepTagII-LAT2 by using the Strep 
MAB-Classic-HRP antibody (IBA) (see 1.6). 
I.11.  Bioinformatic tools 
- Uniprot was used to find the amino acid sequence of the different HAT studied. 
- Protein published 3D structures were searched in the Protein Data Bank (http://www. pdb. org), 
- The PyMOL Molecular Graphics System (http://www. pymol. org) was used to visualize and 
generate the different figures of the 3D structures and models of HAT studied. 
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The second part of the thesis was focused on finding a more stable eukaryotic light subunit 
than human LAT2, which could be suitable for 3D-crystallization studies. In the first Chapter, it was 
shown that purified human LAT2 alone with DDM is highly unstable and aggregates. On the other hand, 
a clear stabilizing effect of the heavy subunit 4F2hc on this light subunit was observed when co-
expressed and purified as a heterodimer. Unfortunately, this effect was not sufficient to make the 
heterodimer 4F2hc/LAT2 suitable for 3D crystallization studies. Nevertheless, if we would succeed in 
finding a more stable light subunit, when trying the co-expression with its respective heavy subunit we 
would expect an increase of the heterodimer stability. In addition, the already 4F2hc-ED solved crystal 
structure (Fort et al., 2007), would help us to solve the structure of the corresponding heterodimer. 
Obtaining high-resolution membrane protein structures is still a difficult challenge that requires 
overcoming many difficulties: protein overexpression, detergent solubilization, and purification of stable 
and active membrane protein at high concentrations. Finally, even if pure and stable protein could be 
obtained, yet crystallization would not be certain. Nevertheless, over the last years novel strategies and 
improvement of crystallization technologies have raised the probability of success.  
In our project we integrated several of the strategies commonly used to identify and optimize 
membrane protein targets for 3D crystallization. To mention some, it has been tried: different 
eukaryotic expression systems depending on the final goal: Saccharomyces cerevisiae, Pichia pastoris or 
Sf9 Insect cells; different detergents that have been successful in membrane protein crystallography; the 
addition of cholesterol and lipids; the elimination of the reactive cysteines to decrease the aggregation 
of the protein and the generation of truncation forms of the protein to reduce the flexibility and, hence, 
improve the chances of crystallizing it.  
- Strategy to find a more stable light subunit than human LAT2 
To identify a more stable eukaryotic light subunit than human LAT2, firstly different light 
subunits from different species were selected for the study. To speed up the process, it was adapted the 
pipeline developed by Dr. Drew from So Iwata laboratory (Imperial College London, Diamond Light 
Source) to achieve a fast screen of the expression levels and stability of eukaryotic membrane proteins. 
This high throughput screening is based on the overexpression in the baker yeast S. cerevisiae the 
protein candidates as GFP fusion proteins (Drew et al., 2008).  
The biggest advantage of this pipeline is the introduction of the GFP-fusion protein technology. 
This strategy allows: 1) to rapidly screen the protein overexpression levels by measuring the whole-cell 
fluorescence, which is specific and sensitive down to 5 ng; 2) thanks to the property of the GFP to 
remain folded in SDS, the integrity of the fusion protein can be detected after SDS-PAGE by in-gel 
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fluorescence; 3) to fast screen the detergent solubilization efficiency and 4) to monitor the 
monodispersity of recombinant proteins in different detergent-solubilized membranes by Fluorescence 
Size Exclusion Chromatography (FSEC) (Kawate and Gouaux, 2006) (Figure 41). In fact, the GFP 
technology could be adapted for other eukaryotic expression systems, as it has been done for P. pastoris 
(Mizutani et al., 2011), and insect cells (Baconguis et al., 2014).  
The best advantage of the GFP-tag is the possibility to monitor at the first step the 
monodispersity of the sample in detergent-solubilized membranes by FSEC without the need to purify 
the protein. Symmetry and broadness of the peak obtained in FSEC indicates how homogeneous is the 
oligomeric state of the protein. This technology was developed in the laboratory of Dr. Gouaux (Howard 
Hughes Medical Institute (HHMI) and Oregon Health & Science University (OHSU)) as a pre-
crystallization screening tool due to different advantages: it is time saving and low resource consuming, 
it requires little amount of sample, and it gives an initial and useful information of the quality of the 
membrane protein produced (Kawate and Gouaux, 2006).  
Figure 41. Advantages of the expression of GFP-tagged membrane proteins. Scheme representing the main 
advantages that allow to screen faster membrane proteins using the GFP-fusion protein technology (adapted from 
Kawate and Gouaux, 2006; Drew et al., 2008). 
In addition, S. cerevisiae proves to be the most suitable expression system to screen large 
amounts of eukaryotic membrane proteins (Drew et al., 2008; Scharff-Poulsen and Pedersen, 2013; 
Parker and Newstead, 2014) because the cloning by homologous recombination and the expression 
screenings are less time consuming in comparison with other eukaryotic expression systems such as P. 
pastoris, insect cells or mammalian cells. Moreover, Saccharomyces have similar protein synthesis 
mechanisms, maturation machinery (such as disulfide bond formation or glycosylation) and membrane-
trafficking pathways as mammalian cells. Furthermore, it has a highly regulated quality control system of 
membrane proteins in the endoplasmic reticulum. On the other hand, growing Saccharomyces is fairly 
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simple and cheap compared to other eukaryotic expression systems. Nevertheless, the differences in 
glycosylation patterns, in lipid membrane composition or lack of cholesterol may compromise in some 
cases the protein folding and function, or the expression levels. In these cases, it would be required to 
try other expression systems. 
 Interestingly, some groups have been successful in determining high-resolution structures of 
eukaryotic membrane proteins using this expression system. Some examples are: the human 
monoamine oxidase A at 2.2 Å (Se-Young Son et al., 2008), the fungal (Piriformospora indica) high-
affinity phosphate transporter at 2.9 Å (Pedersen et al., 2013), the Arabidopsis thaliana H+-ATPase at 3.6 
Å (Pedersen et al., 2007), the rabbit sarcoplasmic-endoplasmic reticulum Ca+2-ATPase isoform 1a 
mutants D351A and P312A, obtained at 3.4 Å and 3.5 Å, respectively (Marchand et al., 2008); the S. 
cerevisiae cytochrome bc(1) complex at 2.3 Å (Hunte et al., 2000), the S. cerevisiae c10 ring of the ATP 
synthase at 2.0 Å (Pagadala et al., 2011; Symersky et al., 2012), the Vigna radiate H-translocating M-
PPase at 2.35 Å (Lin et al., 2012) or the S. cerevisiae vacuolar calcium/proton exchanger at 2.3 Å (Waight 
et al., 2013).  
- Improvement of membrane protein environments by detergents, cholesterol and lipids 
Being successful in crystallization of membrane proteins requires the identification of 
detergents capable of maintaining the protein in a soluble and monodisperse state.  Because of their 
hydrophobic nature, membrane proteins tend to form insoluble aggregates over time which reduces the 
probability of forming regular associations of proteins that are essential to form crystal lattices. 
Detergents provide convenient means for extracting membrane proteins but they poorly mimic the 
native membrane. Detergents should cover all the hydrophobic regions of the membrane protein once it 
is solubilized. This step seriously compromises the stability of this kind of proteins. At the moment, there 
is not any detergent that works for all the membrane proteins yet. For that reason, a careful selection of 
a variety of detergents is needed to find the more suitable one for each protein, since the solubilized 
proteins have to maintain their structural and functional properties and have to allow the generation of 
high quality crystals for X-ray diffraction.  
Addition of cholesterol in the salt form cholesteryl hemisuccinate tris salt (CHS) during 
solubilization; furthermore, purification has been demonstrated to improve eukaryotic membrane 
proteins stability, especially in the case of the overexpressed proteins in S. cerevisiae, that lacks 
cholesterol in its membrane (Yao and Kobilka, 2005; Drew et al., 2008). The use of cholesterol during 
purification and/or crystal screenings have led to solve crystal structures of eukaryotic proteins like the 
human Histamine H1 receptor complex with doxepin (Shimamura et al., 2011).  
Interestingly, some eukaryotic membrane protein structures have been solved with a 
cholesterol molecule inserted between their transmembrane domains. This is the case of the Drosophila 
Dopamine transporter (DAT) (Penmatsa et al., 2013), or the crystal structure of the human β2-
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adrenergic receptor–T4 lysozyme fusion protein (Cherezov et al., 2007). In the case of DAT, 0.1 mM CHS 
was added in the elution step, and in the second case, crystals were grown from a cholesterol-doped 
monoolein cubic phase. In addition, a palmitic acid was found in the structure of β2-adrenergic receptor 
(Cherezov et al., 2007). These are some evidences of the importance of cholesterol and lipids to 
maintain the native structure of membrane proteins, increase their stability and keep them functional.  
The use of synthetic lipids to stabilize eukaryotic membrane proteins has become of common 
use in the recent years (lipids can be added during the solubilization, purification or in the crystallization 
conditions) since it has been demonstrated in many cases their stabilizing effect on the protein. In 
parallel, different new crystallographic techniques have been developed which require the use of lipids 
to form ordered lipidic structures containing the membrane protein. Some of these specific 
crystallographic techniques for membrane proteins are: HiLiDe (Gourdon et al., 2011), Lipidic Cubic 
Phase (Caffrey et al., 2009) and Bicelles (Faham et al., 2002; Agah and Faham, 2012). Some examples of 
structures that have been solved with addition of lipids are the Drosophila Dopamine transporter (DAT) 
(Penmatsa et al., 2013), or the chicken acid-sensing ion channel 1-snake toxin complex (Baconquis et al., 
2014).  
- Choosing the best expression system: 
S. cerevisiae is a great expression system to fast screen a big number of membrane protein 
candidates and to identify putative good solubilization and stability conditions. The protein expression 
levels using this yeast are not usually very high. To overcome this problem, other expression systems are 
needed in order to increase the production of the identified target in Saccharomyces, but taking 
advantage of the optimized stability conditions using Saccharomyces.  
P. pastoris has been successful for more than 15 eukaryotic membrane protein structures. One 
of its major advantages is that it usually produces higher expression levels than other eukaryotic 
expression systems. Some examples are: the human AQP2 Aquaporin from kidney at 2.75 Å (Frick et al., 
2014), the human Leukotriene LTC4 Synthase at 2.75 Å (Niegowski et al., 2014), the human Glioma 
pathogenesis-related protein 1 at 2.2 Å (Asojo et al., 2011) or the rat voltage gated potassium channel 
subunit β2 at 2.9 Å (Tao et al., 2010). 
Insect cells result of special interest since it has been the most successful expression system 
used to solve the 43% of high resolution structures of eukaryotic membrane proteins, especially from 
human (Parker and Newstead, 2014). This fact could be probably due to its ability to produce stable 
proteins in high quantities. Some examples are: the human β2-adrenergic receptor–T4 lysozyme fusion 
protein at 2.4 Å (Cherezov et al., 2007), the human β2 adrenergic G-protein-coupled receptor at 3.4 Å 
(Rasmussen et al., 2007), the human A2A adenosine receptor at 2.6 Å (Jaakola et al., 2008), the human 
CXCR4 chemokine receptor at 2.5 Å (Wu et al., 2010), the human Dopamine D3 receptor at 2.89 Å (Chien 
et al., 2010), the human Sphingosine 1-phosphate receptor at 3.35 Å (Hanson et al., 2012), the human 
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M2 muscarinic acetylcholine receptor at 3.0 Å (Haga et al., 2012),  the human κ-opioid receptor at 2.9 Å 
(Wu et al., 2012), the human 5-HT2B serotonin receptor at 2.7 Å (Wacker et al., 2013), the human BK 
(SLO1) Channel Ca2+-activation apparatus at 3.0 Å (Yuan et al., 2010), the human microsomal 
prostaglandin E synthase 1 at 1.16 Å (Sjögren et al., 2013) or the human GLUT1 N45T/E329Q mutant at 
3.17 Å (Deng et al., 2014). 
Only a few structures have been obtained so far in mammalian cells due to its expensive costs. 
Some examples are: the Drosophila melanogaster Dopamine transporter at 3.0 Å (Penmatsa et al., 
2013), the human Rh C glycoprotein ammonia transporter at 2.10 Å expressed in HEK293S cells 
(Gruswitz et al., 2010) or the human GABAAR receptor (β3 homopentamer) at 2.97 Å expressed in 
HEK293F cells (Miller et al., 2014).  
The variety of aforementioned methods and technologies made possible to find a good light 






II.2.  Protein expression screening in Saccharomyces cerevisiae 
In order to find a more suitable HAT than human 4F2hc/LAT2 for 3D-crystallization trials our 
first aim was to find a more stable light subunit than human LAT2. Afterwards, the corresponding heavy 
subunit would be co-transformed and the stability of the heterodimer tested, if formed. We would 
expect to see an increase of the light subunit stability when adding the heavy subunit as it was observed 
in the case of human 4F2hc/LAT2 (see Chapter I). 
To that aim, 24 eukaryotic light subunits belonging to different species, including human, where 
pre-selected to be cloned and expressed as GFP fusion proteins (table 10) in the baker’s yeast S. 
cerevisiae. The corresponding cDNAs were cloned into pDDGFP-2 vector; then, transformed into S. 
cerevisiae cells (strain FGY217) and finally their expression was tested (see Chapter II: Materials & 
Methods II.1-4). 
asc1 LAT1 LAT2 y+LAT1 y+LAT2 xCT Mnd Jhl-21 b0,+AT 
Homo sapiens (Human) X X X X X X X 
Mus musculus (Mouse) X X X X X X 
Rattus norvegicus (Rat) X 
Bos taurus (Cow) X X 
Xenopus tropicalis1 / laevis2 (Toad) X2 X2 X2 X2 X1 
Danio rerio (Zebrafish) X 
Drosophila melanogaster (Fly) X X 
Table 10. Eukaryotic light subunits included for the expression screening in Saccharomyces. 24 eukaryotic light 
subunits from different species were selected for the expression screening (human, Homo sapiens; mouse, Mus 
musculus; rat, Rattus norvegicus; cow, Bos taurus; toad, Xenopus laevis and Xenopus tropicalis; Zebrafish, Danio 
rerio and fly, Drosophila melanogaster). b0,+AT is the only light subunit of the screening that forms heterodimers 
with rBAT and not with 4F2hc in vivo. Drosophila melanogaster Mnd and Jhl-21 transporters are homologues of 
human system L (Reynolds et al., 2009). 
The expression levels of the different eukaryotic light subunits were established by measuring 
the whole-cell fluorescence in small scale cell cultures 22 h after protein expression and induction with 
2% galactose (see Chapter II: Materials & Methods II.4). Only those light subunits with a fluorescence / 
absorbance ratio 5-fold or higher than the one of the yeast transformed with the empty vector (Figure 
42) were selected as good targets.
In this first step, 14 eukaryotic light subunits were discarded for not reaching the minimum 
expression levels required for this project. These proteins were: asc1 (from human and mouse), LAT1 
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(from human and mouse), y+LAT1 (from mouse and toad), y+LAT2 (from human, mouse and toad), xCT 
(from mouse), Mnd (from fly) and b0,+AT (from human, rat and cow). 
Figure 42. Selection of eukaryotic light subunits after expression screening in S.cerevisiae. A) List of the light 
subunits selected for overexpressing over the cut off (5 fold the negative control). Overexpression levels are 
measured by fluorescence (RFU) / final absorbance at 600 nm (Abs600 nm). B) Graphic representing the RFU/Abs600 
corresponding to the selected light subunits. The line indicates the cut-off at 5 fold background signal.  
After selecting the best candidates with the previous criteria, the amount of overexpressed 
protein related to the fluorescent measurements (Figure 43) was quantified. To that aim, cell culture 
expression of each selected protein was scaled up to 1 L. A stock of purified yEGFP from Pichia pastoris 
previously generated by Dr. Rosell and stored at -80 °C (Figure 43A) was used to prepare a yEGFP 
standard to determine the mg of expressed membrane protein fused to GFP for each candidate (Drew et 
al., 2008) (see Chapter II: Materials & Methods, II.4). The mg of GFP-tagged light subunit produced per 
liter of cell culture ranged from 0.5 to almost 5 (Figure 42B). 
Figure 43. Determination of the amount of GFP-tagged light subunits produced in Saccharomyces. A) Purified 
yEGFP run in a SDS-PAGE, 10% polyacrylamide gel and stained with Comassie. B)  Graphic indicating the mg of 
expressed GFP-tagged light subunits per liter of cell culture.   
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As a result of the quantification studies, LAT2 (Xenopus laevis) was the light subunit with the 
best expression levels (4.5 mg/L), followed by b0,+AT (Xenopus tropicalis) (2 mg/L) and LAT2 (mouse and 
human) (1.8 mg/L) (Figure 43B). Interestingly, LAT2 from three different species has been well 
overexpressed in S. cerevisiae as it was human LAT2 in P. pastoris compared to the rest of light subunits 
(Costa et al., 2013).  
To evaluate the integrity of the GFP fusion proteins, SDS-PAGE in-gel fluorescence of crude-cell 
membrane extracts overexpressing the 10 selected light subunits was performed (Figure 44). The 
presence of free GFP may indicate proteolysis or problems during the translation process of the 
recombinant fusion-protein. Fortunately, all the different light subunits showed the expected molecular 
weight in the in-gel-fluorescence, indicating that there were no proteolysis or translation protein 
problems, probably due to the fact of GFP presence in the C-terminal and not in the N-terminal (Drew et 
al., 2008). On the other hand, this result is important since it assures that the measured fluorescence in 
the whole cell culture to quantify the expression levels is directly measuring the overexpressed protein 
and not free GFP. 
Figure 44. In-gel fluorescence of crude cell membrane extracts overexpressing GFP-tagged eukaryotic light 
subunits. The integrity of xCT (human), LAT2 (human), LAT2 (mouse), b0,+AT(toad), Jhl-21 (fly), y+LAT1 (zebrafish) 
and LAT2 (toad) was analyzed by in-gel fluorescence. All light subunits presented the expected molecular weight 
(~35 kDa + 29 kDa corresponding to the GFP fusion protein). In all the cases, only monomer were present, with the 
exception of LAT2 (toad) that presents dimer forms, and some aggregates. 
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II.3.    Membrane protein-detergent solubilization screening 
The ten light subunits showing the highest expression levels (II.2) were solubilized with 13 
detergents of different characteristics and length that were selected for their relevance in membrane 
protein crystallography (Table 11). To that aim, 1 L cell culture of each light subunit were grown, and the 
resulting cell crude membrane extract was divided in 1 mL stocks to test the 13 different detergents 
from the same batch cell culture.  
Table 11. List of detergents selected for the eukaryotic light subunit solubilization screening. The detergents used 
to perform the solubilization efficiency screening for the selected light subunits belonged to two different families: 
non-ionic detergents (cymal-6, cymal-7, NM, DM, DDM, OG, NG) and zwitterionic detergents (DDAO, LDAO, LAPAO, 
Fos-9, Fos-12, C12E8).  
In all the cases, crude cell membranes were solubilized to a final total membrane concentration 
of 3 mg/mL with 1% (w/v) detergent. The solubilization efficiency was calculated by using the GFP 
fluorescence values obtained from the detergent-solubilized membranes and the non-solubilized 
material (see Chapter II: Materials & Methods, II.6).  
The cut-off value to select the more suitable detergent for each protein was determined at 40% 
solubilization yield. In this screening, 62 conditions fitted the cut-off from the total of 130 conditions 
tested. A protein was discarded, y+LAT1 (from cow), since no detergent achieved to solubilize it over the 
cut-off (Table 12). In addition, two detergent conditions were discarded: octyl glucoside (OG) and 
foscholine-9 (Fos-9) because they were not able to solubilize any of the light subunits tested. 
Thereafter, cholesterol effect in the detergent solubilization yield was tested on the 62 
successful solubilization conditions. For all the conditions tested, 0.2% (w/v) cholesteryl hemisuccinate 
Tris salt (CHS) was added to the 1% (w/v) detergent. Cholesterol effect was tested since it was already 
described to have a stabilizing role on eukaryotic membrane proteins and it helps to increase the 
solubilization efficiency (Drew et al., 2008). In our study, even though cholesterol effect on solubilization 
efficiency is modest, it produces an improvement in the solubilization of the protein in 49 out of the 62 
conditions tested (Table 13). 
Non-ionic detergents Zwitterionic detergents 
6-cyclohexyl-1-hexyl-β-D-maltoside (Cymal-6)  N,N-dimethyldodecylamine N-oxide (DDAO) 
7-cyclohexyl-1-heptyl-β-D-maltoside (Cymal-7) 
Nonyl maltoside (NM)  
Lauryl dimethylamine N-oxide (LDAO)  
3-dodecylamido-N,N′-dimethylpropyl amine oxide (LAPAO) 
Decyl maltoside (DM)  Foscholine-9 (Fos-9) 
Dodecyl maltoside (DDM)  Foscholine-12 (Fos-12) 
Octyl glucoside (OG) Octaethylene glycol monododecyl ether (C12E8) 
























OG  <20% <20% <20% <20% <20% <20% <20% <20% <20% <20% 
NG 50% <20% <20% <20% <20% <20% <20% <20% <20% <20% 
NM 40% <20% <20% <20% <20% <20% 40% <20% 50% <20% 
DM 50% 40% 50% <20% <20% <20% 40% <20% 50% <20% 
DDM 50% 50% 50% 40% 40% <20% 50% 40% 50% <20% 
Cymal-6 50% 50% 50% <20% 40% <20% 40% <20% 40% <20% 
Cymal-7 <20% 50% 50% <20% <20% <20% 50% <20% 50% <20% 
Fos-9 <20% <20% <20% <20% <20% <20% <20% <20% <20% <20% 
Fos-12 <20% 50% 50% 50% 50% 50% <20% <20% 50% <20% 
DDAO 80% 40% 70% 40% 40% <20% 40% 40% 50% <20% 
LDAO <20% 50% 50% 50% 50% <20% 50% 50% 50% <20% 
LAPAO 90% 80%  90% 60% 90% 40% 80% 60% 80% <20% 
C12E8 50% 50% 50% <20% <20% <20% 50% <20% 50% <20% 
Table 12. Screening of the most suitable detergents to solubilize each of the light subunit candidates by analyzing 
its solubilization efficiency. All the selected light subunits were detergent-solubilized with the non-ionic (OG, NG, 
NM, DM, DDM, Cymal-6 and Cymal-7) and zwitterionic detergents (Fos-9, Fos-12, DDAO, LDAO, LAPAO and C12E8) 
indicated in the table. Only conditions with 40% or higher solubilization efficiency were selected as good candidates 
(colored in grey gradient, being darker grey those conditions with higher solubilization efficiency). 68 detergent 
conditions were discarded in this screening. OG and Fos-9 detergents were not able to solubilize efficiently in any 
case.  
Table 13. Effect of cholesterol hemissucinate Tris salt (CHS) on detergent solubilization efficiency. Cholesterol 
effect was tested on the 62 previously selected conditions (Table 12). Conditions where the addition of CHS 
improved the solubilization yield are colored in grey (49 conditions from 62 did improve with cholesterol addition). 
No differences were observed (N.D.). Discarded conditions (d.c) in the previous screening were not tested with CHS.  





















OG  d.c d.c d.c d.c d.c d.c d.c d.c d.c d.c 
NG 11 d.c d.c d.c d.c d.c d.c d.c d.c d.c 
NM 10 d.c d.c d.c d.c d.c 10 d.c 12 d.c 
DM 15 10 10 d.c d.c d.c 17 d.c 16 d.c 
DDM N.D. 11 10 10 10 d.c 16 25 17 d.c 
Cymal-6 10 N.D 10 d.c N.D. d.c 10 d.c N.D d.c 
Cymal-7 d.c 13 13 d.c d.c d.c 12 d.c 10 d.c 
Fos-9 d.c d.c d.c d.c d.c d.c d.c d.c d.c d.c 
Fos-12 d.c 16 18 15 14 64 d.c d.c 16 d.c 
DDAO 12 10 12 N.D 11 d.c 19 11 12 d.c 
LDAO d.c 12 15 16 17 d.c 14 15 14 d.c 
LAPAO N.D N.D 10 N.D N.D. 25 N.D. N.D N.D d.c 
C12E8 12 10 N.D d.c d.c d.c 10 d.c 10 d.c 
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II.4.   Membrane protein stability screening by the Ultracentrifugation 
Dispersity Sedimentation assay 
To get some information about the effect of the detergent conditions previously selected on 
the stability of our light subunit candidates, firstly we performed a stability study by the 
Ultracentrifugation Dispersity Sedimentation Assay (UDS; Gutmann et al., 2007). UDS is faster and 
requires less use of detergent buffer than other methods which is a great advantage to screen a big 
number of conditions. 
Then, UDS assay was tested in all detergent conditions that did solubilize the eukaryotic light 
subunits, with or without cholesterol, in a yield higher than 40%. In this method, the detergent 
solubilized-protein was kept overnight at 4 °C, ultracentrifuged at 80,000 rpm and the % of remaining 
solubilized protein compared to the initial one analyzed (see Chapter II: Materials & Methods, II.7). In 
the graphics from Figure 45 the average of 3 experiments per condition is represented. The cut-off value 
applied in this step was 80% of soluble protein after 16 h at 4 °C.  
From the 124 detergent conditions (with and without CHS) tested using the UDS method, 59 
conditions were discarded because they did not fulfilled the cut-off requirement. From the discarded 
conditions, 44 did not have cholesterol and 15 did have. Even though UDS technique made possible to 
identify detergent conditions able to decrease the kinetic aggregation of light subunits, it does not 
provide information about the quality of the remaining soluble protein. To evaluate the quality of the 8 
remaining transporters, we studied the monodispersity of these proteins in the selected detergent 
conditions by Fluorescence Size-Exclusion Chromatography (FSEC) (Kawate and Gouaux, 2006).  
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Figure 45. Analysis of the stability of the eukaryotic light subunits by the UDS assay. All the detergent conditions 
selected previously were tested with and without CHS addition. Graphic bars show eukaryotic light subunit % 
stability after UDS assay. The cut-off of this screening was 80% of remaining soluble protein after 16 h at 4°C.
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II.5. Light subunit monodispersity study by Fluorescent Size-Exclusion 
Chromatography (FSEC)
Only those conditions with 80% or more of remaining soluble protein after UDS assay were 
tested for FSEC assay stability (see Chapter II: Materials & Methods, II.8) which allows to assess the 
monodispersity of the overexpressed and solubilized protein without the need of purifying it.  
At the beginning of the study of the stability of these transporters analyzed by FSEC, all the 
conditions obtained in the previous step (Figure 45) were selected. However, after observing a clear 
improvement of those conditions which cholesterol was added compared to those without cholesterol 
(Figure 46), it was decided to continue the rest of FSEC screening only with detergent + cholesterol 
conditions. Stability improvement on eukaryotic membrane proteins after cholesterol addition has been 
described in other cases (Penmatsa et al., 2013; Drew et al., 2008). 
 Impact of cholesterol on light subunits 
Figure 46. FSEC profiles showing the effect of cholesteryl hemisuccinate Tris salt (CHS) on the monodispersity of 
some eukaryotic light subunits of HATs. 4 different light subunits solubilized with 4 different detergents at 1% (w/v) 
were analyzed by FSEC without (in red line) or with 0.2% (w/v) CHS (blue dot line). Thereafter, the FSEC profiles 
were superposed to compare the impact of cholesterol on each protein. In all the conditions cholesterol addition 
improves the stability of the light subunit. RFU: Relative Fluorescence Units. 
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In Figure 47 the FSEC profiles corresponding to all the detergent/cholesterol conditions tested for the 
different proteins are presented. Conditions highlighted with an asterisk indicate that those conditions were 
considered good enough to pass to the next step of the project consisting on studying their behavior by size 
exclusion chromatography (SEC) after purification, tag removal and concentration. 
LAT2 (Xenopus laevis) 
xCT (Homo sapiens) 
LAT2 (Homo sapiens) 
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LAT2 (Mus musculus) 
y+LAT1 (Homo sapiens) 
y+LAT1 (Zebrafish) 
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Figure 47. FSEC profiles of light subunits solubilized with the detergent/cholesterol conditions selected by UDS. 
All proteins were solubilized with 1%Detergent/0.2%Cholesterol at a final protein concentration of 3 mg/mL for 1 
hour. Samples were ultracentrifugated at 250,000g for 1 hour and 500 µL were injected to Superose 6 previously 
equilibrated with 0.03% DDM. Detergent conditions marked with an asterisk were selected for the next step of the 
project.   
b0,+AT (Xenopus tropicalis) 
 





Finally, 20 different detergent conditions and 6 light subunits were selected in this screening 
step, in which cholesterol was present in all of the conditions. These proteins were: LAT1 (from 
Xenopus), LAT2 (from Xenopus, human and mouse), y+LAT1 (from Zebrafish) and b0,+AT (from Xenopus). 
On the other hand, xCT (Human), Jhl-21(Drosophila) and y+LAT1(Human) were discarded due to their 
non-monodisperse FSEC profiles.  The effect of cholesterol stabilizing eukaryotic membrane proteins 
has been found in many proteins (Drew et al., 2008).  
II.6. Protein purification and size exclusion chromatography analysis 
The 20 different conditions and the 6 different light subunits selected in the previous FSEC 
screening were overexpressed at large scale to screen their monodispersity by SEC after purification, tag 
removal and concentration for protein crystallization (see Chapter II: Materials & Methods, II.9). In all 
the cases it was used an equivalent start amount of total membrane protein ~250 mg, in order to follow 
the same protocol for the 20 conditions. The six light subunits were solubilized using 1% detergent and 
0.2% CHS, and purified by Immobilized Metal ion Affinity Chromatography (IMAC) using nickel resin. 
Some steps were optimized to minimize protein loss. Firstly, 20 mM Tris, 150 mM NaCl buffer resulted 
better compared to others like PBS, but a further screening could be done. Protein binding was 
performed in batch, since it resulted in higher amount on attached protein than in gravity column. 
Washes were reduced to 2 without affecting protein purity, to avoid losing too much protein. Finally, 
250 mM imidazole was enough to elute the protein reducing the time and protein manipulation when 
changing the buffer. Protein was eluted, concentrated and digested overnight with recombinant TEV 
protease at a 1:1 protein:protease ratio. TEV protease with a Hisx6 tag was produced and purified in the 
laboratory. Stocks at 2 mg/mL were stored at -80 °C (Figure 48) (see Chapter II: Materials & Methods, 
II.9.a).  
Figure 48. SDS-PAGE Comassie staining of recombinant His6-TEV protease produced in E. coli and purified by 
nickel affinity chromatography. A double band at 25-27 kDa is observed corresponding to the autoproteolytic 
activity of this TEV version.  
Nevertheless, it was later replaced for a more efficient version of recombinant TEV produced by 
the Protein Expression IRB Core Facility, which cut 5-fold more the different light subunit-GFP fusion 
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proteins. It was noticed that the first recombinant TEV used was sensitive to imidazole; thus, in the 
previous digestions the buffer was thereafter replaced using a centricon of 100 kDa cut-off. In some 
occasions, low TEV digestion was observed presumably due to the presence of soluble protein 
aggregates. Afterwards, reverse IMAC was performed to eliminate the free GFP-His8 tag resulting from 
the protease digestion, as well as non-digested protein and the His6-TEV. During the purification the 
detergent, concentration was reduced to 3 times the critical micellelar concentration (CMC) of the 
corresponding detergent and the cholesterol amount was decreased as well to keep a 5:1 
detergent/CHS ratio. The cleaved and purified protein was concentrated to ~ 4 mg/mL and then, 
injected into a Superdex 200 5/150 column (see Chapter II: Materials & Methods, II.9).  
Finally, b0,+AT, LAT1 and LAT2, all from Xenopus sp., showed promising SEC monodispersity 
profiles, being b0,+AT the best profile when purified with DDM/CHS. The three best protein candidates 
with each corresponding best detergent condition are shown: b0,+AT (DDM/CHS), LAT1 (Cymal-6/CHS) 
and LAT2 (Foscholine-12/CHS) in Figure 49. 
Figure 49. Size Exclusion Chromatography profiles and SDS-PAGE analysis of the best light subunits candidates 
after purification, tag removal and SEC monodispersity analysis using Superdex 200 5/150 column: LAT2 (Xenopus 
laevis) purified with foscholine-12 and CHS; LAT1 (Xenopus laevis) purified with cymal-6 and CHS; and b0,+AT 
(Xenopus tropicalis) purified with DDM and CHS.  (x axis: absorbance at 280nm (mAU); y axis: volume (mL)).
In all the cases, three different peaks were detected: the first one corresponding to the void 
(aggregated protein), the second one to the soluble transporter, and the last one to 
detergent/cholesterol micelles. It is worth mentioning that in those samples analyzed by tryptophan 
fluorescence size exclusion chromatography the third peak does not appear, indicating that it is not a 
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protein peak. The protein corresponding to the pure protein was quantified, and the yield was 
calculated per liter cell culture. In the case of b0,+AT (DDM/CHS): 0.1 mg/L; LAT1 (cymal-6/CHS) 
0.133mg/L and in the case of LAT2 (foscholine-12/CHS): 0.25 mg/L were obtained. 
Although foscholine-12 was included in the screening since it is a common detergent used for 
this kind of tests and it was started to be used in crystallography screenings as well, we discarded this 
condition since Professor Gouaux, collaborating group (Vollum Institute, Portland), observed that this 
detergent inhibited the function of other transporters even though the peaks they observed were 
monodisperse during purification (personal communication, data not published). Other detergent 
conditions that could be taken into account for future detergent combination to improve the crystals 
resolution were: b0,+AT with DM/CHS and LAPAO/CHS, and LAT1 with LAPAO/CHS (Figure 47C). The 
obtained protein yield were in this case: for b0,+AT (DM/CHS): 0.07 mg/L, b0,+AT (LAPAO/CHS): 0.133 
mg/L, and LAT1 (LAPAO/CHS): 0.13 mg/L. 
Figure 50. Other detergent conditions that could be taken into account. DM/CHS and LAPAO/CHS for b0,+AT 
(Xenopus tropicalis), and LAPAO/CHS for LAT1 (Xenopus laevis). In all the cases in B) and C), 50 µL of purified and 
cleaved protein (~ 4 mg/mL) were injected into a Superdex 200 5/150 GL column equilibrated with the 
corresponding detergent and CHS. Proteins were detected by absorbance at 280 nm and peak collected and 
analyzed by SDS-PAGE (Coomassie and silver staining) (See Chapter II: Materials & Methods, II.9, and II.9.a).  
As a result of the overall studies b0,+AT (Xenopus tropicalis) was chosen as best candidate 
protein for crystallization studies after the screening of the different eukaryotic LATs. In addition, the 
detergent condition of DDM supplemented with CHS has been found, at this point of the study, the 
most promising condition for b0,+AT. The first efforts to improve b0,+AT monodispersity profile in the SEC 
were: firstly it was tried scaling up the purification in a Superdex 200 10/300 using the same conditions 
as in the previous assay. There is still more soluble transporter than aggregates, but there is still the 
third peak corresponding to detergent micelles and cholesterol (Figure 50).  
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To study the protein stability in less amount of detergent, it was tried to reduce from 3xCMC to 
2xCMC during the purification process. Interestingly, the third peak disappeared (Figure 48 right), but 
the protein seems to aggregate more, since the void peak is higher than in 3xCMC.  
Figure 51. Best condition was scaled up and run into a Superdex 200 10/300 in the same purification conditions as 
it was done before (3xCMC) (on the left), or reducing the detergent amount during the purification to 2xCMC, (on 
the right) to check whether it is possible to reduce the detergent excess corresponding to the third peak in all the 
purifications using 3xCMC. Detergent reduction, required to avoid generating pseudocrystals in the cristalliaztion 
screenings produced by detergent excess, is achieved by reducing to 2xCMC. Membrane extract from 8 L S.cervisiae 
cell culture overexpressing b0,+AT(Xenopus tropicalis) was solubilized with 1% DDM/0.2% CHS, then, divided to 
perform two purifications in parallel, one using 3xCMC DDM and adjusted the cholesterol: 0.027% DDM (w/v)  and 
0.0054% CHS (w/v); and the other purification detergent was reduced to 2xCMC of DDM and adjusted 
the cholesterol: 0.018% DDM / 0.0036% CHS. (x axis: absorbance at 280nm (mAU); y axis: volume (mL)).
In addition, a small protocol change that gave notable difference was the buffer preparation, by 
advice of Dr. Rosell during his stay at Dr. Goaux laboratory. Sonication and filtration of the buffer 
previous to its use for protein solubilization and purification produced more homogeneous detergent 
micelles, improved protein solubility and higher monodispersity. 
Even though the best conditions obtained analyzed by SEC are promising, they are still far from 
being used for crystallographic trials. One of the main reasons is that the protein expression should be 
higher in order to have from one batch of cell culture, sample enough so as to screen lots of 
crystallographic conditions, and be able to reproduce in big drop those that produce crystals. At the 
moment, to obtain 0.6 mg of pure b0,+AT in DDM/CHS it is needed 6 L of cell culture, which is far from 
optimal. On the other hand, the SEC profile still shows a peak corresponding to protein aggregates that 
eluted in the void, indicating a tendency to aggregate, for that reason several strategies to improve 
stability were though and detailed in the next points. 
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II.7. Expressing the best light subunit candidates in Pichia pastoris 
b0,+AT (Xenopus tropicalis) and LAT1 (Xenopus laevis) were cloned by Dr. Rosell into pPICZ 
vector. In both cases a TEV protease site was introduced at the C terminus of the light subunits before 
yEGFP (Hisx8 tagged). The design of the fusion protein was the same as it was done for S. cerevisiae. Dr. 
Rosell and Dr. Costa transformed them into Pichia pastoris and selected the best overexpressing clones 
by whole-cell-fluorescence method as it was done for S. cerevisiae (see Chapter I: Materials & Methods, 
I.9, and Chapter II: Materials & Methods, II.4). Afterwards, they checked by In-gel-fluorescence the 
protein integrity (Figure 52A). Then, with Dr. Costa we overexpressed both proteins and purified them 
following the same protocol as it was done before to obtain the best candidate conditions (II.6, Figure 
47, Materials & Methods, II.9). Minor modifications were adopted to perform the expression in P. 
pastoris, namely the solubilization detergent concentration which was increased to 2% detergent 
(w/v)/0.4%CHS (w/v), and an scale-up to run a Superdex 200 10/300 SEC column. The results indicated 
that even though the overexpression in P. pastoris was significantly higher (25,000 RFU and 12,000 RFU 
for b0,+AT and LAT1 respectively, compared to the 2030 RFU and 1160 RFU obtained in S. cerevisiae), the 
quality of the protein was worse, since it aggregated more than the one expressed in S. cerevisiae.  
A) 
B) 
Figure 52. The 2 best light subunits selected in S. cerevisiae b0,+AT (Xenopus) and LAT1 (Xenopus) were 
overexpressed in P. pastoris with GFP-His tag in C-terminal. Then, they were purified, removed their tag and SEC 
analyzed following the same procedure as it was done in S. cerevisiae using a Superdex 200 10/300 column (x axis: 
absorbance at 280nm (mAU); y axis: volume of the column (mL)). The purified protein elute between 9.74-10.99 
mL (should be taken into account that the void volume value for each case) corresponds to a MW around 440 kDa 
(Ferritin in the calibration curve for the standard proteins on Tricorn Superdex 200 10/300).
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II.8.  Improvement of b0,+AT stability for 3D crystallization by lipid 
addition 
Since expressing the best light subunits in P. pastoris offered no advantage, S. cerevisiae was 
maintained as expression system to test the lipid addition effect on protein stability. Detergent-
solubilized membrane proteins, even working with mild detergents, might not be stable enough and 
aggregate during concentration step. This problem might have the origin in the removal of key 
membrane lipids for this membrane protein which might let some hydrophobic areas of the protein not 
protected and then become aggregation start points. The addition of lipids in the solubilization step and 
during protein purification might mimic the protein membrane environment and reduce aggregation. 
Lipid requirement has been shown in many eukaryotic membrane proteins, for example, the voltage 
dependent K+ channel (Long et al., 2007). Lipid screening allowed to check the stability for b0,+AT 
expressed in Saccharomyces cerevisiae (Dr. Rosell, personal communication). In all cases the lipid was 
added during the solubilization and purification processes using the compounds and concentrations 
indicated in the Table 14. 
Condition n° LIPID Solubilization Purification 
1 Asolectin 2 mg/mL 0.1 mg/mL 
2 mC14PC 10 mM 0.5 mM 
3 Brain Polar Lipid 0.05% 0.0025 % 
4 POPC/POPG/POPE (3:1:1) 2 mM/0.7 mM/0.7 mM 0.1 mM/0.035 mM/0.035 mM 
5 POPC/POPG/POPE (3:1:1) 1 mM/0.35 mM/0.35mM 0.05 mM/0.0175mM/0.0175 mM 
6 POPC/POPE (2:1) 1 mM/0.5 mM 0.05 mM/0.025 mM 
7 POPC/POPG (2:1) 1 mM/0.5 mM 0.0 5mM/0.025 mM 
8 POPC/POPS (2:1) 1 mM/0.5 mM 0.05 mM/0.025 mM 
9 POPC 2 mM 0.1 mM 
10 POPE 2 mM 0.1 mM 
11 POPS 1 mM 0.05 mM 
12 POPG 1 mM 0.05 mM 
13 DPPC 5 mM 0.25 mM 
14 DPPC 2.5 mM 0.125 mM 
15 DPPC 1 mM 0.05 mM 
16 DMPC 5 mM 0.25 mM 
17 DMPC 2.5 mM 0.125 mM 
18 DMPC 1 mM 0.05 mM 
19 DMPC/POPE (1:1) 1 mM/1 mM 0.05 mM/0.05 mM 
20 DMPC/DPPC (2:1) 2.5 mM/1.25 mM 0.125 mM/0.0625 mM 
21 DMPC/DPPC (2:1) 2 mM/1 mM 0.1 mM/0.05 mM 
22 DMPC/POPC (1:1) 1 mM/1 mM 0.05 mM/0.05 mM 
23 DMPC/DOPS (2:1) 2.5 mM/1.25 mM 0.125 mM/0.0625 mM 
24 DPPC/DMPC (2:1) 2.5 mM/1.25 mM 0.125 mM/0.0625 mM 
25 DPPC/DOPS (2:1) 2.5 mM/1.25 mM 0.125 mM/0.0625 mM 
Table 14. Lipid conditions used to check b0,+AT stability. b0,+AT was solubilized from Saccharomyces membranes 
using 1%DDM/0.2%CHS and the corresponding lipid concentration (solubilization column). Solubilized protein was 
purified with 0.05%DDM/0.01%CHS and the indicated lipid concentration (purification column). POPC:1-palmitoyl-2-
oleoyl-sn-glycero-3-phosphocholine; POPG:1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol; POPE:   1-palmitoyl-
2-oleoyl-sn-glycero-3-phosphoethanolamine; POPS:1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-L-serine; DPPC: 1,2-




To perform this screening, b0,+AT was solubilized from Saccharomyces membranes and purified 
by nickel affinity chromatography. It was solubilized with DDM/CHS without lipid or together with the 
different lipid combinations (Table 14), then, kept at room temperature or at 4 °C for 16 h and analyzed 
by FSEC.  
Interestingly, a clear improvement of the b0,+AT stability checked by FSEC monodispersity was 
observed by addition of DMPC or DPPC in the solubilization and purification processes in comparison 
with the FSEC profiles corresponding to the purified transporter only in presence of DDM/CHS (Figure 
53) when the purified samples were kept at 4 °C. The two best conditions (DMPC and DPPC) and two
other conditions representatives of the non-working conditions (Asolectin and m14PC) are shown in 
Figure 53. Under more severe conditions (at room temperature) the effect was higher in the case of 
DPPC addition. This lipid was chosen to be included in the solubilization and purification of b0,+AT.  
Effect of lipid addition on b0,+AT (Xenopus) stability 
Figure 53. FSEC profiles showing the effect of different lipids on the monodispersity of purified b0,+AT-GFP. b0,+AT-
GFP was solubilized with DDM/CHS (colored in blue), solubilized and purified with DDM/cholesterol (colored in red) 
and solubilized and purified with DDM/cholesterol and lipid (Asolectin (1 mg/mL), DMPC 0.25 Mm, DPPC 0.25 mM 
or m14PC 0.5 mM). Purified protein was kept at room temperature or at 40C for 16 h, and 100µL of each condition 
were injected into a Superose 6 column previously equilibrated with DDM 0.03% for FSEC analysis.  
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II.9.   Expression and purification of b0,+AT in insect cells 
The project developed in Saccharomyces was very useful since it allowed us to identify b0,+AT 
(from Xenopus tropicalis) as a putative candidate for 3D crystallography, and optimize its stability 
requirements (detergent, cholesterol and lipids). The problem using this expression system was that the 
final purification yield of b0,+AT produced in S. cerevisiae was 0.1 mg of purified protein per liter of yeast 
culture. In order to improve the expression levels of this transporter, b0,+AT was expressed in insect cell 
(Sf9 cell line) (see Chapter II: Materials & Methods, II.11-12). In addition, this expression system has 
been more successful in producing eukaryotic membrane proteins that ended with a solved crystal 
structure, than it has been S. cerevisiae. Actually, the 43% of solved membrane protein structures were 
obtained using baculovirus as expression system (Parker and Newstead, 2014).  
b0,+AT cDNA was cloned into the expression vector pFastBac, as a fusion protein with a GFP-His8 
C-terminal tag and a thrombin protease site between the light subunit and the tag. DH10 E. coli strain 
was transformed with the generated construct and bacmid generated by transposition. Sf9 cells were 
transfected with the purified bacmid containing b0,+AT-GFP-His8 and the first population of 
baculoviruses (P1) was obtained after 96 h, which was used to infect Sf9 cells and generate the P2 after 
96 h post-infection. These baculoviruses were titrated by the end point dilution assay and used to infect 
2 L of Sf9 cells culture (3.106 cells/mL) at a MOI of 2 (see Chapter II: Materials & Methods, II.12.a-13).  
Figure 54. Expression of b0,+AT-GFP in Sf9 insect cells. A) Checking of b0,+AT-GFP production in Sf9 insect cells by 
fluorescence microscopy. B) Design of the recombinant b0,+AT-GFP expressed in insect cells.  
Sf9 cells were disrupted and membranes isolated 48 h post-infection. Protein was solubilized 
with the conditions that were optimized for S. cerevisiae (1% DDM/ 0.2% CHS/ 5 mM DPPC). Protein was 
purified by affinity chromatography (Ni2+ resin), digested with thrombin, concentrated until 4 mg/mL 
and analyzed its monodispersity by tryptophan fluorescence size exclusion chromatography (Trp-FSEC) 
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(see Figure 55). Promisingly, the stability conditions identified in Saccharomyces were reproduced on 
the protein overexpressed in insect cells. In addition, the final expression yield was improved from the 
one obtained in S. cereviaae which was 0.5 mg per liter of cell culture. Thus, we accomplished the 
objective to improve the final purification yield just with changing the expression system.  
Figure 55. Tryptophan FSEC of b0,+AT wild-type overexpressed and purified from Sf9 insect cells using DDM/CHS 
and DPPC selected conditions. A Superose 6 column was used in this case.   
Trials to co-express the heavy subunit, rBAT (X. tropicalis), with b0,+AT (X. tropicalis) were not 
successful, even trying several different expression systems (results by Dr. Rosell during his stage at Dr. 
Gouaux laboratory). For this reason we continued working on the improvement of b0,+AT stability with 
the aim to crystallize it alone.  
II.10.  Improvement of b0,+AT molecule by mutagenesis and generation of 
truncated versions 
- Generation of the C150A b0,+AT mutant (removing reactive cysteines) 
The conserved cysteine involved in the disulphide bridge between the heavy and light subunit 
in HATs is facing the aqueous media, which makes it highly reactive, fact that can compromise the 
stability of the purified b0,+AT. For this reason, the Cysteine 150 was mutated into Alanine, which was 
generated by site-directed mutagenesis (Figure 56) (see Chapter I: Materials & Methods, II.10.b).  
Figure 56. Scheme of b0,+AT C150A design locating the reactive Cysteine 150 in the external loop II as a red circle. 
The GFP-Hisx8 tag is indicated at the C-terminal. 
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- Generation of truncated versions of C150A b0,+AT mutant 
In order to decrease the flexibility of the protein and improve the probability to get high quality 
crystals, different truncated forms of C150A b0,+AT in N-terminus or in C-terminus or in both were 
generated taking into account the predicted topology of the protein (Figure 57). N-terminal ∆10 
and ∆27, and C-terminal ∆28, ∆18, ∆13, ∆8 single truncation forms were generated on the C150A 
b0,+AT. Initially, the single truncations were cloned into pFastBac vector and the respective viruses were 
generated (see Chapter II: Material & Methods, II.12.a-e). 
Figure 57. Amino acid sequence and predicted topology of b0,+AT. A) The different truncations generated in N-
terminal (∆10 and ∆27) and in C-terminal (∆28, ∆18, ∆13, ∆8) are indicated on the amino acid sequence. B) 
Scheme of the b0,+AT topology indicating the N-terminal and C-terminal (previous GFP-His tag) amino acid lengths.    
Then, 40 mL cell cultures of the different truncated versions cloned into Sf9 insect cells were 
grown and checked the protein expression and protein integrity by in gel fluorescence 48 h post-




Figure 58. In-gel fluorescence of the different single truncation versions generated compared with the wild-type 
(WT) (on the left), and the double truncation ∆27Nterm/∆28Cterm (on the right) generated on a C150A 
background. The molecular weight of the wild-type fusion protein corresponds to ~70 kDa (~40 kDa of the light 
subunit + 28 kDa of the GFP). Truncation forms run under the WT molecular weight as expected. In gel fluorescence 
showed good expression of all the forms compared with wild-type.  
C150A b0,+AT single truncated versions were solubilized with 1%DDM/0.2%CHS/5mM DPPC and 
their monodispersity analyzed by FSEC (Figure 59) (see Chapter II: Material & Methods, II.14-15). Since 
the longest single truncations ∆27Nterm and ∆28Cterm were possible to be overexpressed and they 
were monodisperse (Figure 56) it was decided to generate the double truncation form 
∆27Nterm/ ∆28Cterm on C150A b0,+AT. It was also cloned into pFastBac and generated its viruses. 
Thereafter, the expression and protein integrity was examined by in-gel fluorescence, observing that the 
expression levels comparable to the b0,+AT wild-type and without observing proteolysis (Figure 55).  
Furthermore, the monodispersity of the double mutant C150A b0,+AT (∆27Nterm/ ∆28Cterm) 
was analyzed by FSEC (Figure 59), but unfortunately the behavior observed was not as good as the single 
truncations, thus, it was discarded. Comparing the single truncated C150A b0,+AT ∆28Cterm and C150A 
b0,+AT ∆27Nterm monodisperisity profiles, the first one behaved better and it was the one selected for 
the first 3D crystallization trials. 
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Figure 59. FSEC profiles of the truncated forms of C150A b0,+AT compared with wild-type with the selected 
detergent-lipid conditions: DDM/CHS/DPPC. ∆28Cterm truncated form showed the best monodisperse profile, and 
thus, it was selected for 3D crystallization trials.  
II.11.    First 3D-crystallization trial of C150A b0,+AT (∆28 Cter) 
The C-terminal truncated form ∆28 C150A b0,+AT-GFP-Hisx8, previously selected, was 
overexpressed and purified for crystallization screening and 3D structure determination. Overexpression 
was done for 48 h post-infection at a MOI of 2 and a total of 3 liters of Sf9 cell culture were grown (see 
Chapter II: Materials & Methods, II.16.a). Isolated membranes with the overexpressed protein were 
solubilized using the previously optimized (see II.8 and table 14, condition 13) solubilization buffer (SB) 
[1% w/v DDM; 0.2% w/v CHS; 5mM DPPC in 20 mM Tris (pH 8.00), 150 mM NaCl].  
The solubilized protein was purified by affinity chromatography with nickel resin (see Chapter 
II:  Materials & Methods II.16.b). During purification, the detergent, cholesterol and lipid were reduced 
to 0.05% w/v DDM; 0.01% w/v CHS; 0.25mM DPPC in 20 mM Tris (pH 8.00), 150 mM NaCl and 25 mM or 
250 mM imidazole were added in the washing or the elution buffers. The 9 mL of eluted protein were 
concentrated until 1.2 mL using a centrifugal filter of 100 nominal molecular weight limit (NMWL). Then, 
the protein was digested overnight at 4 °C with thrombin at 1:100 ratio (thrombin:fusion protein) to 
remove the GFP-Hisx8 tag. Then, it was concentrated to ~ 8 mg/mL and aggregates were eliminated by 
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high-speed centrifugation conditions. 500 μL of supernatant were injected into a Superdex 200 10/300 
GL column (this last step was done twice because we had 1000 μL of sample). Purified, cleaved and 
concentrated truncated form C150A b0,+AT ∆28 C-terminal was run into a SEC (Figure 60). The peak 
corresponding to the collected fractions 11-19 which correspond to 8.2 mL-9.8 mL was collected and 
dialyzed overnight at 4°C to remove the excess of detergent against Tris 50mM, NaCl 150 mM, DDM 
0.05 %, CHS 0.01%, DPPC 0.25 mM with a 50 kDa cut-off.  
Figure 60. SEC profile of purified, cleaved and concentrated C150A b0,+AT ∆28 C-terminal produced in Sf9 cells. 500 
μL of purified protein and concentrated at 8mg/mL were injected into a Superose 6 column previously 
equilibrated with DDM 0.05%. The fractions between 11 and 19 which correspond to the peak and the volume 
8.2mL-9.8mL were collected.  Then, dialyzed and concentrated at 4.2 mg/mL and seeded for crystallization 
screening. The graphic represents the Absorbance at 280nm (y axis) and the volume of the column in mL (x axis).
Next day, 0.6 mg of protein at 1 mg/mL were concentrated until 4.2 mg/mL and first 3D-
crystallization screening was performed (see Chapter II: Material & Methods II.16.b). There are different 
crystallization methodologies, but the most common one was firstly assayed, namely the vapor diffusion 
and sitting drop. This approach has been proven to be the most successful in crystallizing membrane 
proteins, even though it was originally designed for soluble proteins. 
In the first trial the Memgold crystallization conditions were tested. The first crystallization trial 
ended with some conditions forming precipitates or pseudo-crystals as the showed in Figure 61. These 
pseudo-crystals were analyzed at Alba synchrotron but they did not diffract. Some possible reasons are: 
the excess of lipid and detergent, and the size of the detergent used, DDM, which is not the optimal to 
obtain high resolution structures. 
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Crystallization screening: MemGold plate, 20°C 
Figure 61. Crystallization screening by hanging drop vapour diffusion at 20 °C using the MemGold pack screening.  
A drop ratio of 0.5 µL of protein (4.2 mg/mL concentrated) with 0.5 µL reservoir solution was used. Spherolites 
(detergent precipitates) were obtained in some conditions like the indicated on the left (0.1 M Ammonium Sulfate, 
0.1 M Glycine pH 3.8, 28% (w/v) Triethylene Glycol), and others produced pseudo-crystals (0.1 M Calcium Chloride, 
0.1 M TRIS pH 6.5 13% PEG (w/v) MME 2000) that did not diffract in X-Ray. 
These are preliminary results, since not an exhaustive crystallization screening has been done. 
Usually, several commercial screening conditions are tried, like Membfac, Memplus, Memstart, Memsys 
and Memgold which are adapted to automatic sitting-drop seeding nL scale. Also, crystallization is tried 
at different temperatures, at 4 and 20 °C.  
The purification process in the future should be optimized by reducing lipid and cholesterol 
concentrations previous to the next crystallization trials. Or, taking advantage of the lipid contained in 
the sample, other crystallographic techniques could be tried which are specific for membrane proteins: 
like bicelles (Faham et al., 2002; Agah and Faham, 2012), HiLiDe (Gourdon et al., 2011), or Lipidic Cubic 
Phase (Caffrey et al., 2009). 
In addition, replacement of DDM for shorter detergents in the last steps of the purification 
(during washes, elution or during SEC) can be tested since they would form smaller micelles around 
membrane proteins that would allow to solve in a higher resolution the protein structure.  
To sum up, as a result of this screening and optimization process, a more stable light subunit 
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- Selection of eukaryotic light subunits for crystallization studies 
The adopted GFP-based S. cerevisiae pipeline (Drew et al., 2008) allowed to select three 
candidate light subunits for crystallization studies: b0,+AT, LAT1 and LAT2. The three proteins belonging 
to Xenopus spp, are more stable than human LAT2 overexpressed in P. pastoris (Chapter I).  
The three selected candidates were obtained by solubilization and purification with DDM/CHS 
in the case of b0,+AT (X. tropicalis), cymal-6/CHS in the case of LAT1 (X. laevis), and foscholine-12/CHS for 
LAT2 (X. laevis). The foscholine-12 condition was discarded by recommendation of Dr. Gouaux (Vollum 
institute, Oregon) that was collaborating in the project, since in many cases the purified protein resulted 
not functional. 
The quality of the proteins, analyzed by size exclusion chromatography (SEC), showed in the 
three cases a main peak corresponding to the purified protein, the void peak corresponding to the 
protein aggregates and a third peak corresponding to micelles of detergent and cholesterol (Figure 47). 
The protein with best SEC profile was b0,+AT condition, and followed by LAT1. Even though b0,+AT and 
LAT1 were selected as good targets, this thesis is mainly focused on the study of b0,+AT. 
- Keys of the success in finding the good candidates 
The high-throughput method (Drew et al., 2008) allowed fast screening of the overexpression 
levels, the quality of the recombinant protein and monitoring of the purification steps. S. cerevisiae 
cloning resulted less time-consuming than other eukaryotic expression systems like P. pastoris or Insect 
cells. Conversely, these two expression systems usually produce larger amounts of protein than S. 
cerevisiae, being the main reason to test them after having selected the candidate protein.  
In addition, the GFP technology allowed quickly quantifying the proportion of soluble protein, 
measure the stability of the different detergent conditions in a fast way using the ultracentrifugation 
dispersity sedimentation (UDS) assay and FSEC to analyze the monodispersity of a solubilized-protein 
without the need to be purified (Kawate and Gouaux, 2006).  
Nevertheless, once the optimal conditions of purification would have been set up for 
crystallization trials, the candidate protein could be cloned without GFP, and check whether the stability 
was the same. Seldom is the case where GFP impairs the function in a protein, but it could happen. On 
the other hand, some groups have been successful crystallizing their proteins with the Histidine tag, 
which would reduce the manipulation of the protein, hence reducing steps where the protein can 
aggregate.  
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- Detergent conditions: 
DDM detergent condition selected for b0,+AT purification, is the most successful used in 
crystallization (Yamashita et al., 2005; Kawate et al., 2009; Lee et al., 2014; Althoff et al., 2014; 
Baconguis et al., 2014). Nevertheless, due to its long carbonated tail, sometimes the X-ray diffracted 
crystals cannot be solved at a very high resolution; in those cases, changing the detergent during the 
purification process for shorter-length ones like OG or NG could rise the probability to increase the 
protein resolution (Figure 62) (an example is the protocol followed to screen replacement detergents for 
proteins like pirophosphatases (Kellosalo et al., 2011); or the M2 muscarinic acetylcholine receptor 
(Haga et al., 2012).  
In the case of the LAT1 purification condition, Cymal-6 is a shorter detergent than DDM. 
Interestingly, it was used to determine the structure of the prokaryotic homologue of LATs, AdiC 
(Kowalczyk et al., 2011) (see Introduction 3.b.2). 
Figure 62. Graphics indicating the correlation between structural resolution and the type of crystallization 
detergent. The information to build the graphics was obtained from a database generated by collecting the 
crystallization information from all of the available unique alpha-helical MP structures in the PDB (in 2010). Only 
structures crystallized using a single defined detergent were included. This task was greatly facilitated by the 
‘Membrane Proteins of Known 3D Structure’ web site from the Stephen White laboratory at UC Irvine 
(http://blanco.biomol.uci.edu/Membrane_Proteins_xtal.html). A) Square plots displaying the structural resolution 
for seven of the most successful crystallization detergents; the middle line in each plot represents the median. B) 
Deposited structural resolution for the different membrane protein family members (from Sonoda et al., 2010). 
In addition, new detergents like the MNG-2/3 could be tested, since recent structures solved 
used this detergent: the Xenopus laevis NMDA receptor (Lee et al., 2014), or the β2 adrenaline receptor 
(Roenbaum et al., 2011). 
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- Cholesterol addition improves protein stability: 
Really interesting is the stabilizing effect of cholesterol addition (in the salt form of cholesteryl 
hemisuccinate Tris salt, CHS) on almost all light subunits tested.  FSEC profile of the solubilized protein 
was significantly better when CHS was included in the solubilization step (Figure 45). This stabilizing 
effect was previously described for many eukaryotic membrane proteins (Drew et al., 2008; Jones et al., 
2012) and it has successfully been used for purification and crystallization of GPCRs (Hanso et al., 2008; 
Lee et al., 2014). Cholesterol plays well established regulatory roles in many membrane proteins, either 
indirectly by modulating membrane properties, either by interacting directly by specific interactions 
with the membrane proteins (Burger et al., 2000; Lee, 2004).  
Indeed, it has been found a cholesterol binding site in some membrane proteins structures like 
the β2-adrenergic receptor (Hanson et al., 2008) which showed that these receptors organize as 
monomers in an antiparallel association with two distinct cholesterol molecules bound per receptor. In 
this precise example, thermal stability analysis using isothermal denaturation confirmed that cholesterol 
analog significantly enhanced the stability of the receptor (Hanso et al., 2008).  
But not only cholesterol is widely described to bind GPCR proteins, but also it has been found 
bound in the structure of eukaryotic transporters like the Drosophila dopamine transporter DAT 
(Penmatsa et al., 2013). In fact, it was previously described that the conformation and function of this 
transporter can be affected by manipulating membrane cholesterol. When treating cells with methyl-β-
cyclodextrin (mβCD), which depletes membrane cholesterol affecting raft and non-raft membrane 
domains, the dopamine uptake and efflux rate were reduced. They discarded that it was the raft 
localization because they performed an experiment to disrupt raft-localized DAT by using nystatin 
cholesterol chelating agent, and no effect was observed, whereas repletion with the analog 
desmosterol, which is a non-raft promoting sterol, restored the transport rates (Jones et al., 2012). We 
expect to find specific interactions between cholesterol and HATs, since they have been associated with 
cholesterol as well, at least, in the lipid rafts (Schroeder et al., 2012).  
Figure 63. Cholesterol bound in the solved structure of DAT transporter (Drosophila) (from Penmatsa et al., 2013). 
In the case of human β2-adrenergic structure (Cherezov et al., 2007), in addition to cholesterol, 
it was also found palmitic acid bound to the protein, which may indicate that both are needed to 
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regulate the protein function or the interaction with other membrane proteins. The turkey β1-
adrenergic G protein-coupled receptor structure was solved mutating the Cys residue responsible to 
bind palmitoil at the C-terminal, to reduce protein aggregation rate (Warne et al., 2010). 
Many membrane proteins that interact with cholesterol have a cholesterol recognition / 
interaction amino acid consensus (CRAC) sequence like the GPCRs: β2-adrenergic receptor, serotoninA 
receptor or rhodopsin. The CRAC sequence consists on a sequence of: -L/V-(X)1–5-Y-(X)1–5-R/K-, in 
which (X)1–5 represents between one and five residues of any amino acid (Li et al., 1998; Epand et al., 
2006; Gimpl et al., 2010). The future study of these motifs in HAT transporters could be useful to design 
mutants that lose the interaction with cholesterol with the aim to achieve more stable proteins.  
On the other hand, molecular-dynamics simulations predict that dimerization (calculated for 
the β2-adrenergic receptor) is modulated by membrane cholesterol. It has been found that cholesterol 
binds to transmembrane helix IV of this receptor blocking its involvement at the dimer interface. Dimer 
plasticity in many membrane proteins is relevant for its function (Prasanna et al., 2014).  
Since b0,+AT (Xenopus tropicalis) was the best candidate, it was selected to improve its 
monodispersity profile. The scale-up into a larger SEC (Superdex 200 10/300) using the same conditions 
reproduced the three peaks observed before, and did not show a clear separation of the third peak, the 
one corresponding to micelles of detergent and cholesterol, and it also had a void peak corresponding to 
aggregated protein (Figure 48, on the left). For that reason, reduction of detergent/CHS from 3xCMC to 
2xCMC during the purification process was tried and the third peak corresponding to detergent 
disappeared. But, the protein peak was displaced to the left, indicating a different oligomeric state of 
the protein (Figure 48, right).  
- Lipid addition to improve protein stability 
Solubilized-proteins tend to be less stable in detergent micelles than in the lipid bilayer. For this 
reason, it has become a more common practice during the last years the incorporation of synthetic 
lipids during purification and crystallization which can improve the quality of the membrane protein 
crystals allowing them to diffract at high resolution (Lemieux et al., 2003; Zhang et al., 2003; Yao et al., 
2005; Guan et al., 2006; Hattori et al., 2007; Sobolevsky et al., 2009; Hibbs and Gouaux, 2011; 
Krishnamurthy and Gouaux, 2012). In our case, the addition of lipids to the solubilization and 
purification buffers has enormously improved the stability of the protein after purification -even at 
room temperature-, which is really advantageous for crystallization. After screening 25 different lipid 
conditions DPPC 0.25 mM was the best condition for b0,+AT (results obtained by Dr. Rosell tested in his 
stay at Dr. Gouaux laboratory). In addition, the presence of lipids is a prerequisite for protein 
functionality, as demonstrated in some cases, for example in the cytochrome b6f complex. In this case 
the atomic structure solved at 2.5 Å allowed identifying seven lipid-binding sites, which might function 
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as cross-linking interactions to stabilize the super-complex with the PSI reaction center complex (Zhang 
et al., 2003; Kurisu et al., 2003; Phillips et al., 2009; Hasan et al., 2014).  
- Changing the expression system to increase protein overexpression 
Changing the expression system into P. pastoris strain KM71H resulted in an increase in the 
protein expression of 12 and 10 fold for b0,+AT (X. tropicalis) and of LAT1 (X. laevis) respectively, which 
represented a great advantage over S. cerevisiae, in addition to be a cheaper expression system. But 
unfortunately the FSEC profiles of solubilized and purified proteins using the same conditions as in S. 
cerevisiae, indicated that a bad quality of the protein in both cases (Figure 49). Probably the 
overexpression produced not properly folded protein.  
Finally, insect cells Sf9 cell line, which was set up in Dr. Gouaux laboratory by Dr. Rosell and 
reproduced in our laboratory, was tried and proven to be better in expression yields than S. cerevisiae, 
5-fold higher than S. cerevisiae; 0.5 mg of pure protein from 1 L were obtained in insect cells, whereas 
0.1 mg from 1 L was obtained in S. cerevisiae. Furthermore, the protein produced in insect cells and 
purified showed a monodisperse peak without the third peak corresponding to excess detergent, which 
is another improvement (Figure 57). Finally, this expression system resulted of special interest since it 
has been successful for more than 43% of eukaryotic membrane proteins crystal structures, especially 
from human, being at the moment the best expression system (Parker and Newstead, 2014) (examples 
of structures solved with this expression system are mentioned in the introduction of this Chapter II). 
For all these reasons, this was the expression system chosen for crystallization studies. Other 
improvements that were introduced into the protocol when overexpressing in insect cells were: i) the 
protease TEV replacement for thrombin, which cleaved more efficiently, and ii) the protease removal in 
the SEC step avoiding the reverse IMAC step; thus, reducing protein manipulation steps. 
- Trying the heavy subunit co-expression to find an stability effect 
As it was mentioned in the introduction, the heavy subunit 4F2hc stabilizes LAT2. Hence, it was 
interesting to study the effect of the heavy subunit rBAT on b0,+AT. Several trials to co-express both 
subunits in different expression systems failed (Insect cells, mammal cells and P. pastoris were tried) 
(results by Dr. Rosell). It was not possible to express rBAT, probably to the higher amount of 
glycosilations that make it more complex than 4F2hc. For that reason it was continued working with the 
light subunit alone.   
- Removing the reactive cysteines to reduce aggregation 
Once it was determined that the heterodimer was not forming, it was thought to remove the 
reactive cysteine in b0,+AT responsible of the disulphide bridge in order to increase the protein stability 
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since it is thought that reactive cysteines tend to aggregate proteins. This is a strategy followed by many 
crystallographic groups to reduce the aggregation tendency of a membrane protein.  
- Reducing protein flexibility by generating truncation forms in N and C terminal 
In order to increase the crystal formation, one strategy that is followed in many groups in 
crystallography is the deletion of amino acids in the C and N terminal, in order to reduce the protein 
flexibility when these domains are really long. Some examples of structures solved using this strategy 
are the β2 adrenoceptor (Rasmussen et al., 2011), the chicken acid-sensing ion channel 1-snake toxin 
complex (Baconguis et al., 2014) or the C. elegans GluClα ion channel (Althoff et al., 2014) and the β1-
adrenergic G protein-coupled receptor (Warne et al., 2010). In the last case, also a truncated loop 
between TMD3 and TMD4 was included, which could be considered an idea for future crystallization 
studies. From all the truncated forms tested in C150A b0,+AT Xenopus tropicalis: ∆27Nterm C150A b0,+AT 
and ∆28Cterm C150A b0,+AT were the best individual truncated forms (Figure 56). For that reason it was 
expected that the double truncated mutant (∆27Nterm/∆28Cterm C150A b0,+AT) would be even more 
stable, but, unfortunately the protein FSEC profile was non-monodisperse (Figure 56), and this protein 
was discarded.  
- First crystallization trial 
Finally, ∆28Cterm C150A b0,+AT produced in Sf9 insect cells, purified in presence of DDM, 
cholesterol and DPPC has been so far the best candidate condition for 3D crystallization studies after the 
different strategies followed to improve its stability and crystalizability. 
The first crystallization trial was done in vapor diffusion sitting drop at 20 oC using the 
MemGold crystallization screening (from Molecular Dimensions), which is based on crystallization 
conditions reported for alpha helical membrane proteins up to 2007 from the Protein Data Bank. They 
cover a range of pH, precipitants (mainly PEGs) and salt additives. The two conditions that formed 
“crystals” were the 0.1M Ammonium Sulfate, 0.1M Glycine pH 3.8, 28% (w/v) Triethylene Glycol, and 
the 0.1M Calcium Chloride, 0.1M Tris pH 6.5, 13% PEG (w/v) MME 2000. Nevertheless, they did not 
diffract, probably for being pseudocrystals formed of excess detergent, lipid and cholesterol. Even 
though no good quality crystal was formed in the first crystallization trial, only 96 different conditions 
were tested.  
Nowadays there are many commercial crystallization screenings available for membrane 
protein to be tested in vapor diffusion that could be tried in the future, like: Membfac (Hampton 
Research), Memstart, Memsys, MemBeta or Memgold (from Molecular Dimensions), BetaMem 
(Emerald Biosystems), JBScreen-Membrane (Jena Bioscience) or Mbclass screens (Quiagen), Memplus. 
Vapor diffusion is the method more widely used that has been successful in more membrane proteins, 
and it represents the 80% of structures of the PDB. Some examples of membrane protein structures 
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using this vapor diffusion method are: the C.elegans GluClα ion channel (Althoff et al., 2014), the 
chicken acid-sensing ion channel 1-snake toxin complex (Baconguis et al., 2014), the AMPA receptor 
GluA2 (Dürr et al., 2014), the β1-adrenergic G protein-coupled receptor (Warne et al., 2010). 
Since the excess of detergent can end up with spherulites formation during the crystallization 
trials, the removal of detergent previous crystal seeding is desired. Many strategies could be followed 
for that: 1) solubilize at the lower % detergent possible since the majority of excess detergent of the 
sample comes from the solubilization step, 2) dialyze the sample for longer periods of time (2 days), 3) 
concentrate the less possible to avoid concentrating the detergents as well, and run two SEC with the 
same sample instead of concentrating too much and run a single SEC. 
- Trying other crystallization methods 
In parallel to the introduction of lipids, different new crystallographic techniques have been 
developed which require the use of lipids to form ordered lipidic structures containing the membrane 
protein. Some of these specific crystallographic techniques for membrane proteins are: Lipidic Cubic 
Phase that form 3D crystals (Caffrey et al., 2009) and Bicelles that form 2D crystals (Faham et al., 2002; 
Agah and Faham, 2012) (Figure 64). A specific variant developed in the group of Dr. Nissen (Centre for 
Membrane Pumps in Cells and Disease) which is an approach to achieve diffraction quality membrane 
protein crystals in high concentrations of lipid and detergent (HiLiDe) (Gourdon et al., 2011). Since the 
selected light subunit best condition requires the addition of DPPC lipid to increase its stability, it might 
be a good idea to try any these methods. 
Figure 64. The solubilized and purified protein can be crystallized following several strategies.  
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- Strategies to increase the crystal contacts 
One strategy to improve the chances of obtaining high-quality crystals is to increase crystal 
contacts by expanding the soluble domains. This can be carried out by several strategies. One is using 
epitope-specific antibodies that provide a large stable polar domain for crystal formation. Actually, a 
collaboration with Professor Gouaux is stablished in which they would build the Fab fragment for 
∆28Cterm C150A b0,+AT (Xenopus tropicalis) purified in DDM/CHS/DPPC. Many structures were obtained 
with this strategy like the β2 adrenaline receptor (Rosenbaum et al., 2011), the C. elegans GluClα ion 
channel (Althoff et al., 2014). 
Other common strategy is to replace an external loop for a T4 lysozyme fusion protein which 
confers higher stability to the protein. It is also one common strategy, which has been useful for 
proteins like: membrane-bound pyrophosphatases (Kellosalo et al., 2011), the human β2 adrenaline 
receptor (Cherezov et al., 2007), the human histamine receptor (Shimamura et al., 2011). This strategy 
could be followed if the ones before are finally not achieved. 
In the case of HATs, instead of T4 lysozyme, the co-expression with the heavy subunit 4F2hc 
could achieve the same objective of increasing the contact surface to favor the packing. Even though 
4F2hc/ b0,+AT heterodimer is not found in the nature, it is known to be functional when co-expressed 
(Rajan et al., 1999; Rajan et al., 2000). The strategy of co-expressing Xenopus tropicalis 4F2hc/ b0,+AT has 
already been started in the laboratory by Dr. Rosell. 
- Chosing a thermostable protein increases the chances of crystallization 
Thermostability of integral membrane proteins in detergent solution has proven to be an 
important parameter in the successful production of diffraction quality crystals for structure 
determination by X-ray crystallography. For that reason, screening different membrane proteins, testing 
different detergents, additives, substrates, inhibitors, antibodies, or screening mutants to find a more 
thermostable condition can be done with the FSEC thermostability assay for membrane protein 
precrystallization screening developed by Profesor Gouaux laboratory (Hattorie et al., 2012). Finding a 
thermostable candidate has led to determine many membrane protein structures, like LeuT,ApcT, ASIC, 
P2X, GluA2, and GluCl (Hattori and Gouaux, 2012; Hibbs and Gouaux, 2011; Jasti et al., 2007; Kawate et 
al., 2009; Krishnamurthy and Gouaux, 2012; Shaffer et al., 2009; Sobolevsky et al., 2009; Yamashita et 
al., 2005). 
- Immobilizing the transporter in a conformation by punctual mutations 
Mobility of the transporter could be blocked by finding mutants that could immobilize the 
transporter in a specific conformation. To that aim, residues to be mutated could be selected by 
multialignement with the prokaryotic homologues mutants that have been already crystallized in a 
precise conformation (described in the introduction 3.b.3); or by selecting point mutations found in 
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cystinuria patients where a loss of function was observed, and could be located in the substrate 
pathway. Recently, the human GLUT1 structure of the N45T and E329Q diffracted X-rays beyond 3.2 Å 
(Deng et al., 2014). In this case they blocked the structure in the inward-facing conformation and 
mutated the residue responsible of the glycosylation.  
- Functionality of the protein 
Once the protein would be crystallized, the same conditions of overexpression and purification 
would be used to check that the crystallized protein is functional. To this aim, it is thought to use the 
scintillation proximity assay (SPA) which is already set up in the laboratory by Dr. Bartoccioni (Harder 
and Fotiadis, 2012). This assay can be applied to detergent-solubilized membrane transporters 
expressed with a histidine tag which would be immobilized to copper chelate SPA beads 
(fluoromicrospheres) containing the scintillant. Radiolabeled substrate will be tested on the protein-
beads. Upon binding, the radioligand would emit radiation and induce photon emission from the beads 
that would be measured. Some advantages of this method are that it is possible to study specific 
transporters without interference of other endogenous transporters, that it is not require reconstitution 
into proteoliposomes, it does not need many steps, components are mixed in one well and signal is 
measured after incubation, which it makes it ideal tool for high-throughput screening; for example, to 
study new substrates, inhibitors, and for drug discovery.  Alternatively, the purified protein could be 
reconstituted into proteoliposomes containing CHS and DPPC, as it was previously done for human 
4F2hc/LAT2 (Rosell et al., 2014). To that aim, Xenopus tropicalis b0,+AT wild type and the ∆28Cterm 
C150A b0,+AT version will be functionally tested to assess if the truncation and mutation had an effect on 
the transporter function. 
To sum up, all the steps followed to find a suitable light subunit for crystallization studies have 
been successful. As a result, the ∆28Cterm C150A b0,+AT (Xenopus tropicalis) expressed in Sf9 insect 
cells, solubilized and purified in DDM/CHS/DPPC is at the moment one good candidate to perform 
crystallization screenings.  
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II.1.    Selected cDNAs of eukaryotic light subunits to be expressed in S. cerevisiae 
For this project 24 light subunits from different species were selected (Table 15). The different 
cDNAs were obtained from different sources: either they were already available in the laboratory or 
either they were bought from the German Science Centre for Genome Research (RZPD: www.rzpd.de/). 
In the case of Drosophila light subunits, they were kindly provided by Dr. Goberdhan (University of 
Oxford).  
Light Subunit Specie Uniprot code % identity with human LAT Obtained from 
LAT1 
Homo sapiens Q01650 100 Laboratory 
Mus musculus Q9Z127 86 Laboratory 
Xenopus laevis Q32NQ3 83 Laboratory 
JhI-21 D. melanogaster Q9VKC2 51 Dr. Goberdhan 
Minidiscs D. melanogaster Q9Y1A7 52 Dr. Goberdhan 
LAT2 
Homo sapiens Q9UHI5 100 Laboratory 
Mus musculus Q9QXW9 89 Laboratory 
Xenopus laevis Q6P891 87 RZPD 
y+LAT1 
Homo sapiens Q9UM01 100 Laboratory 
Mus musculus Q9Z1K8 90 Laboratory 
Xenopus tropicalis Q6P4M7 83 RZPD 
Danio renio Q2YDQ4 80 ZGC 
Bos taurus A6QPX4 89 RZPD 
y+LAT2 
Homo sapiens Q92536 100 Laboratory 
Mus musculus Q8BGK6 89 RZPD 
Xenopus laevis Q28I80 83 RZPD 
b0,+AT 
Homo sapiens P82251 100 Laboratory 
Rattus norvegicus P82252 83 RZPD 
Xenopus tropicalis Q0P4R8 79 RZPD 
Bos taurus Q3ZCL6 83 RZPD 
asc1 
Homo sapiens Q9NS82 100 Laboratory 
Mus musculus P63115 88 RZPD 
xCT 
Homo sapiens Q9UPY5 100 Laboratory 
Mus musculus Q9WTR6 89 RZPD 
Table 15. List of the 24 eukaryotic light subunits selected for the project belonging to different species. Light 
subunit specie, Uniprot code and % amino acid identity corresponding to the human LAT are listed, as well as the 
source obtained from (laboratory, RZPD or Dr. Goberdhan laboratory).  
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II.2.      Cloning eukaryotic light subunits cDNAs into GFP-8His-containing vector 
The cDNAs encoding the different eukaryotic light subunits were inserted in the episomal 
pDDGFP-2 plasmid by homologous recombination in S. cerevisiae. This vector was generated by cloning 
the yeast enhanced green fluorescent protein (yEGFP) sequence (Cormack et al., 1997) followed by an 
8xHistidine tag and preceded by a Tobacco Etch Virus (TEV) protease site sequence into the 2 µ vector 
p424GAL1 (Mumberg et al., 1995). Thus, the recombinant eukaryotic light subunits, expressed using this 
expression system, were produced as C-terminal GFP-tagged proteins. pDDGFP-2 contains a GAL1 
promoter to regulate the galactose-inducible gene expression, a URA3 selection marker to select the 
yeast transformed colonies, and an ampicillin resistance to select the vector when transformed in E. coli 
for DNA amplification. This vector was kindly provided by Dr. Bernadette Byrne (Imperial College of 
London).  
To perform the cloning of the eukaryotic light subunits into the pDDGFP-2 plasmid by 
homologous recombination, firstly, the genes of interest were amplified by high-fidelity PCR using the 
primers detailed in the Annex I (1.3. Primers to recombine into pDDGFP-2 plasmid). These primers 
contain: i) 5’ overhangs (35 bp) complementing the upstream (coloured in red in Figure 65) and 
downstream (coloured in blue in Figure 65) recombination sequences to either side of the SmaI site in 
the pDDGFP-2  vector and ii) the corresponding forward and reverse sequence of the gene to be cloned.  
Figure 65. Cloning site used in the 2µ GFP-fusion vector pDDGFP-2. The yEGFP lacked the methionine start (from 
Drew et al., 2008). 
Secondly, pDDGFP-2 vector was linearized by SmaI digestion at 25 °C overnight. Then, the PCR 
products and the digested pDDGFP-2 plasmid were purified from 0.7% agarose gels (Quiagen kit) and 
quantified by using a NanoDrop spectrophotometer (Thermo Scientific). This purified material was used 
to transform the S. cerevisiae strain FGY217 (MATa, ura3-52, lys2D201, pep4δ) (Kota et al., 2007), also 
provided by Dr. Bernadette Byrne (Figure 66). The main characteristic of this strain is that the gene 
encoding for the vacuolar proteinase A, pep4p, has been deleted, reducing possible proteolysis of the 
expressed protein. 
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Figure 66. Cloning by homologous recombination into 2 µ GFP-fusion vector pDDGFP-2. i) SmaI linearized vector; 
ii) amplified gene with overhangs required for homologous recombination (from Drew et al., 2008). 
II.3.      Preparation of S. cerevisiae competent cells and transformation 
Firstly, 5 mL of Yeast Peptone Dextrose (YPD) medium were inoculated with the S. cerevisiae 
strain FGY217 into a 50 mL aerated falcon. This culture was grown overnight at 280 rpm and 30 °C in a 
shaker exclusive for yeast.  The overnight culture was then diluted to an optical density of OD600 = 0.1 in 
a 250 mL shaker flask with 50 mL of YPD medium and grown in the same temperature until OD600 
reached 0.5–0.6. At this cell density, cells were pelleted at 3,000g for 5 min at 4 °C, discarded 
supernatant and resuspended in 25 mL of sterile deionized H2O (dH2O hereafter) to wash the cell 
culture. Cells were pelleted again at 3,000g for 5 min at 4 °C, the supernatant discarded and the cell 
pellet resuspended in 1 mL of 100 mM litic acid (LiAc). Cell suspension was then transferred into a 1.5 
mL eppendorf, cells centrifuged at 8,000g for 15 sec, supernatant discarded and cell pellet resuspended 
in 400 µL of 100 mM LiAc. 240 µL of 50% (wt/vol) PEG 3350 were prepared (on ice) in different 
eppendorf tubes for each transformation. 50 µL of cell suspension were added to each tube containing 
PEG 3350 and vortexed for 5 sec. 25 µl of 2 mg/mL single-stranded carrier DNA was added into each 
tube and vortexed for 5 sec. 50 µL of DNA mix were added (containing 3 µL of 25 ng/µL SmaI-digested 
vector, 5 µL of 150 ng/µL PCR product and 42 µL of sterile dH2O) into each tube and vortexed for 5 sec. 
Cells were then incubated for 30 min at 30 °C, and heat shock was done for 25 min at 42 °C.  After heat 
shock cells were washed (pelleted at 8,000g for 15 sec at room temperature, discarded supernatant and 
resuspended with 100 µL of sterile dH2O). Cells were plated onto -URA selective plates and incubated 
for 2–3 days at 30 °C. Once the colonies reached the desired size, plates were stored at 4 °C previous 
overexpression screening. 
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II.4.   Screening eukaryotic light subunit overexpression using whole-cell 
fluorescence 
A colony of the transformant yeast was inoculated in 10 mL -URA medium supplemented with 
2% glucose in an aerated 50 mL tube and grown overnight at  280 rpm and 30 °C. 10 µL of each 
overnight culture was spotted onto fresh -URA plates, dried at room temperature and incubated at 30 °C 
for 1–2 days. The overnight culture from the first step was diluted to a  OD600= 0.12 into two 50 mL 
aerated tubes, each containing 10 mL -URA medium with 0.1% glucose (high levels of glucose repress 
the GAL1 promoter) and incubated at 280 rpm and 30 °C. When OD600 was 0.6 (~7 hours) expression was 
induced by addition of galactose (2% final concentration). In order to avoid diluting culture medium, 
20% galactose stock in -URA medium was prepared. Induction before OD600 = 0.6 causes a reduced 
biomass that lowers protein production, and later than OD600 = 0.6 it starts to be a greater protein 
degradation. Twenty-two hours after induction, cells were centrifuged at 3,000g for 5 min, removed the 
supernatant and resuspended the cell pellet in 200 µL of Yeast Suspension Buffer (YSB) (50 mM Tris–HCl 
(pH 7.6), 5 mM EDTA, 10% glycerol) supplemented with 1x complete protease inhibitor cocktail (Roche).  
Fluorescence measurements to check the eukaryotic light subunit expression were done by transferring 
200 µL of the cell suspension to a black Nunc 96-well optical bottom plate and measuring GFP 
fluorescence at 512 nm by excitation at 488 nm in a microplate spectrofluorometer (FLx800, Biotek). 
Duplicates were done for each condition. In order to quantify the fluorescence, pure yEGFP at a 
concentration of 0.03 mg/mL (stocks of frozen purified protein were previously prepared in the 
laboratory by Dr. Rosell) was measured in the same plate and at the same final volume of 200 µL. The 
GFP concentration of the fusion proteins was calculated as follows: 
  (Sample fluorescence - Background fluorescence)   x   yEGFP stock (mg/mL) =   GFP concentration (mg/mL) 
        Pure yEGFP fluorescence 
  Molecular Mass of Light Subunit (kDa)    x   Amount of GFP (mg/L) = Light Subunit overexpression (mg/L) 
 Molecular Mass of GFP (kDa) 
To calculate the concentration in 200 µL, the previous value is divided by 40, corresponding to 
the 8,000 µL (cell culture)/200 µL (resuspension volume). It is considered 8mL instead of 10 mL because 
there is an effective 2 mL loss of volume by the transfer of only 200 µL of the resuspended cells to the 
96 well plate, even though the final volume was around 250 µL (200 µL of buffer + cell pellet) (Drew et 
al., 2008). 
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II.5. Confirmation of the integrity of GFP-tagged eukaryotic light subunits by in-gel 
fluorescence 
In-gel fluorescence was done with crude cell membranes. For that, cells were broken using 
glass beads. The 200 µL of cell suspension (in last step of II.4) were transferred into a 1.5 mL eppendorf 
tube where glass beads (500 μm (Sigma)) were placed so that the final volume with the cell suspension 
was 500 μL, and an additional 500 μL of YSB was added. To break the cells a FastPrep was used (3 
rounds for 10 sec each one at maximum intensity) at 4 °C.  Unbroken cells were removed by 
centrifugation at 22,000g in a desktop centrifuge for 5 sec at 4 °C. Then, 500 μL of the supernatant was 
transferred into a new tube. And repeated the process with the mixture of unbroken cell pellet and glass 
beads where new 500 μL of YSB were added. The new supernatant was transferred to the 500 μL batch 
obtained from the first round of cell breakage. Crude membranes were pelleted by centrifuging the 1 mL 
supernatant using a desktop ultracentrifuge (120,000g) for 1 h at 4 °C. Crude membranes were 
resuspended in 50 μL of YSB, and 15 μL transferred into a tube containing 15 μL of Solubilization Buffer 
(SB; 50 mM Tris–HCl (pH 7.6), 5% glycerol, 5 mM EDTA (pH 8.0), 0.02% bromophenol blue, 2% SDS, 0.05 
M DTT). 10 μL were loaded for SDS-PAGE (10% polyacrylamide) gels. Benchmark Fluorescent standard 
(Invitrogen) was included. Samples were not boiled to avoid GFP denaturation. SDS gel was rinsed with 
dH2O and the fluorescent bands detected by exposing the gel to blue light. Bands were visualized using a 
GBOX gel reader (Syngene) and a Safe Imager (Invitrogen) of the Protein Expression IRB Core Facility.   
II.6. Evaluation of the detergent solubilization efficiency on membranes 
containing overexpressed GFP-tagged eukaryotic light subunits 
Those subunits showing the better overexpression levels were tested on detergents of different 
characteristics in order to determine the most efficient detergent solubilizing the overexpressed 
protein. To that aim, 1L of yeast culture for each protein was grown and the following detergents were 
tested for solubilization of light subunits:  
- Non-ionic detergents: octyl glucoside (OG), nonyl glucoside (NG), nonyl maltoside (NM), decyl 
maltoside (DM), dodecyl maltoside (DDM), 6-cyclohexyl-1-hexyl-β-D-maltoside (Cymal-6) and 7-
cyclohexyl-1-heptyl-β-D-maltoside (Cymal-7).  
- Zwitterionic detergents: foscholine-9 (Fos-9), foscholine-12 (Fos-12), N,N-dimethyldodecylamine N-
oxide (DDAO), lauryl dimethylamine N-oxide (LDAO), 3-dodecylamido-N,N′-dimethylpropyl amine 
oxide (LAPAO) and octaethylene glycol monododecyl ether (C12E8).  
All detergents were prepared at a concentration of 10% (w/v) with or without cholesteryl 
hemisuccinate Tris salt (CHS) (Sigma Aldrich) 2% (w/v) in PBS. Since CHS is not easily soluble, it was 
added after detergent was completely soluble in the buffer. 
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- Cell culture: 10 mL of –URA, 2% glucose media in a 50 mL aerated falcon were inoculated with 
spotted yeast culture (see I.4). Next day, this cell culture was added to 150 mL of –URA, 2% glucose 
media in a 500 mL shaker flask, and incubated overnight in an orbital shaker at 280 rpm at 30°C. 
Next day, the 150 mL overnight culture was diluted to a final OD600 of 0.12 into 1 L of –URA, 0.1% 
glucose in a 2.5 L baffled shaker flask and incubated at 280 rpm and 30 °C until OD600 was 0.6. At this 
point, protein expression was induced by adding 100 mL of –URA media supplemented with 20% 
galactose to the 1 L cell culture. Cell culture was induced for 22 hours of incubation at 280 rpm and 
30 °C. Then, cell culture was centrifuged at 4,000g, 4 °C for 10 min. The cell pellet was resuspended 
in 25 mL of Cell Resuspension Buffer (CRB; 50 mM Tris–HCl (pH 7.6), 1 mM EDTA, 0.6 M sorbitol) per 
liter of original cell culture.  
- Cell lysis: Cells were broken using a heavy-duty cell disruptor (of the Protein Expression IRB Core 
Facility) for four passes at incremental pressures of 25, 30, 32 and 35 kpsi at 4–15 °C. The unbroken 
cells and debris were removed by centrifugation at 10,000g at 4 °C for 10 min and the supernatant 
containing membranes was collected.  
- Membrane extraction: Membranes were collected by centrifuging the cleared supernatant at 
150,000g at 4 °C for 120 min. Pellet was resuspended to a final volume of 6 ml per liter of the 
original cell culture with Membrane Resuspension Buffer (MRB; 20 mM Tris–HCl, (pH 7.5), 0.3 M 
sucrose, 0.1 mM CaCl2). The total protein amount was calculated using the BCA protein assay kit 
following the manufacturer’s instructions.  
- Detergent solubilization (with or without CHS): The membrane suspension was adjusted to a final 
protein concentration of 3 mg/mL in PBS. To that aim, membrane suspension aliquots of 900 μL 
were transferred into 1.5 mL eppendorff tubes and 100 μL of each freshly prepared detergent with 
or without CHS (final 1%/0.2% or 1% respectively) were added to each of the 1.5 mL tubes containing 
900 μL of membrane suspension (final 3 mg/mL). The mixtures were then incubated at 4 °C for 1 h 
with mild agitation. 100 μL were transferred into a Eppendorf tube and kept to measure later the 
fluorescence. The protein aggregates were removed by sedimentation at high g forces, 100,000g at 4 
°C for 1 hour, assuming that they are orders of magnitude heavier than solubilized protein particles 
(the ultracentrifuge used in all the cases was Beckman-Coulter Optima Max, and the rotor TLA-55, 
Beckman Coulter). Then, 100 μL of the supernatant were transferred into a black Nunc 96-well 
optical bottom plate and the previous 100 μL previously kept were also transferred and fluorescence 
was measured as previously described (II.6). The detergent solubilization efficiency was calculated by 
comparing to the GFP fluorescence before and after the ultracentrifugation step.  
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II.7. Study of the GFP-tagged eukaryotic light subunits stability by the 
Ultracentrifugation Dispersity Sedimentation Assay (UDS) 
The UDS is a high-throughput assay that allows to determinate rapidly the degree of protein 
aggregation in a detergent condition prior to crystallization, using small volumes of detergent solubilized 
membrane proteins that are removed by ultracentrifugation (Gutmann et al., 2007).  
Solubilized and ultracentrifuged protein as described in step II.6 was kept at 4 °C for 16 hours. 
Next day, 100 µL of sample were kept for later measurements, and the rest of the sample was 
ultracentrifuged at 100,000g at 4 °C for 1 hour (adapted from Gutmann et al., 2007). Then, 100 µL of the 
supernatant were placed into a black Nunc 96-well optical bottom plate and the 100 μL previously kept 
were also transferred. Fluorescence was measured as described before (II.6). The tendency of these 
transporters to aggregate was evaluated by comparing to the GFP fluorescence measured before and 
after the ultracentrifugation, assuming that protein aggregates sediment at high g. 
II.8.  Analysis of the GFP-tagged eukaryotic light subunits monodispersity by 
Fluorescence Size Exclusion Chromatography (FSEC) 
FSEC method was chosen because it allows screening the degree of monodispersity and the 
expression level of solubilized membrane proteins covalently fused to GFP without the need to purify 
the sample (Kawate and Gouaux, 2006).  
To that aim, 0.5 mL of the solubilized and ultracentrifuged protein as described in step II.6 were 
injected into a Superose 6 10/300 column pre-equilibrated with 20 mM Tris–HCl (pH 7.5), 0.15 M NaCl 
and 0.03% DDM. The eluted sample was fractionated row-by-row in 0.2 mL into a 96-well plate after the 
first 6 mL (note that void volume usually appear at 7-8mL). GFP fluorescence at 512 nm by excitation at 
488 nm emission was measured row-by-row. GFP fluorescence was plotted in each well against the 
fraction number. Finally, a graphic of the FSEC profile was generated using GraphPad Prism 5.  
II.9.  Purification of eukaryotic light subunits and monodispersity analysis by SEC 
The 20 different conditions presenting monodisperse peaks in the FSEC assay were screened 
following this protocol. The purification followed several steps: GFP fusion protein solubilization, 
purification, cleavage of GFP-His tag, dialysis to remove detergent excess, removal of GFP-His tag by 
reverse IMAC, concentration of the flow through containing the purified protein, concentration of the 
purified protein to 4 mg/mL and finally SEC monodispersity analysis, which was also checked by SDS-
PAGE silver staining.  
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Solubilization: 200 mg of total membrane protein (from 2L-6L cell culture depending on the 
expression level of each protein) (obtained as described in II.6) were solubilized at final total protein 
concentration of 5mg/mL in 20 mM Tris-Base, (pH 8), 150 mM NaCl, 1% (w/v) detergent / (w/v) 0.2% 
CHS, 10% glycerol for 1 hour at 4°C. Un-solubilized material was pelleted during 1h at 4°C at 100,000g.  
GFP-fusion light subunit purification: Then, detergent-solubilized protein was purified by 
incubation of the supernatant (5 mM imidazole (Sigma) added) with 3 mL of Ni++-NTA resin (Qiagen) for 
2 hours. During the purification the detergent concentration was reduced to 3 times the respective CMC 
and the CHS amount was decreased as well to keep a 5:1 detergent/CHS ratio in 20 mM Tris-Base, (pH 
8), 150 mM NaCl, 10% glycerol (Purification Buffer, PB:).  After incubation, resin was washed twice with 
30 mL of washing buffer (PB with 30mM imidazole (pH 8)). Elution was carried out incubating resin with 
6 bed volumes of elution buffer (PB with 250 mM imidazole (pH 8)) for 30 min. All this process was 
carried out at 4°C. Then, the eluted protein was concentrated with a centricon (Millipore) of 100 kDa 
cut-off until 1 mg/mL.  
GFP-His removal: TEV protease at a ratio of 1:5 was added and the sample was transferred into 
a dialysis tubing of 14 kDa molecular weight cut-off (Spectrumlabs) and dialyze overnight at 4°C against 
dialysis buffer (purification buffer without glycerol) to remove the excess of detergent produced during 
protein concentration and remove the glycerol. Note that TEV protease was initially produced in E. coli 
(see II.9.a), later it was provided by the Protein expression facility that produced in the same way, and 
eventually commercial TEV from Invitrogen was also used. GFP-His and TEV-His removal: Next day, free 
GFP-His and TEV-His were removed by reverse IMAC.  
Concentration of the untagged light subunit: The flow through, containing the purified light 
subunit was collected and concentrated with a centrifugal filter device of 100 kDa cut-uff until a final 
concentration of 4mg/mL (concentration was measured in the Nanodrop and corrected the value by its 
extinction coefficient).  
SEC: After ultracentrifugation (at 100,000g, 4 °C for 1 hour) to remove the aggregates, 500 µL of 
the supernatant of the sample were injected into a ÄKTA purifier in Superdex 200 10/300 GL column to 
analyze the monodispersity of the purified, digested and concentrated eukaryotic light subunits. The 
column was equilibrated with dialysis buffer. The sample was collected into a 96-well plate as in FSEC 
(see II.8) to analyze by SDS-PAGE the eluted sample. 
SDS-PAGE and silver staining: those light subunits that did not aggregate all in the void and had 
a promising SEC profile were analyzed by SDS-PAGE and silver staining. A sample of the different 
fractions interesting to analyze were mixed with LSB and run a SDS-PAGE in a 8% polyacrylamide gel that 
was stained using the Silver staining Pierce kit which stains which can detect proteins easily at low-
nanogram (1-5 ng). 
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II.9.a.  TEV protease overexpression and purification 
Part of the TEV used to digest the GFP-fusion light subunits was obtained as the following 
protocol details, and part were produced by the Protein Expression IRB Facility. 
TEV overexpression: A glycerol stock stored at -80 °C of E.coli BL21(DE3)pLyss (resistant to 
chloramphenicol) clone containing TEV protease with Hisx6 N-terminal tag cloned into a kanamycin 
resistant vector was kindly provided by Dr. Fita laboratory. 5 mL of growing media (LB media 
supplemented with 1 % glucose, 50 mg/mL kanamycin, and 35 mg/mL of chloramphenicol) were grown 
overnight. Next day, this cell culture was used to inoculate 500 mL of growing media for 2 hours at 37 °C 
and 250 rpm, until OD600 reached 0.5. At this point, the incubator was cooled down to 25 °C and the 
culture grown until OD600 was 0.8 (around 30 min). Then, 0.5 mM (final concentration) of isopropyl β-D-
1-thiogalactopyranoside (IPTG) was added to induce TEV overexpression at 25 °C and 250 rpm 
overnight. Next day, cell culture was pelleted at 10,000 rpm for 10 min (using the rotor JA14) and the 
pellet was resuspended in 50 mL of lysis buffer (20 mM Tris (pH 8), 150 mM NaCl, 10 mM imidazole, 2 
mM mercaptoethanol, and protease inhibitor EDTA free (Roche) (1 tablet/50 mL).  
Cell culture lysis: cells were disrupted using the cell disruptor at the Protein Expression IRB 
Core Facility, for 1 cycle at 15 kpsi, and 2 cycles at 20 kpsi. Then, added 10 mL of lysis buffer for 1 cycle 
at 20 kpsi to collect the remaining cells. The non-broken cells were pelleted at 12,000 rpm (using the JA 
25.50 rotor) for 30 min at 4 °C, and the supernatant was filtered for later purification.  
TEV purification: purification was performed by nickel affinity chromatography. The filtered 
supernatant was mixed with pre-equilibrated Ni-NTA resin and let in stirring for 1 hour at 4 °C. Then, it 
was transferred into a column and 3 washes of 10x bed volumes with washing buffer (20mM Tris-HCl 
(pH 8), 1 M NaCl and 10 mM imidazole were performed. His-TEV was eluted with 1 bed volume of 
elution buffer (20mM Tris-HCl (pH 8), 150 mM NaCl and 500 mM imidazole). 
Buffer exchange: using a centricon of 30 kDa cut-off (Millipore), the eluted sample was 
concentrated and replaced by 20 mM Tris-HCl (pH8), 150 mM NaCl, 2 mM DTT, 10 % glycerol, until 2 
mg/mL. Concentration was measured with the BCA method. Aliquots of 200 µL at 1 mg/mL were stored 
at -80 °C. A 20 µL sample was used to check the purification purity by running a 8% polyacrylamide SDS-
PAGE and the gel was stained by Comassie. In all the cases a double band was detected at ~28 kDa due 
to the autoproteolytic activity of TEV. 
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II.10.  GFP-fusion light subunits overexpressed in Pichia pastoris 
Xenopus tropicalis b0,+AT, Xenopus laevis LAT1, selected as the two best candidate light subunits 
in the S. cerevisiae pipeline adapted from Drew et al., 2008, were cloned as GFP-Hisx8 fusion proteins 
(at C-terminal) into pPICZB vector and transformed into P. pastoris KM71H strain by Dr. Rosell to check 
whether this expression system could produce higher amount of protein than S. cerevisiae. This was 
tried before to change into insect Sf9 cells, since it is a cheaper method, and it was already set up in the 
laboratory. The same fusion protein design as in S. cerevisiae cloning was followed (light subunit-TEV 
protease target-GFP-Hisx8). 
The different P. pastoris glycerol stocks stored at -80 °C were used to overexpress the different 
light subunits following the protocol described before for the human LAT2 (see Chapter I: Materials & 
Methods I.9). 
II.11. Baculovirus-Insect Cell Expression system 
The use of insect cell culture for heterologous protein expression for protein crystallography 
has increased in the last years due to its ability to produce relatively large quantities of 
posttranslationally modified eukaryotic proteins in a relatively short period of time. The most extended 
technology is the baculovirus expression vector system since this family of virus are the most common 
infecting insect cells, capable of infecting more than 500 species of insects, and also are ideal vectors for 
a variety of mammalian cell lines (BacMan Technology) (an example is Penmatsa et al., 2013). The most 
extended lepidopteran cells for baculovirus expression vector system are the Sf9 and Sf21 cell lines, 
which were isolated from ovarian tissue of the fall army worm Spodoptera frugiperda, and the High Five 
cell line, also designated BTI-Tn-5B1-4, that was stablished from the Trichoplusia ni embryonic tissue. In 
fact, Sf9 cells are a sub-clone of the Sf21 cells (the IPLBSF-Sf21 cell line) and were selected for their 
faster growth rate and higher cell densities than the Sf21 cells (Vaughn et al., 1977; O'Reilly et al., 1992).  
This technology offers great advantages over bacterial, yeast or mammalian protein expression 
systems since the recombinant proteins they express show similar biological activity, antigenicity and 
immunogenicity to the authentic natural proteins. Moreover, they are not pathogenic for vertebrates or 
plants, and vectors do not depend on helper viruses. Sf9 cell line (Invitrogen, Novagen) was selected to 
overexpress Xenopus b0,+AT, the best light subunit candidate from the screening performed in S. 
cerevisiae. 
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II.11.a. Growth and maintenance of the Sf9 cell line 
Thawing and adaptation of Sf9 insect cells: -80 °C stored Sf9 insect cells were thawed quickly in 
27 °C water bath, opened in sterile conditions under a laminar flow hood and carefully pipetted the 
content into a 15 mL centrifuge tube. 9 mL of pre-warmed 27ºC serum-free media Sf-900TMIII 
(Invitrogen) were added. This will be the media that will be used to manipulate these cells and in the 
expression of the correspondent proteins. Then, cells were resuspended 3 times and centrifuged at 400 
g for 3 min. Then, medium was removed and 10 mL of fresh medium (pre-warmed at 27 °C) was added, 
and cells were resuspended and transferred into a 125 mL shake flask. Incubation was done at 27ºC at 
120 rpm in a non-humidified and non-CO2 regulated environment. After 48 hours, growth and viability 
was determined by Trypan Blue dye exclusion method (see Sf9 cell counting). Cell number over 106 
cells/mL indicates viability over 85%.  
Sf9 cell counting: Cell viability was analyzed by the trypan blue dye exclusion method. For that, 
100 µL of cell culture was pipetted from the cell suspension culture into a 1.5 mL Eppendorf tube and 
mixed with 100 µL of trypan blue dye. Cells were resuspended and 10 µL were pipetted into a Newbauer 
chamber, counted in the several big squares and averaged them. The concentration of cells was 
calculated using:  Nx2x104 cells/mL (the dilution factor 1:1 when applying the Trypan blue is here 
corrected).  
Regular passage in cell suspension: To maintain Sf9 cell line at the maximum viability, cell 
culture was sub-cultured by diluting cells back to the optimal density every 2 to 3 days a week to 
maintain a log phase growth. Suspension cultures reached mid-log phase of growth at 2-4 × 106 cells/mL 
cell density. Then, they were diluted to 2.5× 105 (Friday) or 5× 105 cells/mL (Monday and Wednesday). 
Always a new flask was used, and maintained all the sterile conditions in all the process. The maximum 
volume that corresponds to each flask is 100 mL in 250 mL flask, 200 mL in 500 mL flask, 400 ml in 1L 
flask, and 0.8 L in 2 L flask. Media is always preheated at 27 °C. Cell culture is grown at 27 °C and 115 
rpm in a non-humidified and non-CO2 regulated environment. Maximum passage number for Sf9 cell for 
virus production is 25-30. 
Freezing and storage of insect cells: For freezing insect cells, 300 mL of 2 x 106 cells/mL cell 
cultures were centrifuged at 1500 rpm for 2 min and the cell pellet re-suspended in 30 mL cryo-
preservation media. Aliquots of the cell culture were slowly frozen in the blue-topped isopropanol 
container and cell culture vials were kept for a day at –80 °C before they were transferred to the liquid 
nitrogen tank for long-term storage. 
151 
Chapter II: Materials & Methods
II.12. Expression of Xenopus b0,+AT in the Sf9 insect cell line 
Xenopus tropicalis b0,+AT wild type, the mutant C150A b0,+AT and different truncated forms 
generated in N and C-terminal  on the C150A b0,+AT mutant were produced using this expression system. 
Sf9 cells were infected with baculoviruses containing the genes of interest using the Bac-to-Bac® 
Baculovirus Expression System (Invitrogen) which enables the efficient production of recombinant 
baculovirus for expression testing in insect cells.  
The Bac-to-Bac® Expression System allows the generation of recombinant baculovirus by site-
specific transposition in E. coli rather than homologous recombination in insect cells.  The Bac-to-Bac® 
Vector Kit contains the pFastBac™ vector. This plasmid contains a strong polyhedrin promoter for 
protein expression and a large multiple cloning site for simplified cloning. The pFastBac™ constructs are 
used to transform DH10Bac™ E. coli competent cells, where takes place the recombination between the 
pFastBac™ expression cassette with the parent bacmid to form an expression bacmid. The bacmid is 
then purified and transfected into insect cells for production of recombinant baculovirus particles. The 
parent bacmid in DH10Bac™ E. coli contains a segment of the lacZα gene. The lacZα gene is disrupted 
upon transposition of the expression cassette into the bacmid allowing for blue/white selection 
of recombinants. This enables to identification of recombinant colonies easily (Figure 67). 
Figure 67. Scheme of the steps followed to generate the recombinant baculovirus to express the protein 
of interest using the Bac-to-Bac baculovirus expression system.  
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II.12.a.     Cloning Xenopus b0,+AT into pFastBac vector: 
Xenopus b0,+AT wild-type cDNA was cloned between EcoRI and XhoI sites into pFastBac™ vector 
(Invitrogen). This strategy facilitated the cloning of b0,+AT wild-type cDNA in frame with a Thrombin site-
GFP-His8 cDNA previously cloned into this plasmid. The design of this construct allowed the 
heterologous expression of Xenopus b0,+AT wild-type as a C-terminal GFP-tagged protein. This cloning 
was performed following the protocol described before (see Chapter I: Materials & Methods I.1). In 
order to eliminate the reactive cysteine involved in the disulphide bridge with the corresponding heavy 
subunit (C150), the b0,+AT C150A mutant was generated by site-directed mutagenesis (see Chapter I: 
Materials & Methods, I.2). The primers used for this purpose were (bolded nucleotides are the ones 
mutated): gca ttt tac cct ggc gct gat ccc ccg gtg g (forward) and c cac cgg ggg atc agc gcc agg gta aaa tgc 
(reverse). This mutant was used as a template to generate by PCR different truncated versions in the N- 
and C-terminus of b0,+AT (∆10, ∆27 and ∆8, ∆13, ∆18 and  ∆28, respectively). The b0,+AT C150A mutant 
together with its truncated versions were cloned also between EcoRI and XhoI sites into the pFastBac™ 
vector containing the Thrombin site-GFP-His8.  
II.12.b.    Transformation of DH10Bac E. coli cells with the pFastBac- b0,+AT constructs: 
Firstly, 50 ng of the pFastBac with the desired gene cloned were mixed with 50 µL of DH10Bac 
E.coli competent cells and incubate for 30 min on ice. Heat shock was performed for 45 sec at 42°C, and 
let them 2 min in ice. Then, 200 µL of super optimal broth with catabolite repression media  (SOC) was 
added and incubated for 5 hours at 37°C (225 rpm). 100 µL of cells were plated on LB agar containing: 
50 µg/mL kanamycin, 7 µg/mL gentamicin, 10 µg/mL tetracycline, 100 µg/mL Bluo-gal, and 40 µg/mL 
IPTG and incubated for 24-48 hours at 37°C (48 hours is preferable time because earlier it is hard to 
distinguish between white and blue colonies). Then, up 2-6 white colonies were peaked and grown 
overnight at 37°C in 6 mL of LB media containing 50 µg/mL kanamycin, 7 µg/mL gentamicin and 10 
µg/mL tetracycline. From this 6 mL: 850 µL of cell suspension were mixed with 150 µL of autoclaved 
glycerol and stored at–80°C, and the rest of grown cells (~5 mL) were designated for bacmid isolation. 
II.12.c.    Isolation of the recombinant bacmid DNA from DH10Bac E. coli cells: 
For bacmid isolation, DH10Bac E.coli cells from 5 mL cultures were spin down for 10 min at 
4000 rpm. Supernatant was discarded and pellet dissolved in 200 µL of P1 buffer (Qiagen kits) or in Cell 
Resuspension Solution (Promega kits) and transferred into eppendorf tubes. Then, 200 µL of P2 reagent 
(Qiagen kits) or Cell Lysis Solution (Promega kits) was added and mixed by inverting eppendorf tubes 
few times. Then, 200 µL of N3 reagent (Qiagen kits) or Neutralization Solution (Promega kits) was added 
and mixed by inverting eppendorf tubes few times. Thereafter, a spin at maximum speed for 10 min was 
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done (using a table top centrifuge) and supernatant was collected in 2 mL eppendorf tubes. 1mL of 
isopropanol was added and tubes gently inverted and placed for 20 min at –20°C. Later on, tubes were 
spin for 15 min at RT and maximum speed in a 4ºC table top centrifuge. Supernatant was removed and 
pellet was washed with 1 mL of 70% ethanol by gently inverting eppendorf tube and spin for 15 min at 
room temperature (table top centrifuge). Then, supernatant was removed carefully and the pellet dried 
for 5 min. Finally, pellet was resuspended in 50 µL of autoclaved MilliQ water. Concentration of bacmid 
DNA was determined by using a NanoDrop spectrophotometer (Thermo Scientific) and diluted to 1 
mg/mL. 
II.12.d.   Transfection of Sf9 cells with the recombinant bacmid DNA: 
To produce the first population of virus (P1), Sf9 cells were seeded into 6-well plates at 0.9×106 
cells/well in 2 mL of the serum-free media Sf-900TMIII (Invitrogen) and incubated at 27°C until they 
attach (around 30 min). While waiting, 8 µL of Cellfectin II (Invitrogen) were added to 100 µL of Sf-
900TMIII media for each transfection condition. In parallel, 1 µL of 1mg/mL recombinant bacmid DNA 
was then added to 100 µL of Sf-900TMIII media. Then, the Cellfectin II containing tubes were mixed with 
the bacmid sample and incubated for 30 min at room temperature. DNA mix was added to each well 
and cells were incubated for 96 hours in 27 °C incubator (to prevent strong evaporation of media, plates 
were put into a recipient containing a slide of wet paper under them) in a non-humidified, non-CO2 
regulated environment. Taking advantage of the generation of GFP fusion proteins, the expression was 
checked in a fluorescence microscope previous storage of P1. Then, supernatant containing P1 virus was 
collected by pipetting carefully (~2 mL from each well) and filtered into 2 mL eppendorf tube using 2 mL 
syringe and a filter of 0.2 µm. This stock of P1 virus was stored light protected at 4°C. 
II.12.e.   Infection of Sf9 cells with P1 virus (to produce P2 virus): 
Sf9 cells were sub-cultured in 400 mL pre-warmed media in 1L flask at final concentration of 
1.5×106 cells/mL. Then, infected with the P1 generated previously (see II.12.d) and incubated in an 
orbital shaker at 27 °C and 120 rpm during 96 hours in a non-humidified, non-CO2 regulated 
environment. Then, cells were pelleted for 10-15 min at 4000-5000 rpm and collected supernatant 
containing P2 virus which was then filtered using disposable 0.2 µm filters (0.5 L Corning filter system 
was used) and stored at 4 °C light protected. 
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II.13.  Baculovirus titration by the end point dilution assay: 
A 10mL stock of Sf9 cells at a density of 0.75 x 106/mL in a sterile culture reservoir was needed. 
Then, 100 µL/well were seeded into a 96-well black plate (75,000 cells/well) and let them attach at 27 °C 
in a non-humidified and non-CO2 regulated environment. Using a sterile deep-well 8-strip cluster, 10
-1 to 
10-8 stocks of viruses were made in Sf-900TMIII media by serial dilution (360 µL medium + 40 µL virus): 
End point dilution preparation for baculovirus tritation 
Sf-900TMIII media  P1 o P2 virus Stock viruses 
360 µL + 40 µL 10-1
360 µL + 40 µL 10-1 dilution 10-2
360 µL + 40 µL 10-2 dilution 10-3
360 µL + 40 µL 10-3 dilution 10-4
360 µL + 40 µL 10-4 dilution 10-5
360 µL + 40 µL 10-5 dilution 10-6
360 µL + 40 µL 10-6 dilution 10-7
360 µL + 40 µL 10-7 dilution 10-8
Once cells were attached to the 96-well plate, medium was removed and replaced with 100 µL 
diluted virus. Infection was done in triplicates. 72 hours post-infection, green foci number of cells was 
counted in the dilution that gave <10 foci/well. To calculate the viral titer, the following equation was 
used:   
(Average foci) x dilution factor x 10 = (pfu/ml) 
And to calculate the volume required for subsequent infection, the following equation was used: 
(desired MOI) x (number of cells) =   (mL)  
  Virus titer 
II.14. Expression of truncated versions of C150A b0,+AT: overexpression and cell 
membrane extraction 
40 mL Sf9 cultures at a cell density of 3-4×106 cells/mL were infected by adding P2 viruses, 
obtained as has been described previously, corresponding to the different truncated forms (∆10, ∆27 in 
the N-terminus; ∆8, ∆13, ∆18 and  ∆28 in the C-terminus) and to b0,+AT wild-type as a control. In all 
cases cells were infected using a Multiplicity of Infection (MOI) of 2. Sf9 cultures were incubated for 48 
hours in an orbital shaker at 27°C and 115 rpm. Cells were harvested by spinning for 15 min at 4000 rpm 
and pellets resuspended with 2 mL of cold resuspension buffer (20mM Tris (pH 8) 150mM NaCl with 2 
tablets of protease inhibitor complete-EDTA free). The cell resuspension was lysated by sonication at 4 
°C using 40% amplitude and 0.7 of intensity after adding DNAse to avoid viscosity. Sonication was 
performed for 15 sec 4 times. Then, non lysated cells were removed by centrifugation at 10,000 rpm for 
20 min, and membranes were obtained by ultracentrifugation of the supernatant at 250,000g for 1 
hour. Membranes were resuspended with 2 mL of resuspension buffer using a potter homogenizer. 
Membranes were flash-frozen with liquid N2 and stored at -80 °C.  
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II.15.  In-gel-fluorescence and FSEC to analyze protein expression and stability 
The overexpressed protein in the membrane extracts (II.14) was analyzed by in-gel fluorescence 
(as in II.5) to check the protein expression levels and integrity. In addition, the quality of the C150A 
b0,+AT truncated versions in comparison with b0,+AT wild-type was analyzed by FSEC (similarly to II.8). 
0.5mL of solubilization buffer (20mM Tris 20mM (pH 8) 150mM NaCl 2% DDM, 0.4% CHS) was added to 
an equal volume of the membrane stock. The mixture was incubated at 4 °C for 1 hour with mild 
agitation and the non-solubilized material removed by ultracentrifugation at 100,000g at 4 °C for 1 hour. 
0.5 mL of the supernatant were injected onto a Superose 6 10/300 column equilibrated in 20 mM Tris–
HCl (pH 7.5), 0.15 M NaCl and 0.03% DDM. The eluted sample was collected in fractions row by row in a 
96-well plate and GFP fluorescence was measured. A graphic corresponding to the fluorescence of the 
GFP fusion protein was builded in GraphPad with the data obtained (as in II.8). 
II.16. Large scale expression of b0,+AT C150A (∆28 CTER) and purification 
1,6L Sf9 culture (2x2L flasks) at a cell density of 3-4×106 cells/ml was infected with the b0,+AT 
C150A (∆28 CTER) P2 virus at a final MOI of 2. Cells were incubated for 48 hours in an orbital shaker at 
27°C and 115 rpm and harvested as has been described previously. The pellet was resuspended with 25 
mL of cold resuspension buffer and cells lysed by sonication (see II.6). Membranes were purified 
following the previously described protocol and were resuspended with 20 mL of resuspension buffer 
using a Potter homogenizer. Membranes were flash-frozen with liquid N2 and stored at -80 °C. 
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II.16.a.    Buffer preparation for b0,+AT C150A (∆28 CTER) purification 
All the buffers used in the protein purification contained the resuspension buffer (RB) as a base 
(20mM Tris (pH 8) 150mM NaCl), on which protease inhibitor complete-EDTA free (Roche) was added 
previous addition of detergents. Thereafter, following this order it was added detergent, cholesterol and 
lipids. All buffers were sonicated at 40% amplitude and 0.7 intensity, for 1 minute at intervals of 10 sec, 
and filtered. Note: in all cases imidazole was added from a 1M (pH 8) stock to avoid changes on pH. 
Solubilization buffer (2x DDM, CHS, lipid) (SB): first, fresh complete-EDTA free (1 tablet for 
each 50 mL of final volume) was added and dissolved. Then, DDM 2% w/v was added until completely 
dissolved. Then, Cholesteryl hemisuccinate Tris salt (CHS) 0.4% w/v (Sigma) and 10mM 1,2-dipalmitoyl-
sn-glycero-3-phosphocholine (DPPC) (Avanti Polar Lipids) were added. This buffer was sonicated as 
mentioned before to facilitate the solubility of CHS and lipids. Finally, imidazole was added to obtain a 
10 mM final concentration. This buffer was added to an equal volume of the membrane stock volume to 
obtain a final 1x solubilization buffer with 1% DDM, 0.2% CHS, 5mM DPPC, 5mM imidazole. 
- Equilibration buffer: 1x solubilization buffer was used. 
- Washing buffer (WB): Resuspension buffer with 0.05% w/v DDM, 0.01% w/v CHS, 0.25 mM DPPC 
and 25 mM imidazole. It was obtained from diluting 40 times the solubilization buffer. 
- Elution buffer: WB but with 250 mM imidazole. 
- Dialysis buffer (DB): Resuspension buffer with 0.026% w/v DDM, 0.0052% w/v CHS, 0.25 mM DPPC 
and 5 mM CaCl2. 
- Dialysis buffer after thrombin digestion: DB without CaCl2. 
II.16.b.    Solubilization, purification and preliminary 3D-crystallization screening of 
C150A b0,+AT (∆28 CTER) 
Membranes from 1.6L cell culture were solubilized by adding the same volume of solubilization 
buffer (2x) to the membrane extract volume. Solubilization was performed by stirring for 2 hours and 
sample was ultracentrifuged for 1 hour at 100,000g at 4 °C to remove the aggregated material.  
Supernatant was used to carry out the purification. 2.5 mL of Ni-NTA resin (5 mL of 50% slurry 
for 2.5 mg of GFP fusion to be purified) were equilibrated with five column volumes of equilibration 
buffer for 20 min in an orbital shaker at 4 °C. Detergent-solubilized membranes were added to the 
equilibrated nickel resin for binding. Magnetic stirrer was used to mix the solution at 4 °C for 2 hours. 
Then, it was transferred to a closed-flow column, let the resin precipitate, open the flow and collected 
the flow through. Before the column became dry, flow was stopped or directly added washing buffer. 
100 µL flow through sample was collected to check binding efficiency by fluorescence quantification. 
Then, 20 column volumes of washing buffer were applied to the resin column without let it dry. After 
washes flow was stopped, 15 mL of elution buffer were applied, closed the column entrance and let for 
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15 min in orbital rotation at 4 °C. Then, opened the flow and collected the elution every 1 mL in 
different eppendorf 1.5 mL tubes. First and last tubes were discarded. The 13 mL resulted from elution 
were concentrated until 1.5 mL using a centricon (Amicon Ultra 15 mL 100kDa cut off). Protein amount 
was checked by nanodrop as previously described. A 1/10 dilution was done previous nanodrop 
measurement in order to avoid imidazole interference.  
CaCl2 was added to the sample at 5 mM final concentration, and thrombin from human plasma 
(Sigma) was added at 1:100 ratio (thrombin: fusion protein). Then, placed into a dialysis tubing of 14 kDa 
cut off membrane and dialyzed overnight at 4 °C against 100 times the sample volume with DB. As 
thrombin is ~37 kDa, and GFP tag is also under this MW, size exclusion chromatography will clearly 
separate them from the membrane protein which MW is higher ~54 kDa and together with detergent, 
cholesterol and lipids this MW increases much more.  
A second dialysis was performed with new DB in order to diminish the excess of detergent, CHS, 
lipids, and remove the CaCl2. After dialysis, sample was concentrated until 1 mL using centricon (Amicon 
Ultra 15 mL and 2 mL 100kDa cut off). 
Äkta purifier (GE healthcare) for fast protein liquid chromatography (FPLC) and Superdex 200 
(10/300) column (GE Healthcare Life Sciences) were used. 500 µL of purified sample were run at 4 °C 
with filtered new dialysis buffer. Peaks from 9.8 mL to 11 mL were collected and concentrated. Protein 
concentration was measured with nanodrop and sample was concentrated again with centricon 
(Amicon Ultra 2 mL 100 kDa cut off) until 4 mg/mL for crystallization screenings. 
The crystallization screening was performed by hanging drop vapor diffusion at 20 °C using the 
MemGold pack screening containing 96 different conditions.  A drop ratio of 0.5 µL of protein (4 mg/mL 
concentrated) with 0.5 µL reservoir solution was used. The obtained crystals were flash frozen in liquid 






1. 4F2hc-ED is positioned tilted on LAT2 covering almost completely the external face of the
transporter which is confirmed by three different lines of evidence. The low resolution of the
3D model of TEM negative-staining SPA at 21 Å of purified human 4F2hc/LAT2 overexpressed in
P. pastoris suggested that the 4F2hc ectodomain was positioned on top of LAT2. Crosslinking
experiments using two length arm bismaleimides allowed to identify specific residues that
nearly completely (>80%) crosslinked 4F2hc and LAT2 co-expressed in HEK 293T and triangulate
together with the endogenous intersubunit disulphide bridge the position of 4F2hc-ED on top
of LAT2. In addition, the steric restrictions defined by the results of crosslinking fulfill the best
docking energy model, as well as two additional and highly similar poses, obtained by docking
4F2hc-ED atomic structure with the human LAT2 homology model built based on the structure
of the open-to-out AdiC.
2. The interaction between 4F2hc and the extracellular surface of LAT2 increases the stability of
the detergent-solubilized light subunit. Specifically, the ectodomain of 4F2hc suffices to
increase the stability of DDM-solubilized LAT2. The hydrophobic character of the interaction
between 4F2hc-ED and LAT2 might be at the basis of the stabilization of this light subunit by
4F2hc.
3. The screening of 24 metazoan light subunits of HATs for protein expression, solubility and
stability, based on GFP and S. cerevisiae pipeline, resulted in the selection of b0,+AT (X.
tropicalis) followed by LAT1 (X. laevis) as best candidate proteins for 3D crystallization studies.
b0,+AT and LAT1 were solubilized and purified in DDM/ Cholesteryl hemisuccinate Tris salt (CHS)
and CYMAL-6/CHS, respectively.
4. The stability of the best candidate, b0,+AT, was improved by addition of CHS and 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) during solubilization and purification.
5. Changing the expression system to Sf9 insect cells increased the expression levels up to 5 fold,
and improved the quality of the overexpressed protein when analyzed by size exclusion
chromatography.
6. Furthermore, it was selected the most stable truncation form in N and C-terminal to reduce
protein flexibility. In addition, it was mutated-off the reactive cysteine (C150A) to diminish
protein aggregation, resulting finally b0,+AT (X. tropicalis) C105A, ∆28 C-terminal, as the most
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a b s t r a c t
Human heteromeric amino acid transporters (HATs) play key roles in renal and intestinal re-absorption,
cell redox balance and tumor growth. These transporters are composed of a heavy and a light subunit,
which are connected by a disulphide bridge. Heavy subunits are the two type II membrane N-glycopro-
teins rBAT and 4F2hc, while L-type amino acid transporters (LATs) are the light and catalytic subunits of
HATs. We tested the expression of human 4F2hc and rBAT as well as seven light subunits in the methy-
lotrophic yeast Pichia pastoris. 4F2hc and the light subunit LAT2 showed the highest expression levels and
yields after detergent solubilization. Co-transformation of both subunits in Pichia cells resulted in over-
expression of the disulphide bridge-linked 4F2hc/LAT2 heterodimer. Two sequential afﬁnity chromatog-
raphy steps were applied to purify detergent-solubilized heterodimers yielding 1 mg of HAT from 2 l of
cell culture. Our results indicate that P. pastoris is a convenient system for the expression and puriﬁcation
of human 4F2hc/LAT2 for structural studies.
 2012 Elsevier Inc. All rights reserved.
Introduction
Heteromeric amino acid transporters (HATs)3 are present only in
metazoans. They are the unique example known in all kingdoms of
life of solute transporters composed of two subunits, a heavy
(SLC3 family) and a light subunit (SLC7 family) linked by a conserved
disulphide bridge [1–3]. The heavy subunit is essential for trafﬁcking
of the holotransporter to the membrane [4,5], whereas the light sub-
unit catalyses the transport activity [6]. Functionally, HATs are ami-
no acid antiporters (exchangers) with a 1:1 stoichiometry [7,8]. Two
homologous human heavy subunits have been cloned and are called
rBAT and 4F2hc. rBAT is related to the transport of neutral and cat-
ionic amino acids (system b0,+) and 4F2hc is the heavy chain of the
surface antigen 4F2hc (also named CD98 or fusion regulatory protein
1 (FRP1)) [2]. So far, eight human light subunits have been identiﬁed.
Six of them are partners of 4F2hc (LAT1, LAT2, y+LAT1, y+LAT2, asc1,
xCT), one heterodimerizes with rBAT (b0,+AT) and one (AGT1) seems
to interact with yet unknown heavy subunit(s) [1,3].
Most human cells, if not all, express HATs. It is therefore not
surprising that these transporters have an impact on human health.
Thus, the aminoacidurias cystinuria types A and B, and lysinuric
protein intolerance are caused by mutations in rBAT, b0,+AT and
y+LAT1, respectively [9,10]. The transporter 4F2hc/xCT (system
xc ) controls cell redox balance [11], is required for Kaposi’s
sarcoma-associated herpesvirus infection [12,13] and is involved
in cocaine relapse [14]. Moreover, 4F2hc/LAT1 is overexpressed in
many human tumors, thus providing essential neutral amino
acids for cell growth and stimulation of mTOR (mammalian
target of rapamycin) [15]. In addition to the role of HATs in amino
acid transport, 4F2hc mediates b1- and b3-integrin signaling
[16,17]. Indeed, 4F2hc is necessary for the integrin-dependent
rapid proliferation of B-lymphocytes during clonal growth and
for growth of vascular smooth muscle cells after arterial injury
[17,18].
Structural information on HATs is very scarce [3]. SLC3 mem-
bers (heavy subunits) are type II membrane N-glycoproteins with
a single transmembrane domain (TMD), an intracellular N-termi-
nus and a large extracellular C-terminus (Fig. 1A). The extracellular
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domain of these proteins has amino acid sequence homology with
bacterial a-amylases [19]. Moreover, X-ray diffraction of the extra-
cellular domain of human 4F2hc revealed a three-dimensional
structure similar to that of bacterial glucosidases. The structure
of the 4F2hc ectodomain consists of a triose phosphate isomerase
(TIM) barrel (ba)8 and eight antiparallel b-strands [20]. Despite
this homology, 4F2hc lacks key catalytic residues and has no gluco-
sidase activity [20]. The light subunits are highly hydrophobic and
not glycosylated proteins. Cysteine-scanning mutagenesis studies
with xCT support a twelve TMD topology with intracellular N-
and C-termini (Fig. 2A) as a model for the light subunits of HATs
[21]. Furthermore, the cysteine residue between TMD III and IV,
which is involved in the inter-subunit disulphide bridge, is con-
served. Structure–function studies [22,23] suggest that the struc-
tures of the light subunit of HATs should be similar to those of
amino acid sequence-related (<20% amino acid sequence identity)
prokaryotic transporters AdiC (L-arginine/agmatine antiporter)
[24–27], ApcT (broad-speciﬁcity amino acid transporter) [28] and
GadC (glutamate/GABA antiporter) [29]. These structures present
the so-called ‘5 + 5 inverted repeat’ fold, which was initially de-
scribed in Na+-coupled symporters [30–33]. This fold is character-
ized by ﬁve consecutive TMDs in the N- and C-terminal halves of
the transporter, which are related by a pseudo-twofold symmetry.
The low amino acid sequence identity of AdiC, ApcT and GadC with
the eukaryotic light subunits precludes the generation of a robust
and reliable structural model of HATs based on these prokaryotic
transporters. Moreover, in these prokaryotic structures there are
no clues on the molecular interaction between the heavy and the
light subunits of HATs.
In the present study, we report the ﬁrst attempt to overexpress
heterologously HATs for structure determination. Human HATs
were expressed in the methylotrophic yeast Pichia pastoris, which
can be used for high cell density fermentation and has been suc-
cessfully used for the expression of eukaryotic membrane proteins
[34–37]. Our results indicate that overexpression and puriﬁcation
of milligram amounts of recombinant human heterodimer 4F2hc/
LAT2 is possible using the Pichia expression system. This opens
the path for future structural studies and elucidation of the struc-
ture of human HATs.
Materials and methods
Microorganism strains and plasmid
Escherichia coli DH5 was used for cloning procedures. The P. pas-
toris expression kit, including vectors and host cells, was purchased
from Invitrogen. Human HATs were expressed in the Pichia strain
KM71H using the pPICZB vector.
Generation of expression constructs and P. pastoris transformation
The cDNAs of the full length human light subunit genes (asc1,
LAT1, LAT2, y+LAT1, y+LAT2, xCT and b0,+AT; accession numbers:
Q9NS82, Q01650, Q9UHI5, Q9UM01, Q92536, Q9UPY5 and
P82251) and human heavy subunit genes (4F2hc and rBAT; acces-
sion numbers: P08195 and Q07837) were inserted into the pPICZB
vector between EcoRI and NotI sites. A Kozak consensus sequence
(between brackets), a linker coding for Ala (italics), and a StrepTag-
II sequence (underlined) or a 10 His-tag for the light or heavy
subunits were incorporated before the codon corresponding to
the second amino acid residue of each protein gene as follows:
[ACC ATG G]-CA-TGGTCACATCCTCAATTTGAAAAA. Moreover, a
DNA sequence encoding the Factor Xa cleavage site (ATC-
GAAGGTCGT) was added just after the tag sequences in all cases.
To create the expression construct of 4F2hc/LAT2, the expression
cassette containing the light subunit (AOX1 promoter plus cDNA
for LAT2) was excised from the pPICZB–LAT2 construct using the
BglII and BamHI sites. The cassette was then ligated into the
pPICZB–4F2hc construct that was linearized with BglII. Before liga-
tion, the PmeI restriction site in the AOX1 promoter of the heavy
subunit was removed by site-directed mutagenesis to allow the
Fig. 1. Expression and solubilization of the heavy subunits of HATs: rBAT and 4F2hc. (A) Schematic representation of a heavy subunit. The locations of the termini and the
engineered His-tag are indicated. (B) Left panel: Western blot analysis using anti-4F2hc antibody of untreated and Endo F treated membranes isolated from 4F2hc expressing
Pichia cells. Right panel: Western blot analysis using anti-rBAT antibody of membranes isolated from rBAT expressing Pichia cells. (C) Solubilization with DDM of 4F2hc and
rBAT from isolated membranes. An important fraction of 4F2hc is successfully solubilized by DDM and found in the supernatant (SN) after ultracentrifugation. This is not the
case for rBAT, which aggregates and is exclusively found in the pellet (P).
Fig. 2. Expression and solubilization of the light subunits of HATs: asc1, LAT1, LAT2,
y+LAT2, xCT, b0,+AT and y+LAT1. (A) Schematic representation of a light subunit. The
locations of the termini and the engineered StrepTagII are indicated. TMDs are
numbered. (B) Western blot analysis using anti-StrepTagII antibody of isolated
membranes indicating the expression levels of the different light subunits of HATs.
(C) Solubilization with DDM of the best expressing light subunits, i.e., LAT2, LAT1
and y+LAT2. LAT2 was solubilized best and was mainly found in the supernatant
(SN) after ultracentrifugation. LAT1 only solubilized partially and y+LAT2 not at all,
i.e., all the protein was found in the pellet (P).
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linearization of the 4F2hc/LAT2 construct by this enzyme. The con-
structs containing the heavy subunits (4F2hc or rBAT), the light
subunits (asc1, LAT1, LAT2, y+LAT1, y+LAT2, xCT or b0,+AT), or the
4F2hc/LAT2 heterodimer were used for transformation. P. pastoris
cells were transformed by electroporation (BioRad Micropulser)
using the constructs linearized with PmeI as described in the
manufacturer’s manual. Transformants were selected on YPD
plates containing 100 lg/ml Zeocin (Invitrogen).
Expression screening of human HATs in P. pastoris
Zeocin resistant colonies were grown overnight in 15 ml of buf-
fered complex glycerol medium (BMGY) until the cultures reached
an OD600 of 2–6. After pelleting at 1500g and 4 C for 5 min, the
cells were resuspended in buffered complex methanol medium
(BMMY) using 1/5 of the original culture volume and grown for
72 h at 30 C. Additional methanol was added after 24 and 48 h
to a ﬁnal concentration of 1% (v/v), in order to maintain inducing
conditions. Cell pellets were resuspended in 50 mM sodium phos-
phate, pH 7.4, 1 mM EDTA, 5% (w/v) glycerol and complete EDTA-
free protease inhibitors (Roche). After addition of an equal volume
of acid-washed glass beads (0.25–0.5 mm diameter), the cells were
broken using the FastPrep system (MP Biomedicals) by three cycles
of vortex for 10 s interspersed with 1 min incubations on ice. Glass
beads, unbroken cells and other cell debris were removed by cen-
trifugation at 1500g and 4 C for 10 min. The supernatant was col-
lected and the pellet was resuspended in the original volume with
fresh lysis buffer, subjected to an additional lysis cycle and recen-
trifuged. The combined supernatants were then ultracentrifuged at
250,000g and 4 C for 1 h. The crude membrane pellet was resus-
pended in 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5% glycerol,
and the protein content determined using the bicinchoninic acid
protein (BCA) assay (Pierce).
For each protein and protein complex (i.e., heavy subunits, light
subunits and 4F2hc/LAT2 heterodimer) isolated membranes from
20 clones were tested by Western blot analysis to identify the
clone with the highest expression level and thus optimize expres-
sion. Light subunits, 4F2hc and rBAT were immunodetected using
anti-StrepTagII (IBA GmbH), anti-4F2hc (H-300; Santa Cruz Bio-
technology) and anti-rBAT [38] antibodies, respectively. The
4F2hc/LAT2 expression was analyzed using anti-StrepTagII and
anti-4F2hc antibodies. No remarkable loss of 4F2hc/LAT2 expres-
sion, e.g. by loss of expression cassettes through recombination,
was detected over repetitive rounds of cultivation and induction.
In vivo uptake of radiolabeled L-leucine into P. pastoris expressing
4F2hc/LAT2
The uptake assay was basically performed as described by
Döring et al. [39] with small adaptations. Brieﬂy, transformed
and untransformed Pichia cells were harvested by centrifugation
(2500g, 10 min, room temperature), washed twice with 10 mM
Tris-HEPES, pH 7.4, 150 mM choline chloride, 1 mM MgCl2, 1 mM
CaCl2 (transport buffer) and resuspended by adding 10 ll of the
same buffer per OD600 unit. Uptake was initiated by mixing 10 ll
of resuspended cells with 40 ll of transport buffer containing
0.5 lCi of [3H]L-leucine (American Radiolabeled Chemicals). Up-
take of L-leucine (10 lMﬁnal concentration) was terminated at dif-
ferent time points (see Fig. 3A) by addition of 3 ml of ice cold stop
buffer (10 mM Tris-HEPES, pH 7.4, 150 mM choline chloride, 5 mM
L-leucine) and ﬁltered through membrane ﬁlters (Sartorius,
0.45 lm pore size). Filters were washed twice with 1–2 ml of ice
cold stop buffer and dried. The trapped radioactivity was counted
in a Packard Tri-Carb liquid scintillation counter. All experimental
values were corrected by subtracting zero-time values.
Large-scale expression and puriﬁcation of 4F2hc/LAT2
Large-scale cultures were performed in 2 l ﬂasks using the same
conditions as described for the expression screening, e.g. 10 ﬂasks
for a ﬁnal cell culture volume of 2 l. Cell pellets were resuspended
at a concentration of 0.2 g/ml in 50 mM sodium phosphate, pH 7.4,
1 mM EDTA, 5% glycerol and complete EDTA-free protease inhibi-
tors (Roche). The cells were then lysed in a continuous ﬂow Cell
Fig. 3. Expression, function and solubilization of the human heterodimer 4F2hc/LAT2. (A) [3H]L-leucine (10 lM) uptake into Pichia cells overexpressing 4F2hc/LAT2. Clear
uptake of the radioligand is observed when compared with control (untransformed) cells. Bars represent mean ± SEM from triplicates of two independent experiments. (B)
Western blot analysis of membranes isolated from Pichia cells expressing 4F2hc and LAT2. The anti-StrepTagII antibody indicated the presence of heterodimers only and no
LAT2 monomers under non-reducing conditions. Under reducing conditions (+ DTT), the heterodimer disappeared yielding the LAT2 monomer band. The anti-4F2hc antibody
indicated the presence of 4F2hc/4F2hc homodimer, 4F2hc/LAT2 heterodimer and 4F2hc monomer in the absence of DTT. Under reducing conditions (+ DTT), only 4F2hc
monomers were visible. Western blot analysis using anti-StrepTagII antibody of isolated membranes from LAT2 expressing Pichia cells indicated the presence of LAT2 (major
fraction; at 50 kDa) and an artefactual LAT2 homodimer (minor fraction; at 100 kDa), both under reducing and non-reducing conditions. Such dimerizations of light
subunits in PAGE have been reported [41]. (C) The detergent DDM completely solubilized 4F2hc/LAT2 and 4F2hc/4F2hc from isolated membranes: all protein is found in the
supernatant (SN) and none in the pellet (P) after ultracentrifugation.
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Disrupter (Constant Systems TS series) in two rounds of 20,000 and
40,000 psi. After centrifugation at 20,000g and 4 C for 15 min, the
supernatant was recovered and ultracentrifuged at 250,000g and
4 C for 1 h. The pellet was resuspended and homogenized (50 ml
glass homogenizer) in 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5%
glycerol, and ultracentrifuged again. Finally, the membrane pellet
was resuspended in 20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 5%
glycerol at a protein concentration between 18 and 29 mg/ml. Ali-
quots were frozen in liquid nitrogen and stored at 80 C until use.
Frozen P. pastoris membranes containing overexpressed 4F2hc/
LAT2 were thawed and solubilized for 1 h at 4 C under gentle agi-
tation in 2% n-dodecyl-b-D-maltopyranoside (DDM; Anatrace),
20 mM Tris–HCl, pH 8, 300 mM NaCl and 10% glycerol. The protein
concentration during solubilization was 3 mg/ml. After ultracentri-
fugation for 1 h (100,000g at 4 C), 4F2hc/LAT2 was puriﬁed by two
sequential afﬁnity chromatography steps. The ﬁrst one was a metal
afﬁnity chromatography using cobalt beads (Talon, BD Science)
and 20 mM Tris–HCl, pH 8, 300 mM NaCl, 10% glycerol, 20 mM
imidazole, 0.25% DDM as washing buffer. 4F2hc/LAT2 was eluted
with washing buffer supplemented with 200 mM imidazole. Next,
the eluted heterodimer was puriﬁed by Strep-Tactin afﬁnity chro-
matography (IBA) using 20 mM Tris–HCl, pH 8, 300 mM NaCl, 10%
glycerol, 0.1% DDM as washing buffer. The protein was eluted with
the same buffer supplemented with 3 mM desthiobiotin. The
homogeneity of the puriﬁed 4F2hc/LAT2 was estimated by size-
exclusion chromatography using a Superose 6 10/300 GL column
(GE Healthcare). Protein concentration was determined by BCA
assay.
Results and discussion
Expression screening of human HATs in P. pastoris
The cDNAs encoding the human heavy subunits (4F2hc and
rBAT) were cloned into the pPICZB vector. After transformation of
the constructs into the P. pastoris KM71H strain, expression tests
were performed. His-tagged recombinant proteins were visualized
by Western blot analysis from isolated membranes using anti-
4F2hc and anti-rBAT antibodies, respectively (Fig. 1). Bands were
observed at the expected size of monomers of 4F2hc (70 kDa)
and rBAT (90 kDa) (Fig. 1B). Human 4F2hc is a glycoprotein with
four putative N-glycosylation sites (N264, N280, N323 and N405).
Its expression generated at least two bands corresponding to
unglycosylated and glycosylated 4F2hc forms (Fig. 1B, left lane).
The lowest band was most abundant representing the unglycosy-
lated form of 4F2hc as demonstrated by endoglycosidase F treat-
ment (Fig. 1B, right lane). The expression of rBAT rendered in
addition to the monomer band (90 kDa) a diffuse, lower band
(<75 kDa), most probably representing proteolytic fragments
(Fig. 1B). When 4F2hc and rBAT were solubilized from Pichia mem-
branes using DDM, only 4F2hc was extracted efﬁciently (Fig. 1C).
The dramatic low solubilization yield for rBAT monomers suggests
missfolding of this human protein when expressed in yeast. Re-
cently, it has been reported that b0,+AT, the light subunit associated
to rBAT, facilitates the proper folding of rBAT in mammalian cells
[40]. In order to determine if the co-expression of rBAT and
b0,+AT may increase the stability of the heavy subunit, we tried ini-
tially the expression of b0,+AT alone as a Strep-tagged protein to
check the capability of Pichia to express this transporter. b0,+AT
was not produced efﬁciently in this expression system (Fig. 2B)
and therefore, the co-expression of both subunits (rBAT and
b0,+AT) was not considered.
The human light subunits associated to 4F2hc (asc1, LAT1, LAT2,
y+LAT1, y+LAT2 and xCT) were expressed in P. pastoris as
Strep-tagged proteins as well (Fig. 2B). Recombinant proteins were
visualized by Western blotting using anti-StrepTagII antibody.
Bands were detected at expected sizes, i.e., between 40 and
50 kDa (Fig. 2B). LAT1, LAT2 and y+LAT2 were the light subunits
with the best expression levels, although only LAT2 was efﬁciently
solubilized with DDM (Fig. 2C). In Western blots, monomer and di-
mer bands of LAT2 were discerned at 50 and 100 kDa, respec-
tively (Figs. 2B and 3B, rightmost two lanes). Such unspeciﬁc
dimerizations have been reported for 4F2hc light subunits sub-
jected to SDS–PAGE but not in native plasma membranes [41].
Expression of the human 4F2hc/LAT2 heterodimer in P. pastoris
Since the best light and heavy subunits, in terms of expression
levels and detergent solubilization yields, were 4F2hc and LAT2,
the 4F2hc/LAT2 heterodimer was expressed in P. pastoris. Uptake
experiments with yeast cells expressing 4F2hc/LAT2 indicated
transport of L-leucine (Fig. 3A), a characteristic substrate of this
HAT [42]. To estimate the expression level of this heterodimer in
isolated membranes by Western blotting, anti-StrepTagII and
anti-4F2hc antibodies were used. In both cases, a band at
120 kDa appeared in the absence of DTT, but collapsed when
samples were analyzed under reducing conditions (Fig. 3B). Thus,
only LAT2 (50 kDa) and 4F2hc (70 kDa) were detected in the
presence of DTT. We concluded that recombinant human 4F2hc/
LAT2 heterodimer is functional and correctly expressed in P. pasto-
ris, and contains the characteristic disulphide bridge connecting
both subunits. A less conspicuous band corresponding to 4F2hc
homodimers (140 kDa; above of the heterodimer band) was also
detected, but only with anti-4F2hc antibodies under non-reducing
conditions. In Western blots performed in the presence of DTT, this
band collapsed to the height of 4F2hc monomers (Fig. 3B). Finally,
4F2hc monomers (70 kDa), but not LAT2 monomers or dimers,
were detected under non-reducing conditions showing the excess
expression of 4F2hc over LAT2 in isolated membranes (Fig. 3B).
DDM efﬁciently solubilized 4F2hc/LAT2 heterodimer, 4F2hc
homodimer (Fig. 3C) and 4F2hc monomers (data not shown).
4F2hc/LAT2 heterodimer was puriﬁed using DDM during the whole
process by two sequential afﬁnity chromatography steps: ﬁrst by
cobalt and then by Strep-Tactin afﬁnity chromatography. The puri-
ﬁed heterodimer was analyzed by SDS–PAGE, Western blotting and
size exclusion chromatography (SEC) (Fig. 4). As seen in the silver-
stain SDS–PAGE gel, the most abundant species corresponded to
the 4F2hc/LAT2 heterodimer (Fig. 4A, lane 1). In addition, a low
contribution of 4F2hc monomers and heterodimer aggregates/olig-
omers was found. The presence of the 4F2hc/LAT2 heterodimer,
and 4F2hc and LAT2 monomers was also detected byWestern blot-
ting (Fig. 4A, lanes 2 and 3). Importantly, Western blot analysis
conﬁrmed the absence of 4F2hc dimers indicating the successful
application of our approach of using two different tags on the
two subunits to avoid co-puriﬁcation of 4F2hc dimers. To illustrate
the disruption of the heterodimer under reducing conditions, puri-
ﬁed 4F2hc/LAT2 was incubated with DTT and subjected to SDS–
PAGE. Two major bands corresponding to glycosylated 4F2hc and
LAT2 are discerned, as well as a weak band of residual, non-dis-
rupted 4F2hc/LAT2 heterodimer (Fig. 4A, lane 4). Interestingly, no
aggregates/oligomers were found under reducing conditions
(Fig. 4A, lane 4) compared to SDS–PAGE under non-reducing condi-
tions (Fig. 4A, lane 1). This indicates that the observed higher
molecular weight bands (Fig. 4A, lane 1) might be aggregates/olig-
omers formed during puriﬁcation through oxidation of cysteine
residues into disulphide bridges. The average yield was 1 mg of
puriﬁed heterodimer per 2 l of yeast culture (see Table 1). SEC pro-
ﬁles of puriﬁed 4F2hc/LAT2 indicated a minor (at 13 ml) and a
major peak (at 14 ml), both being relatively broad. A small
amount of heavy protein aggregation was found in the void volume
(Fig. 4B). The presence of 4F2hc and LAT2 monomers (as a
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consequence of the reduction of the inter-subunit disulphide
bridge during the process of membrane solubilization and protein
puriﬁcation), and of heterodimer aggregation in the SDS–PAGE gel
(Fig. 4A, lane 2) explained the broad SEC proﬁles. SDS–PAGE con-
ﬁrmed the major contribution of 4F2hc/LAT2 heterodimer to frac-
tions of the main peak at 14 ml (Fig. 4B, right lane). In contrast,
fractions of the less prominent peak at 13 ml contained higher
amounts of aggregates/oligomers than heterodimers (Fig. 4B, left
lane). In summary, while additional efforts will be needed to im-
prove the integrity of the inter-subunit disulphide bridge, we man-
aged to isolate intact human 4F2hc/LAT2 heterodimer. The present
study represents the ﬁrst successful attempt to express and purify
a HAT transporter at the milligram scale for future structural
studies.
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Heteromeric amino acid transporters (HATs) are the unique ex-
ample, known in all kingdoms of life, of solute transporters
composed of two subunits linked by a conserved disulfide bridge.
In metazoans, the heavy subunit is responsible for the trafficking
of the heterodimer to the plasma membrane, and the light subunit
is the transporter. HATs are involved in human pathologies such as
amino acidurias, tumor growth and invasion, viral infection and
cocaine addiction. However structural information about interac-
tions between the heavy and light subunits of HATs is scarce. In
this work, transmission electron microscopy and single-particle
analysis of purified human 4F2hc/L-type amino acid transporter 2
(LAT2) heterodimers overexpressed in the yeast Pichia pastoris,
together with docking analysis and crosslinking experiments, re-
veal that the extracellular domain of 4F2hc interacts with LAT2,
almost completely covering the extracellular face of the trans-
porter. 4F2hc increases the stability of the light subunit LAT2 in
detergent-solubilized Pichia membranes, allowing functional re-
constitution of the heterodimer into proteoliposomes. Moreover,
the extracellular domain of 4F2hc suffices to stabilize solubilized
LAT2. The interaction of 4F2hc with LAT2 gives insights into the
structural bases for light subunit recognition and the stabilizing
role of the ancillary protein in HATs.
CD98hc | 4F2hc ectodomain
Heteromeric amino acid transporters (HATs) are composedof two subunits, a heavy (SLC3 family) and a light subunit
[SLC7 or L-type amino acid transporter (LAT) family] linked by
a conserved disulfide bridge (1). HATs are amino acid exchangers
(1), and this transport activity resides in the light subunit (2). The
heavy subunit (either 4F2hc or rBAT) is essential for trafficking of
the holotransporter to the plasma membrane (3, 4). In mammals,
six transporters heterodimerize with 4F2hc, and only one hetero-
dimerizes with rBAT. The rBAT/b0,+AT complex is a dimer of
heterodimers in which the light subunit is required for proper
rBAT folding and stability (5, 6). In contrast, 4F2hc-associated
transporters are simple heterodimers (6), and possible stabilizing
roles of the two subunits in the biogenesis of the heterodimer
have not been described.
HATs have major impacts on human health and are involved
directly in amino acidurias (cystinuria and lysinuric protein intol-
erance), tumor cell growth, glioma invasion, Kaposi’s sarcoma-
associated herpesvirus infection, and cocaine relapse (1). In
addition to the role of HATs in amino acid transport, 4F2hc
heterodimers mediate β1- and β3-integrin signaling (7).
Structural information about HATs is scarce (1). The heavy
subunits are type II membrane N-glycoproteins with a single
transmembrane domain (TMD), an intracellular N terminus,
and a large extracellular C terminus with sequence homology
with bacterial α-amylases. Indeed, the atomic structure of the
extracellular domain (ED) of human 4F2hc (4F2hc-ED) is sim-
ilar to that of bacterial glucosidases [i.e., a triose phosphate isom-
erase barrel, (βα)8, (subdomain A) and eight antiparallel β-strands
(subdomain C)] but lacks glucosidase activity (8). The con-
served cysteine residue participating in the intersubunit disul-
fide bridge is located between the single TMD and 4F2hc-ED.
Physical and functional interaction of 4F2hc with integrins has
been mapped to the TMD and cytosolic N-terminal domain
(7, 9), whereas 4F2hc-ED is necessary for functional hetero-
dimerization with the light subunit (9, 10). The light subunits are
nonglycosylated proteins and have a 12-TMD topology with in-
tracellular N and C termini (1). The conserved cysteine residue
involved in the intersubunit disulfide bridge is located between
TMD3 and TMD4 (11). Structure–function studies (12, 13)
suggest that the structures of the light subunit of HATs should
be similar to those of remote bacterial amino acid/polyamine/
organocation (APC) transporters (∼20% amino acid sequence
identities), which present the LeuT-fold (14–17). In contrast,
there is no structural information about the interaction between
the two HAT subunits. In the present study, we show that infor-
mation from transmission electron microscopy (TEM) and single-
particle analysis (SPA) of human 4F2hc/L-type amino acid
transporter 2 (LAT2) heterodimers is compatible with 4F2hc-
ED interacting with the extracellular loops of LAT2. Docking
analyses and crosslinking experiments indicated a location of
4F2hc-ED almost completely covering the external face of LAT2.
Moreover, 4F2hc increases the stability of detergent-solubilized
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LAT2, allowing functional reconstitution of the heterodimer into
proteoliposomes. The interaction of 4F2hc-ED with LAT2 pro-
vides insights regarding the structural bases for recognition of
the light subunit and the stabilization of this complex and other
4F2hc associated transporters.
Results
TEM, SPA, and 3D Reconstruction of the Human 4F2hc/LAT2 Complex.
Recombinant 4F2hc/LAT2 purified by Co2+- and Strep-Tactin
affinity chromatography (18) was analyzed by negative-stain
TEM and SPA to unveil the supramolecular architecture of
HATs (Fig. 1). On electron micrographs distinct particles cor-
responding to purified 4F2hc/LAT2 complexes are discerned as
composed of two globular domains of different sizes (Fig. 1A,
boxed particles and gallery). From 15,210 single-particle pro-
jections, class averages were calculated (Fig. S1A). Most class
averages indicate a clear difference in size between the two
domains. A few smaller particles reflecting 4F2hc or LAT2 from
disrupted heterodimers were also found on electron micrographs
(Fig. 1A, arrowheads). In addition, some small protein aggre-
gates are seen on electron micrographs (Fig. 1A, asterisks). We
determined the structure of 4F2hc/LAT2 by 3D reconstruction
from negatively stained complexes (Fig. 1B). The resolution of
the 3D map obtained from the final refinement run was 21 Å
(Fig. S1B) and had a homogeneous angular distribution of pro-
jections (Fig. S1C). The calculated 3D map reflects a structure
composed of a smaller and a larger density (Fig. 1B; see Fig. S1D
for additional views). The smaller domain lies tilted (not flat) on
the larger domain (Fig. 1B, black dotted line). Consequently, the
complex has a cleft on one side (Fig. 1B, arrowhead) and a seal
on the opposite side (Fig. 1B, white dotted curve). Importantly,
the crystal structure of 4F2hc-ED fits nicely into the smaller
density (Fig. 1C), making the assignment of 4F2hc and LAT2 in
the 3D map possible. As determined by scanning TEM mass
measurement, unstained n-dodecyl-β-D-maltoside (DDM)-puri-
fied membrane proteins prepared in a conventional way for
TEM are associated with >55 kDa of copurified endogenous
lipids and DDM molecules (19). Thus, the total mass of the
LAT2/lipid/DDM ternary complex plus the single TMD and the
cytoplasmic N-terminal domain of 4F2hc containing the His-tag
and the protease cleavage site (>120 kDa) is significantly larger
than that of the 4F2hc-ED (∼50 kDa). This result, together with
the fitting of the 4F2hc crystal structure into the smaller density,
supports the assignment of LAT2 to the larger domain of the 3D
map. In Fig. 1C the location of the N terminus in the 4F2hc-ED
crystal structure is marked by an asterisk. This location is close to
an additional density connecting the small and large domains
that possibly arises from the N-terminal TMD of 4F2hc and
extracellular loops of LAT2.
Crosslinking of 4F2hc-ED and LAT2. To confirm the interaction be-
tween 4F2hc-ED and LAT2, specific intersubunit crosslinking
between cysteine residues were assessed in purified 4F2hc/LAT2
heterodimers (Fig. 2). To this end, homogenates from HEK293T
cells transiently cotransfected with N-terminally His-tagged 4F2hc
(His-4F2hc) and N-terminally Strep-TagII–tagged LAT2 (Strep-
LAT2) were solubilized with DDM and purified by Ni2+-affinity
chromatography and then were crosslinked with the nonreducible
cysteine crosslinkers bis(maleimido)ethane (BMOE) (with a
spacer arm up to 10.5 Å) or 1,8-bis(maleimido)diethylene glycol
[BM(POE)2] (with a spacer arm up to 14.3 Å). Crosslinking
experiments were performed in mammalian cells because
mutants could be generated more conveniently in mammalian
cells than in Pichia cells. Western blotting under reducing con-
ditions and using an anti-Strep antibody revealed intersubunit
crosslinking as DTT-resistant heterodimers. Human 4F2hc has
two cysteine residues: Cys109, participating in the intersubunit
disulfide bridge (located in the “neck” connecting the TMD and
ectodomain) and Cys330, a partially hidden residue (located in
the A-subdomain of the ectodomain). To avoid doubtful results,
residue Cys330 was mutated to serine (C330S) in all mutants
studied, and residue Cys109 was maintained to hold the disulfide
intersubunit bridge. This strategy was validated by demonstrating
heterodimerization of His-4F2hc C330S with Strep-LAT2 and
induction of L-alanine transport in HEK293T cells (Fig. S2 A–D).
Fig. 1. TEM, SPA, and 3D reconstruction of human 4F2hc/LAT2. (A) Over-
view electron micrograph of purified, negatively stained 4F2hc/LAT2 heter-
odimers. The boxed 4F2hc/LAT2 complexes were magnified and are displayed
in the gallery. Arrowheads mark 4F2hc or LAT2 monomers from disrupted
heterodimers. Asterisks indicate small protein aggregates. (Scale bar: 50 nm.)
The frame sizes of the magnified particles in the gallery are 21.8 nm. (B) 3D
reconstruction of 4F2hc/LAT2 calculated from projections of negatively
stained heterodimer particles. Different side views of the 3D model are
shown. 4F2hc/LAT2 is composed of a large and a small density. The small
density is located on top of the large density and is tilted, as indicated by the
black dotted line. As indicated by an arrowhead, the 3D model features
a distinct cavity. On the opposite side, both subunits are in close contact, as
marked by the white, dotted curve. (Scale bar: 5 nm.) (C) Side (Upper) and
top (Lower) views of the 4F2hc/LAT2 3D reconstruction without and with the
fitted crystal structure of the 4F2hc-ED (Protein Data Bank ID code: 2DH2).
The fitting assigns the small and large subunits to 4F2hc and LAT2, re-
spectively. The structure of 4F2hc-ED is represented as a cartoon and surface
model. Asterisks indicate the location of the N terminus in the 4F2hc-ED
crystal structure. (Scale bar: 5 nm.)








According to our homology models of human LAT2 (Fig. S3 A
and B), which are based on the atomic structure of the bacterial
L-arginine/agmatine exchanger AdiC (17), seven of the nine en-
dogenous cysteine residues in LAT2 are located in TMDs and
internal loops (Fig. S3 A and C). The remaining two cysteine
residues are in external loops: Cys154, participating in the
intersubunit disulfide bridge, is located in the external loop
TMD3–4, and Cys210 is located in the external loop TMD5–6
(Fig. S3 A and C). Nine serine residues spread over the surface
of 4F2hc-ED potentially facing LAT2 (8) were selected and
mutated individually to cysteine for crosslinking experiments
(see locations in Fig. S2E). Five of the nine mutants were not
considered for further studies because they produced proteo-
lyzed proteins (S191C and S200C) (Fig. S2F, lanes 2 and 3) or
lacked (S270C) (Fig. S2F, lane 4) or inefficiently formed (S497C
and S506C) (Fig. S2 G and H, lanes 7 and 8) intersubunit
disulfide bridges when cotransfected with Strep-LAT2. The other
four 4F2hc mutants (S151C, S185C, S393C, and S412C), also
containing the C330S mutation, heterodimerized with Strep-
LAT2 (Fig. S2G andH, lanes 1, 3, 5, and 6) and induced L-alanine
transport similar to 4F2hc C330S (Fig. S2I). Of these four
mutants, only S151C and S412C could be crosslinked with wild-
type LAT2 using BMOE and BM(POE)2 [Fig. 2A; BMOE:
lanes 1 and 7; BM(POE)2: lanes 9 and 12]. Interestingly, cross-
linking with 4F2hc mutants S151C and S412C was totally
abolished when LAT2 Cys210 was mutated to serine (C210S) [Fig.
2A; BMOE, lanes 2 and 6; BM(POE)2, lanes 8 and 11]. The C210S
(LAT2) mutant is fully functional (i.e., heterodimerized (Fig. S2 G
andH, lanes 2 and 4) and induced L-alanine transport with 4F2hc
(Fig. S2I). In contrast, mutant C330S (Fig. 2A, lanes 5 and 10),
and mutants S185C (Fig. 2A, lane 3) and S393C (Fig. 2A, lane 4)
incorporated in this background did not show crosslinking with
Fig. 2. Crosslinking of 4F2hc/LAT2 and docking model of the 4F2hc-ED and LAT2 complex. (A and C) Intersubunit crosslinking. Versions of His-4F2hc/Strep-
LAT2 heterodimers expressed in HEK293T cells and purified by His-affinity chromatography were treated with the DTT-uncleavable crosslinkers BMOE or BM
(POE)2. Crosslinking was detected as DTT-resistant 4F2hc/LAT2 heterodimers (arrowhead) by Western blotting using αStrep antibodies under reducing con-
ditions. The band of LAT2 monomer corresponds to LAT2 forming heterodimers with 4F2hc (i.e., copurified but not crosslinked). Single cysteine mutants were
introduced in 4F2hc (C330S)/LAT2 wild-type (A) or LAT2 (C210S) (C). In all cases, crosslinking was abolished when 4F2hc (C330S) or LAT2 (C210S) was used,
indicating the specificity of the crosslinked sites. (B) Lowest-energy model of the 4F2hc-ED–LAT2 complex. Highlighted cysteine residues (endogenous or
added through mutation) are shown as sphere models (C atoms, gray; O atoms, red; N atoms, blue; S atoms, yellow). The putative N-glycosylation sites (N264,
N280, N323, and N405 indicated in purple) and the non-crosslinked residues (C185 and C393 in gray) of 4F2hc are located in the most external face. (D)
Summary of the crosslinked residues. The 4F2hc-ED–LAT2 model in B was rotated by 90°, i.e., viewed from 4F2hc-ED. Only the cysteine residues (endogenous
or added through mutation) of the 4F2hc-ED are shown as sphere models with C atoms in green. In LAT2 (cartoon in blue) the cysteine residues (endogenous
or added through mutation) are shown as sphere models with C atoms in gray. Crosslinked residues are connected by a line denoting the percentage of
crosslinking (solid red line: 80–95%; solid yellow line: ∼60%; red dotted line: 5–10%). Similarly, the intersubunit disulfide bridge between C109 (4F2hc) and
C154 (LAT2) is represented by a solid red line because it is present in >95% of the expressed LAT2 (see text for details).
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wild-type LAT2. These results demonstrated specific crosslinking
between cysteine residues at positions 151 or 412 (which are
located in the loop Aα1–Aβ2 and helix Aα8′′′, respectively) of
subdomain A of 4F2hc-ED and Cys210, which is located in the
extracellular loop TMD5–6 in LAT2.
Docking Analysis of 4F2hc-ED and LAT2. To characterize the inter-
actions between 4F2hc-ED and LAT2, protein-docking analyses
between the atomic structure of 4F2hc-ED (8) and homology
models of human LAT2 (Fig. S3B) were performed with only
two restrictions: (i) allowing the formation of the disulfide bridge
between residues Cys109 (4F2hc-ED) and Cys154 (LAT2), and
(ii) avoiding clashes between 4F2hc-ED residues and the plasma
membrane (SI Methods). Of 3,145 possible docking poses, the
model with the lowest energy is depicted in Fig. 2B. According to
this model, 4F2hc-ED interacts with all the extracellular loops or
ends of TMDs of LAT2. 4F2hc is N-glycosylated in Pichia (18)
and mammalian cells (8), and in the model the four putative sites
are located in the most external face of 4F2hc-ED, out of the
contact interface with LAT2 (Fig. 2B). There is a large in-
teraction surface between the two proteins, with the buried
surface area of LAT2 upon 4F2hc binding being 1,735 Å2 (Fig.
S4A). As much as 60% of the LAT2 interaction surface is formed
by hydrophobic residues, and 40% is formed by aromatic resi-
dues. This composition is consistent with the major contribution
of desolvation to the binding energy as calculated by our scoring
function. The most important contacting residues are shown in
Table S1 and Fig. S4B.
Interestingly, the lowest-energy 4F2hc-ED–LAT2 model com-
plies with the crosslinking analysis described above. Thus, cross-
linked residues S151C (4F2hc)–Cys210 (LAT2) and S412C
(4F2hc)–Cys210 (LAT2) were located at minimal interatomic
distances of 13.4 Å and 11.5 Å, respectively (Table S2). These
distances are in good agreement with the results obtained from
crosslinking with BMOE and BM(POE)2, in which the distances
separating both reactive maleimide ends range from 6.3 to 10.5
Å and from 3.5 to 14.3 Å, respectively (20). In contrast, the
4F2hc residues that did not crosslink, S393C and S185C, are
located at distances of 18.8 Å and 28.2 Å, respectively, from
LAT2 Cys210, also corroborating the docking model (Table S2).
Then, guided by this docking model, additional cysteine mutants
in protein domains not studied previously were considered for
crosslinking, i.e., S195C in helix 2 of subdomain A and S487C
and G505C in subdomain C of 4F2hc-ED and A235C, A315C,
G392C, and S441C in four external loops of LAT2 (Table S2).
To ascribe the crosslinked residues unequivocally, 4F2hc mutants
were generated in C330S background, and LAT2 mutants were
generated in the C210S background, taking advantage of the fact
that LAT2 C210S heterodimerized with the newly considered His-
4F2hc mutants (Fig. S5 A and B, lanes 7, 12, and 17) in HEK293T
cells. Moreover, the rest of the additional 4F2hc and LAT2
mutants heterodimerized and induced L-alanine transport in the
transfected cells (Fig. S5). Six new paired positions in 4F2hc and
LAT2 were crosslinked by BMOE and/or BM(POE)2 (Fig. 2C and
Fig. S6 A and B). Interestingly, the new pairing of G505C (4F2hc)
with A235C and S441C (LAT2) (Fig. 2C, lanes 6 and 7) and the
already mentioned pairing of S151C and S412C (4F2hc) with
Cys210 (LAT2) (Fig. 2A) crosslinked almost completely (80–95%)
(Table S2). Together with the intersubunit disulfide bridge be-
tween Cys109 (4F2hc) and Cys154 (LAT2), which links >95% of
the expressed LAT2 mutants to 4F2hc (Fig. S2G, lanes 1 and 3
and Fig. S5A, lanes 15 and 16), these results triangulate the lo-
cation of 4F2hc-ED over the external face of LAT2 (Fig. 2D).
Indeed, our crosslinking studies showed that four of the six ex-
ternal loops of LAT2 (Cys210 and Ala235 in TMD5–6, Ala315 in
TMD7–8, Gly392 in TMD9–10, and Ser441 in TMD11–12) (Fig.
S3, asterisks) are in the vicinity of residues in subdomains A
and C of the 4F2hc-ED in addition to the intersubunit disulfide
bridge connecting Cys154 in TMD3–4 of LAT2 and Cys109 lo-
cated five residues away from the C-terminal end of the 4F2hc
TMD (Fig. 2D and Table S2). According to the lowest-energy
4F2hc-ED–LAT2 model, all the crosslinked positions in the
present work are 8.1–17.5 Å apart (Table S2). In contrast, paired
positions separated by >15 Å or >18 Å were not crosslinked by
BMOE or BM(POE)2, respectively (Fig. 2A, Fig. S6A, and Table
S2). The lack of crosslinking in the indicated paired positions was
not caused by cysteine residues being blocked by the formation
of a direct disulfide bridge as the result of very close proximity
(Fig. S6 B and C). Thus, the lowest-energy docking model is in
full agreement with all crosslinking experiments. Moreover, if a
slightly larger crosslinking distance is considered, only two very
similar additional docking solutions comply with the five stron-
gest (≥60% efficiency) crosslinking experiments (Fig. S4C). Like
the 3D 4F2hc/LAT2 map from TEM and SPA, these docking
models place 4F2hc-ED tilted on top of LAT2. Unfortunately, at
the resolution of 21 Å, the large volume of the larger domain in
the map (Fig. 1C), which contains LAT2, the TMD and the N-
terminal domain of 4F2hc, lipid, and detergent, precludes a re-
liable fitting of the 4F2hc-ED–LAT2 docking model into the 3D
4F2hc/LAT2 map. In summary, TEM, SPA, docking, and cross-
linking studies strongly indicate that 4F2hc-ED is positioned tilted
on LAT2, almost completely covering the extracellular face of
the transporter.
The Ectodomain of the Heavy Subunit 4F2hc Increases the Stability of
LAT2. The interaction between 4F2hc-ED and the overall exter-
nal face of LAT2 suggests that the heavy subunit may affect the
stability of the light subunit. To investigate this possibility, we
studied the behavior of purified 4F2hc/LAT2 and LAT2. Solu-
bilization with DDM of isolated membranes from yeast cells
coexpressing His-4F2hc and Strep-LAT2 and sequential purifi-
cation by Co2+- and Strep-Tactin affinity chromatography
yielded 4F2hc/LAT2 heterodimers (18). In contrast, DDM sol-
ubilization of yeast membranes expressing Strep-LAT2 alone
and subsequent Strep-Tactin affinity chromatography and size-
exclusion chromatography yielded only aggregates of LAT2 (Fig.
3A). To study whether 4F2hc was able to conserve the func-
tionality of LAT2, we tried to reconstitute purified 4F2hc/LAT2
heterodimers into liposomes, but our attempts failed. As an al-
ternative approach to test the functionality of 4F2hc/LAT2
heterodimers and LAT2 monomers, isolated Pichia membranes
were solubilized in DDM and reconstituted into proteoliposomes.
Interestingly, only 4F2hc/LAT2 heterodimers, but not LAT2
monomers, could be reconstituted successfully into proteolipo-
somes as functional proteins (Fig. 3B), because LAT2 monomers
aggregated before being inserting into liposomes (Fig. S7A).
Surprisingly, expression of Strep-LAT2 alone, as well as coex-
pression of His-4F2hc and Strep-LAT2, resulted in a similar
transport of 10 μM L-leucine over background in P. pastoris cells
(Fig. S7B). These results suggest that LAT2 is properly folded
and trafficked to the plasma membrane in yeast cells. However,
the interactions with 4F2hc would be essential to maintain the
correct folding of the light subunit in detergent. Kinetic analysis
of L-leucine transport via His-4F2hc/Strep-LAT2 and Strep-
LAT2 revealed similar Kms: 178 ± 15 μM and 120 ± 7 μM, re-
spectively (Fig. S7C). Thus, the interaction between 4F2hc and
the extracellular surface of LAT2 increased the stability of the
detergent-solubilized light subunit but did not alter dramatically
the substrate apparent affinity of this transporter in vivo.
Next, we asked whether the ectodomain of 4F2hc is able to
stabilize LAT2 without the generation of the conserved disulfide
bridge between both HAT subunits. Pichia membranes express-
ing Strep-LAT2 were incubated with purified His-4F2hc-ED,
and then LAT2 was solubilized with different concentrations of
DDM (Fig. 4A). Interestingly, preincubation with 4F2hc-ED, but
not with same concentration of BSA, increased the solubilization
of LAT2 at the three concentrations of detergent tested (1%,
0.5%, and 0.25% DDM). These results suggested that 4F2hc-ED
stabilizes LAT2 in solution. To test this possibility, LAT2 solu-
bilized in 1% DDM in the absence or presence of 4F2hc-ED was
ultracentrifuged at 2 h, 24 h, and 72 h after solubilization. Re-
markably, the presence of 4F2hc-ED dramatically prevented the








precipitation of LAT2 (Fig. 4 B and C). In summary, these
results indicate that the ectodomain of 4F2hc interacts with the
external face of LAT2, thus increasing the stability of the de-
tergent-solubilized transporter and allowing its functional re-
constitution into proteoliposomes.
Discussion
This study reports on the supramolecular organization and the
structural bases of the interactions of the heavy and light sub-
units of HATs. Specifically, three lines of evidence (TEM, SPA,
and docking and crosslinking analyses) strongly support the no-
tion that 4F2hc-ED almost completely covers the extracellular
surface of the transporter subunit LAT2. Indeed, we identified
specific residues that crosslinked 4F2hc and LAT2 nearly com-
pletely (>80%). This crosslinking, together with the endogenous
intersubunit disulfide bridge, triangulates the position of the
4F2hc-ED over the external face of LAT2 (Fig. 2D). Impor-
tantly, the proposed docking model, as well as two additional and
highly similar poses, fulfills the steric restrictions defined by the
results from crosslinking (Fig. S4C).
Our docking analysis used the atomic structure of human
4F2hc-ED and homology models of human LAT2 based on the
atomic structure of the amino acid transporter AdiC in an out-
ward-facing conformation. Because of the low sequence con-
servation in the loops of AdiC and LAT2 (Fig. S3A), our docking
models do not represent high-resolution structures of the 4F2hc-
ED–LAT2 complex. Nevertheless, docking analysis revealed
desolvation as the main contributor to the binding energy of
4F2hc-ED and LAT2. Indeed, the LAT2 residues that are pre-
dicted to be more relevant for the interactions are mainly hy-
drophobic, and they can be grouped into two clearly defined
patches [see Normalized Interface Propensity (NIP) residues in
Table S1 and Fig. S4 A and B]. One of the patches, which is
totally hydrophobic, is composed of nine residues distributed
along three external loops or TMD ends of LAT2 (TMD3–4,
which harbors the Cys154 residue involved in the disulfide
bridge, TMD9–10, and TMD11–12). The other is a mixed patch
composed of four polar and five hydrophobic residues located in
loops TMD1–2, TMD5–6, and TMD7–8. The interaction be-
tween 4F2hc-ED and LAT2 raises the question of whether the
heavy subunit might have an impact on the LAT2 transport cycle.
The structural paradigms of HAT light subunits, the bacterial
APC transporters, present the LeuT-fold (14–17). Secondary
transporters, upon the binding of an external substrate, transit to
inward-facing conformations to release the substrate inside the
cell. Besides transporter-specific changes, atomic structures of
LeuT-fold transporters showed a commonality of features in this
transition (21, 22): the “hash” domain (TMDs 3, 4, 8, and 9) and
the extracellular ends of the “bundle” domain (TMDs 1, 2, 6, and
7) become closer, and the loop TMD7–8 occludes the external
vestibule of the transporter. Our results indicate that these
conformational changes are compatible with 4F2hc-ED directly
contacting the external loops or ends of TMDs of LAT2. The
highly conserved hydrophobic patch in LAT2 (Fig. S4B and
Table S1), together with the intersubunit disulfide bridge, glue
the hash domain and TMDs 11 and 12 to 4F2hc-ED. TMDs 11
and 12 are, according to the structural homolog AdiC (17), the
most static TMDs. In contrast, the mixed patch is less conserved
and involves the bundle domain and the occluding loop (TMD7–
8). This architecture suggests that 4F2hc/LAT2, and probably
other HATs, have evolved to bind the ectodomain of the heavy
subunit firmly to the hash domain. In this scenario, energetically
similar interactions of 4F2hc-ED with the bundle domain and
loop TMD7–8 would be broken and replaced by the different
conformations that the light subunit undergoes during the
transport cycle.
According to amino acid transporters with LeuT-fold, the
substrate-binding site in LAT2 is expected to be located at the
bottom of the extracellular vestibule (1, 13) and therefore far
away from the interacting 4F2hc-ED residues (Fig. S4 D and E).
Moreover, our docking analysis located 4F2hc-ED in a tilted
Fig. 3. (A) Size-exclusion chromatography profiles of purified 4F2hc/LAT2
(thick curve) and purified LAT2 (thin curve). 4F2hc/LAT2 elutes at 9.8 mL,
whereas LAT2 is eluted in the void volume (8 mL). (B) Time-course of L-leu-
cine uptake in 4F2hc/LAT2 and 4F2hc proteoliposomes. Transport of 10 μM
L-[3H]leucine into proteoliposomes was measured at 10, 30, 60, 90, 120, 150,
180, and 210 min and at 20 h. Proteoliposomes were loaded or not loaded
with 4 mM cold L-isoleucine. Data are mean ± SEM of a representative ex-
periment performed in triplicate. Transport of 10 μM L-[3H]leucine into
4F2hc/LAT2 proteoliposomes preloaded with 4 mM L-isoleucine resulted in
an overshoot. In contrast, L-leucine transport into 4F2hc/LAT2 proteolipo-
somes with no amino acids inside showed passive diffusion similar to that
shown by 4F2hc proteoliposomes filled or not filled with L-isoleucine. This
behavior is characteristic of coupled transporters such as the H+/lactose
cotransporter LacY (27) and exchangers such as the LAT transporter SteT, an
L-serine/L-threonine exchanger from Bacillus subtilis (28).
Fig. 4. 4F2hc-ED increases LAT2 solubility and stability. (A) Western blot
analysis of DDM-solubilized LAT2 in the presence of 1 mg/mL of 4F2hc-ED or
BSA or plain buffer, as indicated. (B) Western blot analysis of solubilized
LAT2 (1% DDM) in the presence or absence of 1 mg/mL of 4F2hc-ED at
different times. (C) Quantification of the soluble LAT2 at the indicated time.
Data are the mean ± SEM of three independent experiments as described in
B. LAT2 remaining in solution after ultracentrifugation was considered sol-
uble LAT2. LAT2 was detected using αStrep antibody. The presence of 4F2hc-
ED increased LAT2 stability at all analyzed times.
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position, with subdomain C interacting with LAT2 TMD11–12
and leaving open a window in the opposite location flanked by
LAT2 TMD7–8 for the entrance of the substrate to the binding
site (Fig. S4D). Despite the different structures of the LAT2
monomer and the 4F2hc/LAT2 heterodimer, the measured Km
values for L-leucine transport in Pichia cells were comparable,
suggesting that 4F2hc would have no significant impact on the
substrate affinity of LAT2.
The hydrophobic character of the interaction between 4F2hc-
ED and LAT2 might be the basis for the stabilization of this light
subunit by 4F2hc. We show that 4F2hc allows functional re-
constitution into proteoliposomes and purification of the trans-
porter after solubilization with DDM. Moreover, we show here
that 4F2hc-ED suffices to increase the stability of DDM-solu-
bilized LAT2. The binding of 4F2hc-ED to the extracellular
surface of LAT2 would bury a large hydrophobic patch that
otherwise would be exposed to solvent, thus reducing aggrega-
tion and increasing stability. In addition, the compact and ther-
mally stable structure (Tm ∼59 °C) (23) of 4F2hc-ED may have
additional effects in improving LAT2 stability.
HATs appeared in metazoans with an ancient heavy subunit
that evolved to differentiated 4F2hc and rBAT in vertebrates (1).
The fact that LAT2 monomers elicited amino acid transport in
Pichia cells, which do not express 4F2hc or related proteins,
indicates that 4F2hc is not required for proper folding of LAT2,
as also has been demonstrated for the light subunit b0,+AT in the
absence of rBAT (2). In contrast, 4F2hc and rBAT are necessary
for heterodimerization and functional expression of light sub-
units at the cell surface when expressed in Xenopus oocytes and
mammalian cells (1). Specifically, 4F2hc-ED is necessary for
these functions (9, 10). Desolvation of hydrophobic residues
might be extended to the recognition of other light subunits by
4F2hc. The hydrophobic NIP residues in our docking analysis are
highly conserved in 4F2hc-associated light subunits but are poorly
conserved in cyanobacterial, yeast, and fungal LATs, which are the
closest homologs to vertebrate LATs (up to 37% amino acid se-
quence identity) that do not interact with a heavy subunit (Table
S1). Hydrophobic NIP residues also are largely conserved in
b0,+AT (Table S1). Thus, desolvation of hydrophobic residues also
might contribute to the binding of the ectodomain of rBAT and its
light subunit. Indeed, cotransfection of 4F2hc and b0,+AT (i.e., the
rBAT-associated light subunit) in mammalian cells yielded func-
tional transporter at the cell surface (24). Interaction through
a hydrophobic patch seems like a clever way to glue 4F2hc to six
different light subunits (LAT1, LAT2, y+LAT1, y+LAT12, asc1,
and xCT) that share as little as ∼43% amino acid sequence
identity (1). Our work revealed that 4F2hc-ED covers the ex-
ternal face of LAT2, increasing transporter stability. The idea
that a common hydrophobic patch serves for subunit recognition
by 4F2hc merits future experimental examination.
Methods
The indicated tagged versions of human 4F2hc and LAT2 were expressed and
purified as reported previously (18). L-leucine transport by Pichia cells was
performed as described (18). Transport activity of LAT2, 4F2hc, and 4F2hc/
LAT2 was tested as described previously (13) by measuring their L-leucine/
L-isoleucine exchange activity in reconstituted proteoliposomes. TEM, SPA,
and 3D reconstruction were performed as described in SI Methods. Docking
calculations of 4F2hc-ED–LAT2 interaction were performed based on the
pyDock protocol (25), and the most relevant LAT2 residues for the in-
teraction with 4F2hc were identified by using the NIP value (26). To validate
the docking model, intersubunit crosslinking was performed in different
versions of purified 4F2hc/LAT2 heterodimer expressed in HEK cells. The
effect of 4F2hc-ED on the detergent solubilization and stability of human
LAT2 was tested by incubating Pichia membranes expressing LAT2 (18) with
purified 4F2hc-ED (8) before solubilization with DDM. Soluble LAT2 protein
was detected and quantified by Western blotting. See SI Methods for details.
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SI Methods
Protein Expression and Purification and L-Leucine Transport in Pichia
pastoris Cells. Tagged versions of human 4F2hc and L-type amino
acid transporter 2 (LAT2) were expressed and purified as
reported previously (1). The L-leucine transport assay using Pichia
cells was performed as described previously (1).
Functional Reconstitution of LAT2, 4F2hc, and 4F2hc/LAT2 into Liposomes.
Liposomes from soybean and pig brain lipids were prepared as
described (2) in reconstitution buffer [5 mM Tris-SO4 (pH 7.4),
120 mM KPi, 0.5 mM EDTA, 1 mM MgSO4, 1% glycerol] with
or without 4 mM L-Ile. Pichia membranes containing expressed
LAT2, 4F2hc, and 4F2hc/LAT2 were solubilized in 0.5%
n-dodecyl-β-D-maltoside (DDM) for 30 min at 4 °C and ultra-
centrifuged (250,000 × g; 1 h; 4 °C). The supernatant was mixed
with the preformed liposomes at a lipid/protein (wt/wt) ratio of
50 for 10 min on ice. Reconstitution was performed by adding
0.1 g wet Bio-Beads (Bio-Beads SM2 Adsorbent; Bio-Rad) to
500 μL of mixture followed by incubation for 3 h at 4 °C. Pro-
teoliposomes were harvested by ultracentrifugation (250,000 × g;
1 h; 4 °C) and were resuspended in half of the original volume of
reconstitution buffer. For transport assays, proteoliposomes
(10 μL) were mixed with 180 μL of transport buffer [10 mM Tris-
Hepes (pH 7.4), 150 mM choline chloride, 1 mM MgCl2] con-
taining 10 μM L-[3H]Leu (0.5 μCi). Transport was stopped at the
indicated times (Fig. 3B) by the addition of 850 μL ice-cold stop
buffer [10 mM Tris-Hepes (pH 7.4), 150 mM choline chloride,
5 mM L-Leu] and filtered (Sartorius membrane filters, 0.45-μm
pore size). Filters were washed three times with 2 mL of stop
buffer and dried. Trapped radioactivity was counted in a Packard
Tri-Carb Liquid Scintillation Counter. Experimental values were
corrected by subtracting the signal at time 0.
Negative-Stain Transmission ElectronMicroscopy. Purified 4F2hc/LAT2
at ∼6 μg/mL was adsorbed for ∼5 s to Parlodion carbon-coated
copper grids, which were rendered hydrophilic by glow discharge at
low pressure in air. Grids were washed with three drops of double-
distilled water and stained with two drops of 0.75% uranyl formate.
Electron micrographs were recorded with a Philips CM12 trans-
mission electron microscope operated at 80 kV and equipped with
a Morada CCD camera (Soft Imaging System).
Image Processing and 3D Reconstruction. For image processing and
3D reconstruction, the software package EMAN2 (3) was used.
Initially, 23,838 single particles of 4F2hc/LAT2 were picked with
a box size of 128 pixels using the e2boxer program. Electron
micrographs were corrected for the contrast transfer function of
the microscope using the e2ctf program. Reference-free classi-
fication and averaging was done with the e2refine2d program,
which yielded about 200 class averages. From these class averages
the e2initialmodel algorithm built a starting 3D model. The pre-
liminary model was refined against a final set of 15,210 projections
by running the iterative refinement procedure e2refine. During
the refinement process the angular spacing was decreased from
15° to 2.5°. The resolution of the 3D reconstruction was 21 Å, as
estimated by calculating the Fourier shell correlation with the
e2eotest program. The density threshold for volume rendering of
the 4F2hc/LAT2 map was determined by fitting the surface re-
presentation of the 4F2hc ectodomain (4F2hc-ED) crystal struc-
ture into the small density of the 3D reconstruction and adjusting
the threshold. Visualization of the 3D model and fitting of the
4F2hc-ED crystal structure was done in UCSF Chimera (4).
Docking Model of 4F2hc-ED with LAT2.This docking experiment had
two major challenges: the lack of the 3D structure for one of
the subunits, human LAT2, and the fact that this protein is
a membrane protein. For this reason, we needed to develop ad
hoc protocols based on our standard program, pyDock (5). To
overcome the first problem, we usedModeler 8v1 (6) tomodel the
structure of human LAT2, using as template the X-ray structure
of the prokaryotic homolog AdiC from Escherichia coli [Protein
Data Bank (PBD) ID code 3OB6, chain A; ∼20% amino acid
sequence identity] (7), and an extensive multiple sequence align-
ment between AdiC and 250 close homologs including bacterial
and simple eukaryotic and metazoan LATs (part of the align-
ment is shown in Fig. S3A). Given the structural uncertainty in
some of the loops, we decided to select for docking the 20 models
with the lowest digital optimized protein energy (DOPE) score
as provided by Modeler. As shown in Fig. S3B, major differences
between models were found in the transmembrane domain
(TMD) loops TMD5-6 and TMD7–8, suggesting flexibility in these
regions. We used each of these models and the structure of
4F2hc-ED (PDB ID code 2DH2, chain A) (8) to perform an in-
dependent docking search using FTDock 2.0 (9) and ZDock 2.1
(10), which generated 10,000 and 2,000 rigid-body docking poses,
respectively, for each LAT2 model. This search resulted in a to-
tal of 240,000 different docking models. It is known that LAT2
Cys154 residue forms a conserved disulfide bond with the 4F2hc
Cys109 residue (Fig. S6 B and C) (11). Therefore, we removed the
docking solutions that could not satisfy this condition. For that
purpose, and according to B factors of the crystal structures of
4F2hc-ED (PDB ID codes 2DH2 and 2DH3) (8), we assumed
that the N terminus of the 4F2hc-ED (residues 109–116) was
flexible. Therefore, we selected the docking solutions in which the
minimal interatomic distance between 4F2hc Lys116 and LAT2
Cys154 residues was ≤20.9 Å; this value was defined from the
pyDockTET linker length database (12), considering the flexible
N terminus in 4F2hc as an interdomain linker. An important
issue in modeling this interaction is that LAT2 is a trans-
membrane protein. Because the transmembrane regions were
known, we also removed docking solutions that would clash
badly with the membrane, i.e., in which >20% of residues in
4F2hc contained atoms within 3 Å distance of any atom of the
membrane. The position of the membrane around 4F2hc was
modeled based on a recent molecular dynamics simulation of the
LAT2 homolog AdiC within the membrane (7). These two fil-
tering steps reduced the initial 240,000 docking solutions to 3,145
true candidate docking models, which were scored and ranked
according to their binding energy using pyDock (5). Finally the
docking model with the lowest energy (the one ranked first) was
minimized using Tinker (13). This model satisfies all crosslinking
experiments with an error margin of <5 Å (Table S2).
Docking-Based Contributions of LAT2 Residues to Interactions with
4F2hc-ED. The docking model described above is a good repre-
sentation of the overall binding mode between LAT2 and 4F2hc,
but it is not intended to represent a high-resolution structure
of the complex. Indeed, other, slightly different docking con-
formations are also possible (Fig. S4C). Furthermore, we should
not disregard possible small side-chain and backbone rear-
rangements. As a consequence, the model is not sufficiently ac-
curate for a detailed analysis of the contributions of every
specific residue to the binding energy. Nevertheless, based on the
analysis of the docking results (after filtering by disulfide-bridge
restraints and membrane clashing), we can identify the LAT2
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residues that are most relevant for the interaction with 4F2hc
using the Normalized Interface Propensity (NIP) value, as pre-
viously described (14). The NIP value indicates how frequently
a given residue is located at the interface in the 100 lowest-
scoring docking orientations, after normalizing between 0 (ran-
dom) and 1 (maximum). The residues with NIP >0.4 (usually
indicating hot-spot residues for the interaction) are listed in
Table S1.
Solubilization and Stability Assays of Human LAT2.N-terminally His-
tagged human 4F2hc-ED was produced in E. coli and purified as
previously described (8). Membranes of P. pastoris overex-
pressing N-terminally Strep-TagII–tagged human LAT2 were
obtained as previously described and kept at −80 °C (1). Purified
4F2hc-ED or BSA at a final concentration of 1 mg/mL in solu-
bilization buffer [20 mM Tris·HCl (pH 7.4), 150 mM NaCl] or
solubilization buffer without protein was added to LAT2 mem-
branes (total membrane protein concentration in solubilization
buffer: 20 mg/mL) and incubated overnight at 4 °C on a rotating
orbital shaker. Then, membranes were solubilized with the in-
dicated concentration of DDM (Fig. 4A) for 1 h at 4 °C and ul-
tracentrifuged at 200,000 × g for 1 h to remove nonsoluble proteins
and aggregates. When analyzing protein stability, supernatants were
ultracentrifuged again at the indicated times (Fig. 4 B and C).
Supernatants in Laemmli sample buffer were loaded for SDS/
PAGE (8% polyacrylamide) and analyzed by Western blotting.
Expression of 4F2hc and LAT2 in HEK293T Cells. Human His-4F2hc
(N-terminally tagged) cloned in pcDNA4His-MaxC (8) was used.
Human Strep-TagII-LAT2 (N-terminally tagged) cloned in pPICZ
(1) was subcloned, adapting to the mammalian Kozak sequence,
into EcoRI and XbaI sites in pcDNA3.1+. The QuikChange
Lightning Site-Directed Mutagenesis Kit (Agilent) was used to
generate all mutants, which were confirmed by sequencing.
HEK293T cells (11–30 passages) were grown in DMEM (Gibco
41966) supplemented with 10% FBS. Cells were kept at 37 °C
in a humidified atmosphere containing 5% CO2. Transient trans-
fections were performed at 70% cell confluence with polyethy-
lenimine in 15-cm-diameter plates with a mixture of DNA
containing 2.5 μg of pEGFP (Clontech), 15 μg of pcDNA4HisMax
human 4F2hc mutants, and 15 μg of pcDNA3.1+ human Strep-
TagII–tagged LAT2 (wild-type or mutants). A transfection of
a single construct was cotransfected with the same amount of
the corresponding empty vector DNA. Cell medium was replaced
4 h after transfection.
Transport of L-Alanine in HEK293T Cells. Transfected cells were
scraped and transferred into 24-well dishes previously treated with
poly-L-lysine (100 μL per well at 0.1 mg/mL for 30 min at 37 °C).
One day later, L-alanine transport was measured. To this end, cells
were washed twice with 2.5 mL of MGA buffer [10 mM Hepes
(pH 7.4), 137 mM N-methyl-D-glucamine, 2.8 mM CaCl2·2H2O,
1.2 mMMgSO4·7H2O, 5.4 mMKCl] at 37 °C. The uptake solution
(270 μL per well) contained 50 μM of cold L-alanine plus 0.5 μCi
per well of L-[3H]alanine (Hartman) in MGA buffer at 37 °C.
After the indicated time, uptake was stopped by two washes with
MGA buffer at 4 °C (2.5 mL per well). Cells were then lysed with
250 μL per well of lysis solution (100 mM NaOH, 0.1% SDS) by
agitation for 30 min at room temperature. Then 200 μL was used
for radioactivity counting in a Packard Tri-Carb Liquid Scintilla-
tion Counter, and 25-μL duplicates were used to determine pro-
tein content using the Pierce BCA kit, Pierce.
Intersubunit Crosslinking. Two days after transfection, cells were
washed with 10 mL PBS (pH 6.5), scrapped with 1 mL of lysate
buffer [1% DDM in PBS (pH 6.5) with protease inhibitors
(Complete EDTA free; Roche)] per 15-cm plate, and transferred
into a 1.5-mL Eppendorf tube. Cell disruption was facilitated by
homogenizing 15 times with a 25-gauge syringe and incubation on
a rotating orbital shaker at 4 °C. After 1 h, the insoluble material
was removed by centrifugation at 200,000 × g for 30 min at 4 °C.
Part of the supernatant was frozen in Laemmli sample buffer and
kept at −20 °C for analysis of expression by Western blot anal-
ysis; the rest was used for crosslinking experiments. To this end,
supernatants (1 mL) were incubated for 1 h at 4 °C with 150 μL
of Ni-NTA-agarose beads (Qiagen), previously equilibrated with
1 mL lysate buffer. Then beads were washed with 1 mL lysate
buffer containing 25 mM imidazole, and proteins were eluted by
shaking incubation for 15 min at 4 °C with 250 μL of elution
buffer [PBS (pH 6.5) containing 250 mM imidazole]. The puri-
fied protein (100 μL) was incubated with 30 μL of the cross-
linking buffer [200 μM bis(maleimido)ethane (BMOE) or 1,8-bis
(maleimido)diethylene glycol [BM(POE)2] (Pierce)] in lysate
buffer containing 50% (vol/vol) DMSO] for 1 h at 4 °C. The
crosslinking reaction was terminated by adding 100 mM DTT.
Fourfold concentrated Laemmli sample buffer was added for
Western blot analysis.
Western Blot Analysis. DDM-solubilized proteins (20 μg) from
HEK293T cells or Pichia membranes were resolved in reducing
(100 mM DTT) or nonreducing SDS/PAGE (8% polyacrylamide)
and immunoblotted using αStrep (Strep MAB-Classic-HRP; IBA)
and αHis (anti–HisG-HRP antibody; Invitrogen) antibodies.
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Fig. S1. Class averages and 3D reconstruction of human 4F2hc/LAT2. (A) Set of 4F2hc/LAT2 class averages. Two distinct densities of different sizes are discerned
in most averages. Class averages were calculated from 15,210 single-particle projections. The frame sizes of the class averages are 39.6 nm. (B) The Fourier shell
correlation (FSC) function indicates a resolution of 21 Å for the 3D map of 4F2hc/LAT2 using the 0.5 criterion. FSC was obtained by running the e2eotest
program on the last refinement cycle. (C) The Euler angle distribution of the projections in the last refinement cycle indicates a homogenous sampling of the
4F2hc/LAT2 complex. (D) Different views of the 4F2hc/LAT2 3D reconstruction. The 3D map of 4F2hc/LAT2 is rotated in 45° increments along the y axis (Upper)
and x axis (Lower). (Scale bar: 5 nm.)
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Fig. S2. Heterodimer formation and amino acid transport in HEK293T cells cotransfected with 4F2hc and LAT2 mutants generated before docking analyses.
(A–C) Western blot analysis of 1% DDM-solubilized homogenates of cells transfected with the indicated versions of His-4F2hc and Strep-LAT2 using αStrep
(A and C) or αHis (B) antibodies. Bands corresponding to heterodimers (4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc), and monomers (4F2hc or LAT2) are
indicated under nonreducing conditions (A and B). In contrast, under reducing conditions only LAT2 monomers are visible (C). The low expression of 4F2hc/
LAT2 heterodimers in cells transfected only with wild-type LAT2 (lane 2 in A) probably was caused by heterodimerization with endogenous 4F2hc. The minus
sign (−) indicates transfection with the corresponding empty vector. 4F2hc monomers were revealed as doublets of bands (B) that correspond to core and
Legend continued on following page
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mature N-glycosylation forms, as previously described (1). (D) Transport of L-alanine. Cells were analyzed for transport of 10 μM L-[3H] alanine for the indicated
times. Cotransfection with His-4F2hc (C330S) and wild-type Strep-LAT2 (closed squares) resulted in the induction of L-alanine transport over background [mock
transfected or His-4F2hc (C330S) transfected cells]. Transfection with Strep-LAT2 alone induced L-alanine transport over background but less than co-
transfection with both proteins (P ≤ 0.001; Student t-test). Induction of L-alanine transport by LAT2 alone results from heterodimerization with endogenous
4F2hc and thus traffic to the plasma membrane (lane 2 in A) or from LAT2 monomers reaching the cell surface because of overexpression. Data (mean ± SEM)
are from three experiments run in quadruplicate. (E) Positions of cysteine residues introduced in 4F2hc-ED before docking analysis. The two LAT2 extracellular
cysteine residues (encircled) are also indicated according to the lowest-energy docking model (Fig. S3B), i.e., C210 with C atoms shown in cyan and C154 with C
atoms shown in purple. LAT2 C154 forms the disulfide bridge with 4F2hc C109 (C atoms shown in purple). The N-terminal end of 4F2hc-ED [C109-S-E-L-P113
(one-letter-code amino acid sequence)] is colored orange to denote its high mobility. 4F2hc cysteine mutants are written in different colors: proteolytic 4F2hc
production (black), inefficient formation of heterodimers with LAT2 (orange), lack of crosslinking with LAT2 C210 (red), and positive crosslink with LAT2 C210
(blue). C atoms for other cysteine residues are in gray, and in all cases O atoms are in red, N atoms are in blue, and S atoms are in yellow. (F) Lack of formation
of 4F2hc/LAT2 heterodimers by some 4F2hc mutants in HEK293T cells. Western blot analysis of cells transfected with the indicated versions of His-4F2hc and
Strep-LAT2 using αHis under nonreducing conditions (Upper) or αStrep under reducing conditions (Lower). Bands corresponding to heterodimers (4F2hc/LAT2),
4F2hc homodimers (4F2hc/4F2hc), and monomers (4F2hc or LAT2) are indicated. Degraded 4F2hc, bands corresponding to proteolytic fragments of the protein.
WT, wild-type version of LAT2. (G and H) Expression of 4F2hc/LAT2 heterodimers by mutants of 4F2hc and LAT2 generated before the docking studies. Western
blot analysis of 1% DDM-solubilized homogenates of HEK293T cells transfected with the indicated versions of His-4F2hc and Strep-LAT2 using αStrep (G) and
αHis (H) antibodies under nonreducing conditions. All mutants in 4F2hc were generated in the C330S background. Bands corresponding to heterodimers
(4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc), and monomers (4F2hc or LAT2) are indicated under nonreducing conditions (G and H). WT, wild-type version of
LAT2. (I) Induction of L-alanine transport by the 4F2hc and LAT2 mutants generated before the docking analysis. HEK293T cells were transfected with wild-type
or the C210S mutant of Strep-LAT2 alone or together with the indicated mutants of His-4F2hc. Cells were analyzed for transport of 10 μM L-[3H]alanine for 15 s.
Transport resulting from 4F2hc and LAT2 coexpression was calculated by subtraction of transport elicited by transfecting Strep-LAT2 alone. For 4F2hc C330S
and wild-type LAT2 these transport values were 2463 ± 163 pmol L-alanine during 15 s (mean ± SEM from four experiments run in quadruplicate). For the
mutants shown, transport is expressed as the percentage of the transport of 4F2hc C330S and wild-type LAT2. Data (mean ± SEM) are from two experiments
run in quadruplicate. The coexpression of all of the indicated mutants induced L-alanine transport over the background caused by expression of the corre-
sponding LAT2 version alone (i.e., without cotransfecting any version of 4F2hc). Thus, all LAT2 mutants studied were functional.
1. Fort J, et al. (2007) The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane. J Biol Chem 282(43):
31444–31452.
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Fig. S3. Human LAT2 homology models. (A) Part of the extensive multiple amino acid sequence alignment between AdiC from E. coli and 250 close homologs
(including bacterial, simple eukaryotic, and metazoan LATs) (1) used for homology modeling of human LAT2 is shown. The TMDs in human light subunits of
HATs and the prokaryotic LAT SteT (serine/threonine exchanger) from Bacillus subtilis based on the crystal structure of AdiC are indicated over the alignment,
and the TMD residues in AdiC are highlighted in green. Residues in external loops are shown as open circles. Conserved cysteine residues involved in the
intersubunit disulfide bridge are boxed in black. Other endogenous cysteine residues in human LAT2 are boxed in blue. LAT2 residues mutated to cysteine are
boxed in red. Human LAT2 residues crosslinked with 4F2hc-ED residues are indicated by an asterisk over the alignment. Conserved NIP residues are highlighted
Legend continued on following page
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in gray. Small adjustments have been made by hand in loops TMD5–6, TMD7–8, TMD8–9, TMD10–11, and TMD11–12 of SteT and human LATs. (B) Superposition
of the 20 homology models of human LAT2 built from AdiC monomer atomic structure (PDB ID code 3OB6) (2). Maximal divergence between the selected
models occurs in the more flexible loops TMD5–6 and TMD7–8. (C) Cysteine residues in the best human LAT2 homology model. Lateral view with atoms of
cysteine residues shown as spheres. The orientation of LAT2 in the membrane (marked by horizontal lines) was predicted using the OPM database (3). In B and
C there are only two external cysteine residues: C154 (C atoms shown in purple), which is involved in the intersubunit disulfide bridge, and C210 (C atoms
shown in cyan), which is located almost diametrically opposite.
1. Bartoccioni P, et al. (2010) Role of transmembrane domain 8 in substrate selectivity and translocation of SteT, a member of the L-amino acid transporter (LAT) family. J Biol Chem 285
(37):28764–28776.
2. Kowalczyk L, et al. (2011) Molecular basis of substrate-induced permeation by an amino acid antiporter. Proc Natl Acad Sci USA 108(10):3935–3940.
3. Lomize MA, Lomize AL, Pogozheva ID, Mosberg HI (2006) OPM: Orientations of proteins in membranes database. Bioinformatics 22(5):623–625.
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Fig. S4. 4F2hc-ED–LAT2 docking models showing LAT2 residues interacting with 4F2hc-ED and accessibility of substrate to binding site. (A and B) The most
important residues of LAT2 for binding to 4F2hc-ED according to docking-derived NIP values. (A) Residues with NIP >0.4 are highlighted in the representation
of LAT2 (blue, atoms shown as spheres) with the following color code: aromatic residues (orange), aliphatic residues (yellow), asparagine (light pink), glutamic
acid (red), and lysine (cyan). The cartoon representation of 4F2hc-ED on top of LAT2 is shown in green. The hydrophobic patch of LAT2 interacts with sub-
domain C (antiparallel β8) of 4F2hc-ED. The cysteine residues involved in the disulfide bridge are indicated: LAT2 C154 is partially hidden, and one of its C atoms
is indicated by a circle; 4F2hc C109 corresponds to the N-terminal end of the structure of 4F2hc-ED (indicated by black line). (B) Location of NIP-based in-
teracting residues with cartoon representation of LAT2. Two defined patches (separated by the broken line) are evident: one hydrophobic and one mixed
patch. The residues are represented by sticks color-coded as in A. C154 is highlighted with its atoms represented as spheres (C, gray; O, red; N, blue; and S,
yellow). Totally or highly conserved residues are written in red, and nonconserved residues are written in black. Residues not conserved in cyanobacteria, yeast,
and fungi homologs of LAT2 are underlined. Loop TMD5–6, containing residues N221 and F223, is larger in LAT2 than in AdiC and other bacterial LATs,
precluding the generation of a robust homology model. A significant part of this loop is not at the interface with 4F2hc-ED, perhaps because of the poor
modeling of this loop. (C) The three 4F2hc-ED–LAT2 docking models that satisfy the crosslinking experiments (Table S2) are displayed. The lowest-energy
docking model (4F2hc-ED in red; LAT2 in gray) best satisfies the crosslinking experiments. Two additional docking models (ranked 3 and 15) satisfy the five
strongest (≥60%) crosslinking experiments (considering an additional distance of 6 Å to account for small conformational changes). Docking models ranked
3 and 15 are shown with 4F2hc-ED/LAT2 in green/blue and yellow/cyan, respectively. A side view (Upper) and a top view (Lower) of the three best 4F2hc-ED–
LAT2 docking models are shown. (D and E) The LAT2 external substrate vestibule is accessible in the lowest-energy 4F2hc-ED–LAT2 model. To visualize the
accessibility of the LAT2 substrate vestibule from the exterior, we have docked L-isoleucine substrate with AutoDock and show here the most populated
docking poses in blue and red. (D) The entrance of the substrate vestibule, where one of the most populated L-isoleucine positions is located, is accessible from
the exterior. TMD7–8 loop (cartoon in cyan) flanks the entrance to this vestibule. (E) The interior of the substrate vestibule is visualized showing a second
putative binding site of L-isoleucine (red) as determined by docking.
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Fig. S5. Expression of 4F2hc/LAT2 heterodimers and induction of amino acid transport by mutants of 4F2hc and LAT2 generated after the docking studies.
(A and B) Western blot analysis of 1% DDM-solubilized homogenates of HEK293T cells transfected with the indicated versions of His-4F2hc and Strep-LAT2
using αStrep (A) and αHis (B) antibodies under nonreducing conditions. Bands corresponding to heterodimers (4F2hc/LAT2), 4F2hc homodimers (4F2hc/4F2hc),
and monomers (4F2hc or LAT2) are indicated. WT, wild-type version of LAT2. (C) Transport of L-alanine by the generated 4F2hc and LAT2 mutants. HEK293T
cells were transfected with wild-type or the indicated mutants of Strep-LAT2 alone or together with the indicated mutants of His-4F2hc. One day later, cells
were analyzed for transport of 10 μM L-[3H]alanine for 15 s. Transport is expressed as the percentage of the transport elicited by the coexpression of 4F2hc
C330S and wild-type LAT2 and has been calculated as indicated in the legend of Fig. S2I. Data are the mean ± SEM from one or two experiments run in
quadruplicate. The coexpression of all of the indicated mutants induced L-alanine transport over the background caused by expression of the corresponding
LAT2 version alone. Thus, all LAT2 mutants studied were functional.
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Fig. S6. Additional crosslinking analysis confirming the lowest-energy docking model of 4F2hc-ED and LAT2 complex. (A) Versions of His-4F2hc/Strep-LAT2
heterodimers from HEK293T cells purified by affinity chromatography were treated with the DTT-uncleavable crosslinkers BMOE or BM(POE)2. Crosslinking was
detected as DTT-resistant 4F2hc/LAT2 heterodimers (arrowhead) by Western blotting using αStrep antibodies under reducing conditions. The band of LAT2
monomer corresponds to LAT2 forming heterodimers with 4F2hc (i.e., copurified but not crosslinked). Single cysteine mutants were introduced in 4F2hc
(C330S) and LAT2 (C210S). Weak but significant crosslinking in 4F2hc–LAT2 was detected between positions S487C–G392C (lane 4) by BMOE and between
positions S195C–A315C (lane 1), S195C–Cys210 (wild-type LAT2) (lane 5), and S487C–G392C (lane 13) by BM(POE)2. These crosslinking products were specific to
these positions because crosslinking could be abolished by using the single mutants C330S (4F2hc) or C210S (LAT2). Crosslinking by BMOE and by BM(POE)2 was
Legend continued on following page
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negative for the following positions (4F2hc–LAT2): S151C–A235C, S412C–A235C, S412C–A315C, and S487C–A235C. Crosslinking by BMOE was negative for the
paired positions S487C–S441C. (B and C) Cysteine pairs negative for crosslinking do not form direct intersubunit disulfide bridges. HEK293T cells were
transfected with the indicated mutants of His-4F2hc and Strep-LAT2. Two days after transfection Western blot analyses using αStrep (B) or αHis (C) under
nonreducing conditions were performed to detect the formation of intersubunit disulfide bridges. As indicated, analyzed mutants were introduced in 4F2hc
(C330S/C109S) and LAT2 (C154S/C210S) or LAT2 (C154S) where the endogenous cysteine residues involved in the intersubunit disulfide bridge have been
eliminated. In this way, 4F2hc/LAT2 heterodimers connected by a possible new disulfide bridge will be revealed under nonreducing conditions. With the
exception of the positive control (cotransfection of 4F2hc C330S and wild-type LAT2 in lanes 7 and 11), none of the studied mutants showed the formation of
4F2hc/LAT2 heterodimers. Cysteine residues in several positions (S151C, S195C, S393C, S412C, and S487C), but not in position S185C, produced disulfide bridge-
linked homodimers of 4F2hc (C). (D and E) Induction of L-alanine transport in transfected HEK293T cells. To validate our strategy, 1 d after transfection, the
mutants studied in B and Cwere assayed for L-alanine transport for 15 s. Transport is presented as the percentage of the transport induced by cotransfection of
4F2hc (C109S/C330S) and LAT2 (C154S/C210S) (D), and 4F2hc (C109S/C330S) and LAT2 (C154S) (E), as described in the legend of Fig. S2I. Transport in these
control conditions was 3,062 ± 167 and 3,017 ± 280 pmol L-alanine during 15 s (mean ± SEM from two experiments run in quadruplicate), respectively. In-
duction of L-alanine transport over the background elicited by LAT2 alone demonstrates the functional interaction of the mutants of 4F2hc and LAT2 that
were studied.
Fig. S7. Reconstitution into liposomes and functional characterization of 4F2hc/LAT2 and LAT2 in Pichia. (A) (Left) Reconstitution of heterodimers and LAT2
into liposomes. Membranes from P. pastoris coexpressing His-4F2hc and Strep-LAT2 or expressing Strep-LAT2 alone were solubilized with 1% DDM. Then
detergent was removed to induce reconstitution of the membrane proteins into proteoliposomes. To distinguish between reconstituted and aggregated
proteins, preparations were centrifuged (1,500 × g, 1 h, 4 °C) to precipitate proteoliposomes or were ultracentrifuged (250,000 × g, 1 h, 4 °C) to precipitate
proteoliposomes and protein aggregates. (Right) Western blot analysis under nonreducing conditions with αStrep was used to detect Strep-LAT2 as monomers
(LAT2) or heterodimers (4F2hc/LAT2). P, pellet; SN, supernatant. (B) In vivo uptake of L-leucine in different Pichia clones. Uptake of 10 μM L-[3H]leucine over
5 min was determined in clones cotransformed with His-4F2hc and Strep-LAT2, transformed with Strep-LAT2, transformed with His-4F2hc, and in untransformed
yeast cells (control). Data are the mean ± SEM of two independent experiments performed in triplicate. (C) Kinetic analysis of L-leucine transport in P. pastoris
cells transformed with His-4F2hc and Strep-LAT2 (Left) or Strep-LAT2 alone (Right) yielded comparable Kms of 178 ± 15 μM and 120 ± 7 μM, respectively.
Transport was measured in linear conditions over 3 min. Data points were corrected for basal activity in untransformed yeast cells. The concentrations used
were 10, 30, 50, 100, 300, 500, and 1,000 μM. (Insets) Eadie–Hofstee plots. Data are the mean ± SEM of representative experiments performed in triplicate.
When not visible, error bars are smaller than symbol. R2, correlation coefficient of the linear regression.
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yeast, and fungiLoop Residue Location Human All
TMD1–2 K63 TMD1 Yes No* No* Yes No
G64 TMD1 Yes Yes Yes No No
E67 TMD1 (C-term) Yes No No No No
TMD3–4 F155 Loop Yes No No No No
P157 Loop Yes Yes Yes Yes No
TMD5–6 N221 Loop Yes† Polar Polar Polar No
F223 Loop Yes Yes Yes Yes No
L239 TMD6 Yes L/Y L/Y L/Y V/Y/I
TMD7–8 L297 Loop Yes Yes L/I/V‡ Yes No
N300 Loop Yes Polar Polar Polar Polar
A301 Loop Yes Yes Yes Yes No
A303 Loop Yes Yes Yes Yes Yes
TMD9–10 M384 Loop Yes§ No No No No
Y385 Loop Yes Y/F{ Y/F{ NO Y/F
Y390 Loop Yes Y/F Y/F Y/F Y/L/F
F393 TMD11 (N-term) Yes Yes Yes Yes No
TMD11–12 F440 Loop Yes F/V/L F/V/L No No
L442 TMD12 Yes L/F L/F/Y L/Y/I L/V/F/Y
W443 TMD12 W/Y W/Yk W/Yk I No
The amino acid sequence of 72 proteins belonging to the LAT family (SLC7) and grouped in seven categories
(LAT2, LAT1, y+LAT1, y+LAT2, asc1, xCT, b0,+AT) (with eight vertebrate proteins per category) and cyanobacte-
rial, yeast, and fungal LATs (with 16 proteins per category) were aligned by the ClustalW2 program. The
conservation of the NIP residues was analyzed in vertebrate LAT2, in other vertebrate light subunits (LS) asso-
ciated with 4F2hc, in vertebrate b0,+AT, in cyanobacterial LATs, and in fungal LATs. The protein sequences were
retrieved from the UniProt and GenBank databases. The following protein sequences were retrieved from the
UniProt database: LAT1: Homo sapiens (Q01650), Mus musculus (Q9Z127), and Xenopus tropicallis (F6QFZ9);
LAT2: Homo sapiens (Q9UHI5), Mus musculus (Q9QXW9), Anolis carolinensis (H9GCK9), Xenopus tropicallis
(Q6P891), Carassius carassius (B8YMU3) and Takifugu rubripes (H2SUN0); y+LAT1: Anolis carolinensis
(H9G4U3), Xenopus tropicallis (F6S1W4), and Latimeria chalumnae (H3A009); y+LAT2: Homo sapiens (Q92536),
Mus musculus (Q8BGK6), Gallus gallus (F1ND99), Xenopus tropicallis (Q28I80), Pelodiscus sinensis (K7G1V4); asc1:
Homo sapiens (Q9NS82), Mus musculus (P63115), Xiphophorus maculatus (M4AC17), and Pelodiscus sinensis
(K7FII9); xCT: Homo sapiens (Q9UPY5), Mus musculus (Q9WTR6), and Gallus gallus (E1C734); b0+AT: Homo
sapiens (P82251), Gallus gallus (E1BT87), Anolis carolinensis (H9GCM6), Xenopus laevis (A9JS28), and Danio rerio
(F1QGJ2). The following protein sequences were retrieved from the GenBank database: LAT1: Ornithorhynchus
anatinus (XM_001508884), Orcinus orca (XM_004280070), Gallus gallus (XM_414194), and Danio rerio
(NM_001128358); LAT2: Ornithorhynchus anatinus (XM_003429011), Orcinus orca (XM_004283215), and Danio
rerio (NM_001271897.1); y+LAT1: Homo sapiens (NP_001119577.1), Rattus norvegicus (AAF07216.1), Ornitho-
rhynchus anatinus (XP_003430084.1), Orcinus orca (XP_004283244.1), and Danio rerio (NP_001032648.1);
y+LAT2: Orcinus orca (XM_004273192), Anolis carolinensis (XM_003222960), and Danio rerio (NM_001020474);
asc1: Orcinus orca (XM_004284140), Gallus gallus (XM_414136), Xenopus tropicallis (XM_002935793), and Danio
rerio (XM_690716); xCT: Orcinus orca (XM_004265135), Anolis carolinensis (XM_003221678), Xenopus tropicallis
(XM_002932048), and Danio rerio (XM_002664447); b0+AT: Rattus norvegicus (NM_053929), Orcinus orca
(XM_004284134), and Salmo salar (NM_001173819); Cyanobacterial LATs: Chroococcidiopsis sp. (WP_015152622.1),
Cyanothece sp. (WP_012630008), Fischerella sp. (WP_009454021.1), Gloeobacter violaceus (NP_924598), Oscillatoria
sp. (WP_007357767), Pleurocapsa minor (WP_015143465), Microcoleus sp. (WP_015184929.1), and Rivularia sp.
(WP_015120455.1); Yeast and fungal LATs: Saccharomyces cerevisiae (NM_001181184), Arthroderma gypseum
(XM_003171846), Schizophyllum commune (XM_003036114), Yarrowia lipolytica (XM_505103), Aspergillus niger
(XM_001396535), Coprinopsis cinerea (XM_001833155), Nectria hematococca (XM_003050065), and Ajellomyces
dermatitidis (XM_002620161).
*K not present only in LAT1.
†H in Anolis carolinensis LAT2.
‡M in Xenopus tropicallis and H in Mus musculus y+LAT2.
§I in Anolis carolinensis LAT2.
{D in human xCT and H in Xiphophorus maculatus and Danio rerio asc1.
jjI in human asc1.
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Table S2. Crosslinking analysis summary







Crosslinked S151 Aα1-Aβ2 WT (C210) TMD5–6 50 80 13.4
A315 TMD7–8 25 60 14.9
S195 Aα2 WT (C210) TMD5–6 NA 5 17.5
A315 TMD7–8 NA 10 15.5
S412 Aα8′′′ WT (C210) TMD5–6 35 95 11.5
S487 Cβ5 G392 TMD9–10 5 10 12.9
G505 Cβ6 A235 TMD5–6 90 NA 8.4
S441 TMD11–12 90 NA 8.1
Not crosslinked S151 Aα1-Aβ2 A235 TMD5–6 No No 27.0
S185 Aα2 WT (C210) TMD5–6 No No 28.2
S195 A235 TMD5–6 NA No 37.9
S393 Aα6-Aβ7 WT (C210) TMD5–6 No No 18.8
S412 Aα8′′′ A315 TMD7–8 No No 27.1
A235 TMD5–6 No No 19.9
S487 Cβ5 A235 TMD5–6 No No 27.2
S441 TMD11–12 No NA 14.2
NA, not analyzed for crosslinking; No, residues not crosslinked.
*Percentage of LAT2 crosslinked was calculated as the amount of LAT2 crosslinked from the total LAT2 coimmunoprecipitated with His-4F2hc.
†The structural element where the residues are located is shown.
‡The range of crosslinking distance of BMOE and BM(POE)2 is indicated in parentheses.
§Minimal interatomic distance between crosslinking residues in the lowest-energy docking model.







Debido  a  su  relevancia  fisiológica,  las proteínas de membrana  representan  actualmente dos 
tercios de  las dianas  terapéuticas  (Hediger et al., 2013). No obstante, hasta el momento, sólo se han 
depositado  466  estructuras  resueltas  en  la  base  de  datos  ‘Protein  Data  Bank’  (PDB,  abril  2014), 
representando menos del 2% del total de estructuras resueltas por cristalización y, siendo mayormente 
proteínas de membrana de organismos procariotas. Este número tan bajo se debe principalmente a el 
carácter  hidrofóbico  de  los  segmentos  integrales  de  las  proteínas  de  membrana  los  cuáles  se 




proteínas,  la  regulación  del  metabolismo,  crecimiento  celular,  regulación  del  volumen  celular, 
producción  de  energía  metabólica,  transmisión  neuronal,  y  moléculas  de  señalización  celular.  Los 
transportadores de aminoácidos  son esenciales para  la absorción de  los aminoácidos en  la nutrición, 
mediando  la  transferencia  de  aminoácidos  entre  órganos,  entre  células,  y  entre  compartimentos 
celulares.  Conjuntamente  con  otros  transportadores,  ayudan  al mantenimiento  de  la  concentración 
iónica celular, flujo de nutrientes, abasteciendo de aminoácidos a los tejidos del cuerpo (Christensen et 
al., 1990). 
Los  transportadores  de  aminoácidos  heteroméricos  (HATs)  sólo  se  encuentran  en metazoos 
mediando el transporte de aminoácidos a través de la membrana celular y jugando papeles clave como 
reguladores  de  la  síntesis  de  proteínas,  crecimiento  celular,  regulando  el metabolismo,  el  volumen 
celular,  la  producción  de  energía metabólica,  la  transmisión  neuronal,  y moléculas  de  señalización 
molecular.  
Los HATs  se  caracterizan por  ser el único ejemplo  conocido en  todos  los  reinos animales de 
transportadores de solutos constituidos por dos subunidades unidas distintas  las cuales se encuentran 
unidas  por  un  puente  disulfuro  (Palacín  &  Kanai,  2004).  En  mamíferos  han  sido  identificadas  dos 
subunidades pesadas (4F2hc o CD98, y rBAT) y 10 subunidades ligeras (Fernández et al., 2005). 
La  subunidad  pesada,  perteneciente  a  la  familia  SLC3  de  transportadores  de  solutos  en 
mamíferos,  es  la  responsable  del  tráfico  del  heterodímero  a  la membrana  plasmática.  Así  como  la 
subunidad ligera, pertenece a la familia de transportadores LAT, dentro de la familia SLC7, y es la unidad 




Estructuralmente,  las  subunidades  pesadas  son  glicoproteínas  de  tipo  II  (N‐terminal 
intracelular)  con  un  solo  segmento  transmembrana,  mientras  que  las  cadenas  ligeras  no  están 
glicosiladas y están formadas por  12 segmentos transmembrana.  
Figura 1. Modelo de 4F2hc/LAT1 (SLC3A2/SLC7A5) como miembro representativo de las proteínas HAT. Muestra 









Por  otro  lado,  la  subunidad  ligera  xCT  asociada  a  4F2hc  media  el  intercambio  de  cistina 
(captación) y glutamato (eflujo) (sistema xC‐) (Sato et al., 1999; Bassi et al., 2001), y es esencial para la 
infección del herpesvirus  asociado  al  sarcoma de  Kaposi  (herpesvirus humano 8)  (Kaleeba & Berger, 
2006; Veettil et al., 2008). El sistema xC‐ también está involucrado en la recaída a la adicción a cocaína a 
través del control de los niveles basales de glutamato extrasináptico (Baker et al., 2003).  








que  tengan una  función en el  transporte, ni en  su modulación. Mientras que 4F2hc es una proteína 




4F2hc,  además  de  llevar  el  transportador  a  membrana,  juega  múltiples  funciones  que  se 
encuentran relacionadas con  la regulación de  la señalización de β‐integrinas. Se ha demostrado que  la 




ratones supone  la muerte del feto, debido a que  los embriones no consiguen  implantarse (Tsumura et 
al., 2003; Domínguez et al., 2010).  
rBAT  Y  4F2hc  comparten  un  30%  de  identidad  en  secuencia  y  un  50%  de  similitud.  Son 
proteínas muy glicosiladas: 4F2hc humano presenta 4 sitios de glicosilación y rBAT presenta 6.  
Actualmente  sólo  se  conoce  la  estructura  atómica  de  la  parte  extracelular  de  4F2hc  (el 
ectodominio),  la  cual  fue  resuelta a 2.1Å en nuestro grupo  (Fort et al., 2007),  la  cual  se vio era muy 
similar a las alfa‐amilasas procariotas. 4F2hc‐ED adolece de los residuos catalíticos clave pero mantiene 

















Estudios  bioquímicos  indican  una  topología  de  12  segmentos  transmembrana,  así  como  la 
localización intracelular de ambos extremos de la proteína (Gasol et al., 2008).  
La  formación  del  puente  disulfuro  con  la  subunidad  pesada  no  impide  la  formación  del 
heterodímero,  que  igualmente  consigue  llegar  a  membrana,  sugiriendo  la  existencia  de  otras 










AdiC  Tetrámero  Fab Fragmento  3.2 Å  3NCY  Fang et al., 2009 
Dímero ‐ 4 Å  3LRC  Gao et al., 2009 
L‐arginina  3 Å  3L1L  Gao et al., 2010 
L‐arginina  3 Å  3OB6  Kowalczyk et al., 2011 
ApcT ‐ ‐ 2.32 Å  3GIA  Shaffer et al., 2009 
Fab Fragmento  2.48 Å  3GI9
2.59 Å  3GI8
GadC  Dímero ‐ 3.1 Å  4DJK  Ma et al., 2012 




LATs.  Estos  transportadores  muestran  el  plegamiento  prototípico  “5+5  repetición  invertida”, 
inicialmente  descrito  en  el  transportador  de  aminoácidos  LeuT  (Aquifex  aeolicus)  (Yamashita  et  al., 




transportadores.  La  existencia  de  estructuras  para  cada  estado  conformacional  ha  permitido  la 
comprensión de su mecanismo de transporte de acceso alternante a sustrato (Fotiadis et al., 2013). 
La hidrofobicidad de las proteínas de membrana dificulta la obtención de cristales para estudios 
de cristalización. Particularmente,  las subunidades  ligeras son altamente  inestables en solución aún en 




Si  bien  las  estructuras  publicadas  de  los  transportadores  APC  homólogos  a  las  subunidades 
ligeras  y  del  ectodominio  de  4F2hc  significan  un  claro  avance  en  nuestro  conocimiento  de  estos 






de  los  transportadores  de  aminoácidos.  Por  un  lado,  se  ha  estudiado  el  transportador  de 
arginina/agmatina bateriano, homólogo procariota de  las subunidades  ligeras, AdiC (~18% homologo a 
los  LATs),  del  cual  se  obtuvo  la  estructura  en  conformación  abierta  con  sustrato  unido  (PDB  3BO6) 
(Kowalczyk et al., 2011). Por otro lado, el estudio del transportador bacteriano más cercano a los LATs y 
que  se  encuentra  bien  caracterizado  funcionalmente:  SteT  (intercambiador  de  L‐serina/L‐threonina) 
(comparte  ~30%  de  identidad  de  secuencia  de  aminoácidos  con  los  LATs). Desafortunadamente,  los 
intentos de cristalización con la versión salvaje fueron fallidos.  
Con este escenario, en el laboratorio se inició un proyecto para probar la sobreexpresión de los 
HATs humanos en un  sistema de expresión eucariota, Pichia pastoris.  Se  clonaron  las 7  subunidades 
ligeras  humanas  y  4F2hc  y  rBAT  humanos  en  pPICZ  con  tags  localizados  ambos  en N‐terminal  de  8 
Histidinas y StrepII‐tag para las subunidades pesadas y ligeras respectivamente.  Se testó la expresión y 
solubilización  en  varios  detergentes  en  todas  las  subunidades  (resultados  de Dr.  Rosell  y Dr.  Costa) 
(Costa et al., 2013).  
Figura  2.  Resultados  de  expresión  y  solubilización  de  las  subunidades  ligeras  de  los  HATs:  asc1,  LAT1,  LAT2, 
y+LAT2, xCT, b0,+AT y y+LAT1.  A) Representación esquemática del diseño de la cadena ligera con StrepIItag en N‐
terminal.  B)  Análisis  por  western  blot  usando  anticuerpo  anti‐StrepTagII  de  la  expresión  de  las  diferentes 
subunidades  ligeras  a  partir  de membranas  aisladas.  C)  Solubilización  con  DDM  de  las  tres mejor  subunidades 





Figura 3. Resultados de expresión y  solubilización de  las  subunidades pesadas de  los HATs: 4F2hc y  rBAT.   A) 
Representación esquemática del diseño de la cadena pesada con tag de 8xHistidinas en N‐terminal. B) Análisis por 




De  las  cuales,  4F2hc  y  LAT2,  presentaron  los  candidatos  que  mejor  se  expresaron  y 
solubilizaron. Por ello, se probó su co‐expresión que también resultó con buenos niveles de expresión y 
solubilización. A partir de un cultivo de 2  litros, se extrajeron membranas, solubilizaron en DDM y tras 
dos  purificaciones  secuenciales  por  cromatografía  de  afinidad  de  Ni++  y  anti‐strepTaqII  se  consiguió 
alrededor de 1mg de HAT. Se evaluó su perfil de estabilidad por cromatografía de exclusión molecular 
que presentó un pico formado mayormente por heterodímero y algunos monómeros debido a la rotura 
del  puente  disulfuro  (figura  4A).  Además,  se  expresó  y  purificó  la  subunidad  ligera  LAT2,  pero 
sorprendentemente,  sin  la  presencia  de  4F2hc,  la  subunidad  ligera  agrega  toda  una  vez  purificada, 














microscopía  electrónica  de  transmisión,  haciendo  tinción  negativa  y  analizando  computacionalmente 






A partir de esta galería de  imágenes  se pudo  reconstruir el primer modelo estructural de un 
HAT (4F2hc/LAT2) a baja resolución (21Å) (Rosell et al., 2014). 
Figura 6. Reconstrucción en 3D del heterodímero 4F2hc/LAT2. La estructura de 4F2hc‐ED se corresponde con  la 
densidad más  pequeña  de  la  estructura.  El  asterisco muestra  la  posible  localización  del  puente  disulfuro  y  la 













cada  una  de  las  subunidades,  se  presentó  la  necesidad  de  validar  dicho modelo mediante  técnicas 
complementarias. En este escenario, los dos objetivos de la tesis se han centrado en:  
1. Validar  la  primera  estructura  atómica  a  baja  resolución  (21  Å)  de  un  HAT  (4F2hc/LAT2
humano)  (capítulo  I  de  la  tesis)  mediante  estudios  de  crosslinking  de  cisteínas  entre
subunidades.
















Para realizar  los estudios de crosslinking se cambió de sistema de expresión a  la  línea celular 




analizaron  las  cisteínas  endógenas.  En  el  caso  de  4F2hc  sólo  hay  dos,  la  C109  formando  el  puente 
disulfuro con  las subunidades  ligeras, y  la C330, más  internalizada, que mutamos a serina para evitar 
cualquier  tipo  de  especificidad  en  la  reacción  de  crosslinking.  En  el  entorno  C330S  se  generaron  9 
mutantes de cisteína localizados sobre la región más probable de estar interactuando con LAT2: S151C, 













en  HEK293T  durante  24  horas,  2)  lisado  celular  y  solubilización  de  las  membranas  con  DDM  1% 
(condición igual que la usada para la obtención del modelo 3D), 3) purificación de His‐4F2hc utilizando 
resina de Ni++, quedando una población de proteína: monómero de 4F2hc, homodímeros de 4F2hc‐














en  los  controles:  4F2hc  C330S/LAT2 WT  (WT:  salvaje).  Sólo  se  testó  de  aquellos mutantes  que
habían  formado  heterodímero:  S151C,  S185C,  S393C,  S412C.  Todos  ellos  eran  mutantes
funcionales.
Resultando  positivos  los  crosslinkings  de  las  cisteínas  412  y  210  en  4F2hc  con  la  cisteína 
endógena 210 en LAT2, representando la primera evidencia sobre el modelo 3D (Figura 8 A y C). En este 
momento  justo acaban de  calcular  también el docking Dr.Fdz‐Recio y Dr. Pérez, y  se  compararon  las 
soluciones de crosslinking obtenidas en su modelo, coincidiendo  las distancias en el modelo de mejor 
energía que tenían  (docking representado en Figura 8B con  las cisteínas señaladas). Así pues, tanto el 






Finalmente, dirigiendo  el diseño de nuevos mutantes  sobre  el docking  calculado  (Figura  8D, 
todas  las posiciones de cisteína sobre LAT2 en blanco coloreado el carbono, o cysteínas de 4F2hc, en 
verde sobrevolando la estructura, se encuentran señaladas, se encontraron nuevas posiciones positivas 






entre  subunidades.  Versiones  de  heterodímeros  His‐4F2hc/StrepLAT2  expresados  en  células  HEK  293T  fueron 
purificadas por cromatografía de afinidad de histidinas y tratadas con los crosslinkers BMOE y BM(PEG)2 resistentes 
a DTT. Crosslinking entre subunidades  fue detectado como heterodímeros  resistentes a DTT  (flecha) por western 
blot utilizando anticuerpos anti‐Strep bajo condiciones reductoras. La banda de monómero de LAT2 se corresponde 
con  los  heterodímeros  formados  con  4F2hc  (co‐purificados,  pero  no  crosslinkados). Mutantes  puntuales  fueron 
introducidos en 4F2hc  (C330S)/LAT2 salvaje  (A) o en LAT2  (C210S)  (C). No se observó crosslinking cuando se usó 
4F2hc (C330S) o LAT2 (C210S), indicando la especificidad del crosslinking. B) El modelo de docking de menor energía 
con  los  residuos de  cisteína marcados  (endógenos o añadidos mediante mutación)  se encuentran  señalados por 
modelos de esferas  (átomos C en gris, átomos de O, en  rojo, átomos N, en azul; átomos de S, en amarillo).  Los 




en verde. En LAT2  (en azul)  los  residuos de cisteína  (endógenos o añadidos por mutagénesis) se muestran como 







Una  vez  se  supo que 4F2hc/LAT2 podía  ser purificado  sin  agregar  (Figura 4A), mientras que 
LAT2 expresado solo agregaba todo sin la presencia de 4F2hc, se pensó en probar de añadir 4F2hc‐ED  a 
las membranas de P.pastoris  sobreexpresando LAT2 para determinar  si el ectodominio  (sin el puente 
disulfuro, ni  segmento  transmembrana e  intracelular) ejercía  algún efecto  sobre  LAT2. Así pues,  tras 
incubar toda la noche 4F2hcED purificado con membranas de P.pastories sobreexpresando LAT2, y al día 









de 4F2hc‐ED  sobre  la  subunidad  ligera, ofreciendo una explicación estructural de  la estabilización del 
complejo. Asimismo, se ha comprobado que el papel estabilizador de 4F2hc reside en el ectodominio, el 






1. Tres  líneas experimentales  independientes evidencian que 4F2hc‐ED  se encuentra  sobre  la parte
extracelular  del  transportador.  Los  resultados  de  los  pares  de  residuos  entre  subunidades
crosslinkados casi completamente (>80%) triangulan con el puente disulfuro endógeno la posición
de  4F2hc‐ED  sobre  LAT2,  demostrando  el  modelo  3D  de  baja  resolución,  y,  confirmando  las
predicciones del docking calculado de 4F2hc‐ED sobre el modelo de LAT2 humano.
2. La  interacción entre 4F2hc y la parte extracelular de LAT2 aumenta  la estabilidad de  la subunidad
ligera  solubilizada  en  detergente.  Específicamente,  el  ectodominio  de  4F2hc  es  suficiente  para
aumentar  la estabilidad de LAT2 solubilizado en DDM. El carácter hidrofóbico de  la  interacción de
4F2hc‐ED y LAT2 puede ser la base de la estabilización de esta subunidad ligera por 4F2hc.
Capítulo II: 
El  segundo objetivo  se  centró en  la  identificación del mejor  candidato HAT para estudios de 
cristalización 3D. Debido a que 4F2hc/LAT2 era poco estable para estudios cristalografía, se  inició una 
proyecto para  en encontrar una nueva  subunidad  eucariota  con mejores  características. Para  ello  se 
seleccionaron 24 subunidades pequeñas de distintas especies, y se adaptó una estrategia desarrollada 
para seleccionar proteínas candidatas para cristalización  (Drew et al., 2008). Se expresaron  todas con 
GFP  en  C‐terminal  tras  insertarse  en  el  plásmido  pDDGFP‐2  por  recombinación  homóloga.  La 





Asc‐1  LAT1  LAT2  y+LAT1  y+LAT2  xCT  Mnd  Jhl21  b0,+AT 
Humano  X  X  X  X  X  X  X 
Ratón  X  X  X  X  X  X 
Rata    X 
Vaca    X    X 
Sapo  X  X  X  X    X 
Pez zebra    X 
Mosca    X  X 
Tabla 1. 24 subunidades ligeras de diferentes especies (desde mosca a humano) seleccionadas para ser clonadas 
en S. cerevisiae y testar su expresión. 









estructurales  (Figura  12).  El  efecto  del  colesterol  sobre  la  estabilidad  de  las  subunidades  ligeras  fue 
clave.  Observado  en  los  perfiles  de  elución  de  las  FSEC:  cromatografías  de  exclusión  molecular 
fluorescentes de la figura 11. 
Figura  11.  Efecto  estabilizador  del  colesterol  sobre  todas  las  subunidades  ligeras  testadas. Mediante  FSEC  la 
monodispersión  de  distintas  proteínas  solubilizadas  con  distintos  1%  (p/v)  detergentes  está  representada  (línea 




Figura  12.  Perfiles  de  elución de  las  subunidades  ligeras  seleccionadas  en  el  screening  anterior,  purificadas  y 
concentradas  a  4mg/mL.  Inicialmente  se  seleccionaron  LAT2  (Xenopus  laevis),  LAT1  (Xenopus  laevis)  y  b0,+AT 
(Xenopus tropicalis) para estudios de cristalización 3D después del screening descrito anteriormente.  
b0,+AT  (Xenopus  tropicalis)  resultó  ser  la proteína con mejor perfil de elución después de  ser 
purificada  y  concentrada  a  4mg/mL,  seguida  de  LAT1  (Xenopus  laevis).  LAT2  (Xenopus  laevis)  fue 
descartada por recomendación de Dr. Gouaux, con quien colaborábamos, debido a que  la mayoría de 




1) Eliminar  la cisteína  reactiva posible causante de agregación, para ello  la mutamos  la cisteína
150, responsable del puente disulfuro, a alanina (C150A).
2) Adición de  lípidos durante  todo el proceso de purificación. El mejor candidato  fue DPPC que
incrementó enormemente la estabilidad de la proteína.
3) Aumentar  la expresión de  la proteína cambiando a otro sistema de expresión: Sf9 células de
insecto.
4) Disminuir la flexibilidad de la proteína para aumentar la probabilidad de cristalización. Distintas




















Se  pudo  seleccionar  b0,+AT,  LAT1  de  Xenopus  como  mejores  candidatos  para  estudios  de 
estructura 3D. Se comprobó que el colesterol estabilizaba enormemente los transportadores eucariotas, 
como  las  estructuras  resueltas  recientemente:  Transportador  de  Dopamina  (Drosophila)  (DAT)  que 
contiene una molécula de colesterol en su estructura. Ello concuerda con el hecho de encontrar 4F2hc 
en  los  lípids rafts, zonas de  la membrana ricas en colesterol. Por ello, se especula cual es el papel del 
colesterol sobre el transportador. 
Además, la adición de lípidos DPPC ha aumentado enormemente la estabilidad de la proteína. 
La eliminación de  la  cisteína  reactiva C150  junto  con  la deleción de  las  zonas móviles de  la proteína 





1. b0,+AT  (Xenopus  tropicalis)  seguida  de  LAT1  (Xenopus  laevis)  fueron  seleccionadas  como  las








a  5  veces  y  mejoró  la  cualidad  de  la  proteína  sobreexpresada  cuando  fue  analizada  por
cromatografía de exclusión molecular.
4. Además, se seleccionó la forma truncada en N  y C‐terminal más estable con el fin de reducir la
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